Section 12

EurekaMag PDF full texts Chapter 11,668


Robles-Flores, M.; Rendon-Huerta, E.; Gonzalez-Aguilar, H.; Mendoza-Hernandez, G.; Islas, S.; Mendoza, V.; Ponce-Castaneda, M.V.ronica; Gonzalez-Mariscal, L.; Lopez-Casillas, F. 2002: P32 (gC1qBP) is a general protein kinase C (PKC)-binding protein. Interaction and cellular localization of P32-PKC complexes in rat hepatocytes. Journal of Biological Chemistry 277(7): 5247-5255
Kao, G.D.; McKenna, W.G.; Muschel, R.J. 1999: P34(Cdc2) kinase activity is excluded from the nucleus during the radiation-induced G(2) arrest in HeLa cells. Journal of Biological Chemistry 274(49): 34779-34784
Nozoe, T.; Honda, M.; Inutsuka, S.; Korenaga, D. 2003: p34cdc2 expression is an independent indicator for lymph node metastasis in colorectal carcinoma. Journal of Cancer Research and Clinical Oncology 129(9): 498-502
Wiesener, B.; Hauser-Kronberger, C.E.; Zipperer, E.; Dietze, O.; Menzel, C.; Hacker, G.W. 1998: P34cdc2 in invasive breast cancer: Relationship to DNA content, Ki67 index and c-erbB-2 expression. Histopathology 33(6): 522-530
Figueroa, Y.; Wald, F.A.; Salas, P.J.I. 2002: P34cdc2-mediated phosphorylation mobilizes microtubule-organizing centers from the apical intermediate filament scaffold in CACO-2 epithelial cells. Journal of Biological Chemistry 277(40): 37848-37854
Ko, J.; Humbert, S.; Bronson, R.T.; Takahashi, S.; Kulkarni, A.B.; Li, E.; Tsai, L.H. 2001: P35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment. Journal of Neuroscience: the Official Journal of the Society for Neuroscience 21(17): 6758-6771
Town, T.; Zolton, J.; Shaffner, R.; Schnell, B.; Crescentini, R.; Wu, Y.; Zeng, J.; DelleDonne, A.; Obregon, D.; Tan, J.; Mullan, M. 2002: P35/Cdk5 pathway mediates soluble amyloid-beta peptide-induced tau phosphorylation in vitro. Journal of Neuroscience Research 69(3): 362-372
Kesavapany, S.; Lau, K.F.; McLoughlin, D.M.; Brownlees, J.; Ackerley, S.; Leigh, P.N.; Shaw, C.E.; Miller, C.C. 2001: p35/cdk5 binds and phosphorylates beta-catenin and regulates beta-catenin/presenilin-1 interaction. European Journal of Neuroscience 13(2): 241-247
Warny, M.; Keates, A.C.; Keates, S.; Castagliuolo, I.; Zacks, J.K.; Aboudola, S.; Qamar, A.; Pothoulakis, C.; LaMont, J.T.; Kelly, C.P. 2000: P38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis. Journal of Clinical Investigation 105(8): 1147-1156
Meja, K.K.; Seldon, P.M.; Nasuhara, Y.; Ito, K.; Barnes, P.J.; Lindsay, M.A.; Giembycz, M.A. 2000: P38 MAP kinase and MKK-1 co-operate in the generation of GM-CSF from LPS-stimulated human monocytes by an NF-kappaB-independent mechanism. British Journal of Pharmacology 131(6): 1143-1153
Schulz, R.; Belosjorow, S.; Gres, P.; Jansen, J.; Michel, M.C.; Heusch, G. 2002: P38 MAP kinase is a mediator of ischemic preconditioning in pigs. Cardiovascular Research 55(3): 690-700
Sun, A.; Liu, M.; Nguyen, X.V.; Bing, G. 2003: P38 MAP kinase is activated at early stages in Alzheimer's disease brain. Experimental Neurology 183(2): 394-405
Wagner, A.C.; Metzler, W.; Höfken, T.; Weber, H.; Göke, B. 1999: P38 MAP kinase is expressed in the pancreas and is immediately activated following cerulein hyperstimulation. Digestion 60(1): 41-47
Kozawa, O.; Kawamura, H.; Matsuno, H.; Uematsu, T. 2000: P38 MAP kinase is involved in the signalling of sphingosine in osteoblasts: sphingosine inhibits prostaglandin F(2alpha)-induced phosphoinositide hydrolysis. Cellular Signalling 12(7): 447-450
Goh, K.C.; Haque, S.J.; Williams, B.R. 1999: p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. EMBO Journal 18(20): 5601-5608
Ito, T.; Kozawa, O.; Tanabe, K.; Niwa, M.; Matsuno, H.; Sakai, N.; Ito, H.; Kato, K.; Uematsu, T. 2000: p38 MAP kinase is required for vasopressin-stimulated HSP27 induction in aortic smooth muscle cells. Hypertension 35(2): 673-678
Guan, Z.; Kim, J-Hun.; Lomvardas, S.; Holick, K.; Xu, S.; Kandel, E.R.; Schwartz, J.H. 2003: p38 MAP kinase mediates both short-term and long-term synaptic depression in aplysia. Journal of Neuroscience: the Official Journal of the Society for Neuroscience 23(19): 7317-7325
Cheng, A.; Chan, S.L.; Milhavet, O.; Wang, S.; Mattson, M.P. 2001: p38 MAP kinase mediates nitric oxide-induced apoptosis of neural progenitor cells. Journal of Biological Chemistry 276(46): 43320-43327
Tangkijvanich, P.; Santiskulvong, C.; Melton, A.C.; Rozengurt, E.; Yee, H.F. 2002: p38 MAP kinase mediates platelet-derived growth factor-stimulated migration of hepatic myofibroblasts. Journal of Cellular Physiology 191(3): 351-361
Werz, O.; Klemm, J.; Rådmark, O.; Samuelsson, B. 2001: p38 MAP kinase mediates stress-induced leukotriene synthesis in a human B-lymphocyte cell line. Journal of Leukocyte Biology 70(5): 830-838
Thellung, S.; Villa, V.; Corsaro, A.; Arena, S.; Millo, E.; Damonte, G.; Benatti, U.; Tagliavini, F.; Florio, T.; Schettini, G. 2002: p38 MAP kinase mediates the cell death induced by PrP106-126 in the SH-SY5Y neuroblastoma cells. Neurobiology of Disease 9(1): 69-81
Feranchak, A.P.; Berl, T.; Capasso, J.; Wojtaszek, P.A.; Han, J.; Fitz, J.G. 2001: p38 MAP kinase modulates liver cell volume through inhibition of membrane Na+ permeability. Journal of Clinical Investigation 108(10): 1495-1504
Kintscher, U.; Bruemmer, D.; Blaschke, F.; Unger, T.; Law, R.E. 2003: P38 MAP kinase negatively regulates angiotensin II-mediated effects on cell cycle molecules in human coronary smooth muscle cells. Biochemical and Biophysical Research Communications 305(3): 552-556
Meloche, S.; Landry, J.; Huot, J.; Houle, F.; Marceau, F.; Giasson, E. 2000: p38 MAP kinase pathway regulates angiotensin II-induced contraction of rat vascular smooth muscle. American Journal of Physiology. Heart and Circulatory Physiology 279(2): H741-H751
Hashimoto, S.; Gon, Y.; Asai, Y.; Asai, Y.; Machino, T.; Jibiki, I.; Takeshita, I.; Anazawa, H.; Horie, T. 1999: p38 MAP kinase regulates RANTES production by TNF-alpha-stimulated human pulmonary vascular endothelial cells. Allergy 54(11): 1168-1172
Lee, Y.B.; Schrader, J.W.; Kim, S.U. 2000: p38 map kinase regulates TNF-alpha production in human astrocytes and microglia by multiple mechanisms. Cytokine 12(7): 874-880
Touyz, R.M.; He, G.; El Mabrouk, M.; Schiffrin, E.L. 2001: P38 MAP kinase regulates vascular smooth muscle cell collagen synthesis by angiotensin II in SHR but not in WKY. Hypertension 37(2 Pt 2): 574-580
Ji, R-Rong.; Samad, T.A.; Jin, S-Xue.; Schmoll, R.; Woolf, C.J. 2002: P38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 36(1): 57-68
Marais, E.; Genade, S.; Strijdom, H.; Moolman, J.A.; Lochner, A. 2001: P38 MAPK activation triggers pharmacologically-induced beta-adrenergic preconditioning, but not ischaemic preconditioning. Journal of Molecular and Cellular Cardiology 33(12): 2157-2177
Gysembergh, A.; Simkhovich, B.Z.; Kloner, R.A.; Przyklenk, K. 2001: p38 MAPK activity is not increased early during sustained coronary artery occlusion in preconditioned versus control rabbit heart. Journal of Molecular and Cellular Cardiology 33(4): 681-690
Kang, S.W.; Adler, S.G.; Lapage, J.; Natarajan, R. 2001: p38 MAPK and MAPK kinase 3/6 mRNA and activities are increased in early diabetic glomeruli. Kidney International 60(2): 543-552
Jang, S.-Byeol; Lee, K.-Haeng 2000: P38 MAPK and NF-kappaB are required for LPS-induced RANTES production in immortalized murine microglia (BV-2). Korean Journal of Physiology and Pharmacology 4(5): 339-346
Cain, B.S.; Meldrum, D.R.; Meng, X.; Dinarello, C.A.; Shames, B.D.; Banerjee, A.; Harken, A.H. 1999: p38 MAPK inhibition decreases TNF-alpha production and enhances postischemic human myocardial function. Journal of Surgical Research 83(1): 7-12
Yilmaz, A.; Kliche, S.; Mayr-Beyrle, U.; Fellbrich, G.; Waltenberger, J. 2003: P38 MAPK inhibition is critically involved in VEGFR-2-mediated endothelial cell survival. Biochemical and Biophysical Research Communications 306(3): 730-736
Gao, F.; Yue, T-Li.; Shi, D-Wei.; Christopher, T.A.; Lopez, B.L.; Ohlstein, E.H.; Barone, F.C.; Ma, X.L. 2002: P38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation. Cardiovascular Research 53(2): 414-422
Khurana, A.; Dey, C.S. 2003: p38 MAPK interacts with actin and modulates filament assembly during skeletal muscle differentiation. Differentiation; Research in Biological Diversity 71(1): 42-50
Mainiero, F.; Colombara, M.; Antonini, V.; Strippoli, R.; Merola, M.; Poffe, O.; Tridente, G.; Ramarli, D. 2003: P38 MAPK is a critical regulator of the constitutive and the beta4 integrin-regulated expression of IL-6 in human normal thymic epithelial cells. European Journal of Immunology 33(11): 3038-3048
Song, S.; Freedman, J.; Mody, M.; Lazarus, A.H. 1999: P38 MAPK is activated but not necessary in porcine von Willebrand factor-dependent platelet activation. British Journal of Haematology 107(3): 532-538
Ogihara, T.; Watada, H.; Kanno, R.; Ikeda, F.; Nomiyama, T.; Tanaka, Y.; Nakao, A.; German, M.S.; Kojima, I.; Kawamori, R. 2003: p38 MAPK is involved in activin A- and hepatocyte growth factor-mediated expression of pro-endocrine gene neurogenin 3 in AR42J-B13 cells. Journal of Biological Chemistry 278(24): 21693-21700
Furukawa, F.; Matsuzaki, K.; Mori, S.; Tahashi, Y.; Yoshida, K.; Sugano, Y.; Yamagata, H.; Matsushita, M.; Seki, T.; Inagaki, Y.; Nishizawa, M.; Fujisawa, J.; Inoue, K. 2003: P38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts. Hepatology 38(4): 879-889
Meldrum, K.K.; Meldrum, D.R.; Hile, K.L.; Yerkes, E.B.; Ayala, A.; Cain, M.P.; Rink, R.C.; Casale, A.J.; Kaefer, M.A. 2001: P38 MAPK mediates renal tubular cell TNF-alpha production and TNF-alpha-dependent apoptosis during simulated ischemia. American Journal of Physiology. Cell Physiology 281(2): C563-C570
Sakai, N.; Wada, T.; Furuichi, K.; Iwata, Y.; Yoshimoto, K.; Kitagawa, K.; Kokubo, S.; Kobayashi, M.; Takeda, S-ichi.; Kida, H.; Kobayashi, K-ichi.; Mukaida, N.; Matsushima, K.; Yokoyama, H. 2002: P38 MAPK phosphorylation and NF-kappa B activation in human crescentic glomerulonephritis. Nephrology Dialysis Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association 17(6): 998-1004
Xu, X.; Malave, A. 2000: P38 MAPK, but not p42/p44 MAPK mediated inducible nitric oxide synthase expression in C6 glioma cells. Life Sciences 67(26): 3221-3230
Li, X.; Udagawa, N.; Itoh, K.; Suda, K.; Murase, Y.; Nishihara, T.; Suda, T.; Takahashi, N. 2002: p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. Endocrinology 143(8): 3105-3113
Alvarado-Kristensson, M.; Porn-Ares, M.Isabella.; Grethe, S.; Smith, D.; Zheng, L.; Andersson, T. 2001: p38 Mitogen-activated protein kinase and phosphatidylinositol 3-kinase activities have opposite effects on human neutrophil apoptosis. FASEB Journal 16(1): 129-131
Adachi-Yamada, T.; Nakamura, M.; Irie, K.; Tomoyasu, Y.; Sano, Y.; Mori, E.; Goto, S.; Ueno, N.; Nishida, Y.; Matsumoto, K. 1999: p38 mitogen-activated protein kinase can be involved in transforming growth factor beta superfamily signal transduction in Drosophila wing morphogenesis. Molecular and Cellular Biology 19(3): 2322-2329
Iwata, Y.; Wada, T.; Furuichi, K.; Sakai, N.; Matsushima, K.; Yokoyama, H.; Kobayashi, K.I.hi 2003: P38 Mitogen-activated protein kinase contributes to autoimmune renal injury in MRL-Faslpr mice. Journal of the American Society of Nephrology 14(1): 57-67
Li, X.; Udagawa, N.; Takami, M.; Sato, N.; Kobayashi, Y.; Takahashi, N. 2003: p38 Mitogen-activated protein kinase is crucially involved in osteoclast differentiation but not in cytokine production, phagocytosis, or dendritic cell differentiation of bone marrow macrophages. Endocrinology 144(11): 4999-5005
Hashimoto, S.; Matsumoto, K.; Gon, Y.; Maruoka, S.; Takeshita, I.; Hayashi, S.; Koura, T.; Kujime, K.; Horie, T. 1999: P38 Mitogen-activated protein kinase regulates IL-8 expression in human pulmonary vascular endothelial cells. European Respiratory Journal 13(6): 1357-1364
McLaughlin, B.; Pal, S.; Tran, M.P.; Parsons, A.A.; Barone, F.C.; Erhardt, J.A.; Aizenman, E. 2001: P38 activation is required upstream of potassium current enhancement and caspase cleavage in thiol oxidant-induced neuronal apoptosis. Journal of Neuroscience: the Official Journal of the Society for Neuroscience 21(10): 3303-3311
Zayzafoon, M.; Botolin, S.; McCabe, L.R. 2002: P38 and activating transcription factor-2 involvement in osteoblast osmotic response to elevated extracellular glucose. Journal of Biological Chemistry 277(40): 37212-37218
Wu, Z.; Woodring, P.J.; Bhakta, K.S.; Tamura, K.; Wen, F.; Feramisco, J.R.; Karin, M.; Wang, J.Y.; Puri, P.L. 2000: P38 and extracellular signal-regulated kinases regulate the myogenic program at multiple steps. Molecular and Cellular Biology 20(11): 3951-3964
Chen, C.C.; Wang, J.K. 1999: p38 but not p44/42 mitogen-activated protein kinase is required for nitric oxide synthase induction mediated by lipopolysaccharide in RAW 264.7 macrophages. Molecular Pharmacology 55(3): 481-488
Hunt, J.A.; Kallashi, F.; Ruzek, R.D.; Sinclair, P.J.; Ita, I.; McCormick, S.X.; Pivnichny, J.V.; Hop, C.E.C.A.; Kumar, S.; Wang, Z.; O'Keefe, S.J.; O'Neill, E.A.; Porter, G.; Thompson, J.E.; Woods, A.; Zaller, D.M.; Doherty, J.B. 2003: p38 Inhibitors: piperidine- and 4-aminopiperidine-substituted naphthyridinones, quinolinones, and dihydroquinazolinones. Bioorganic and Medicinal Chemistry Letters 13(3): 467-470
Redman, A.M.; Johnson, J.S.; Dally, R.; Swartz, S.; Wild, H.; Paulsen, H.; Caringal, Y.; Gunn, D.; Renick, J.; Osterhout, M.; Kingery-Wood, J.; Smith, R.A.; Lee, W.; Dumas, J.; Wilhelm, S.M.; Housley, T.J.; Bhargava, A.; Ranges, G.E.; Shrikhande, A.; Young, D.; Bombara, M.; Scott, W.J. 2001: p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas. Bioorganic and Medicinal Chemistry Letters 11(1): 9-12
Kim, M-Sung.; Lee, E-Jung.; Kim, H-Reh.Choi.; Moon, A. 2003: p38 kinase is a key signaling molecule for H-Ras-induced cell motility and invasive phenotype in human breast epithelial cells. Cancer Research 63(17): 5454-5461
Kusuhara, M.; Takahashi, E.; Peterson, T.E.; Abe, J.; Ishida, M.; Han, J.; Ulevitch, R.; Berk, B.C. 1998: P38 kinase is a negative regulator of angiotensin II signal transduction in vascular smooth muscle cells: Effects on Na+/H+ exchange and ERK1/2. Circulation Research 83(8): 824-831
Hensley, K.; Floyd, R.A.; Zheng, N.Y.; Nael, R.; Robinson, K.A.; Nguyen, X.; Pye, Q.N.; Stewart, C.A.; Geddes, J.; Markesbery, W.R.; Patel, E.; Johnson, G.V.; Bing, G. 1999: P38 kinase is activated in the Alzheimer's disease brain. Journal of Neurochemistry 72(5): 2053-2058
Huang, C.; Ma, W.Y.; Maxiner, A.; Sun, Y.; Dong, Z. 1999: p38 kinase mediates UV-induced phosphorylation of p53 protein at serine 389. Journal of Biological Chemistry 274(18): 12229-12235
Rane, M.J.; Coxon, P.Y.; Powell, D.W.; Webster, R.; Klein, J.B.; Pierce, W.; Ping, P.; McLeish, K.R. 2000: p38 Kinase-dependent MAPKAPK-2 activation functions as 3-phosphoinositide-dependent kinase-2 for Akt in human neutrophils. Journal of Biological Chemistry 276(5): 3517-3523
Kim, S-Ja.; Kim, H-Gyul.; Oh, C-Do.; Hwang, S-Gu.; Song, W-Keun.; Yoo, Y-Joon.; Kang, S-Sung.; Chun, J-Soo. 2002: p38 kinase-dependent and -independent Inhibition of protein kinase C zeta and -alpha regulates nitric oxide-induced apoptosis and dedifferentiation of articular chondrocytes. Journal of Biological Chemistry 277(33): 30375-30381
Dalrymple, S.A. 2003: p38 mitogen activated protein kinase as a therapeutic target for Alzheimer's disease. Journal of Molecular Neuroscience: Mn 19(3): 295-299
Xu, J.; Clark, R.A.; Parks, W.C. 2001: P38 mitogen-activated kinase is a bidirectional regulator of human fibroblast collagenase-1 induction by three-dimensional collagen lattices. Biochemical Journal 355(Pt 2): 437-447
Tokuda, H.; Kozawa, O.; Miwa, M.; Uematsu, T. 2001: P38 mitogen-activated protein (MAP) kinase but not p44/p42 MAP kinase is involved in prostaglandin E1-induced vascular endothelial growth factor synthesis in osteoblasts. Journal of Endocrinology 170(3): 629-638
Barger, P.M.; Browning, A.C.; Garner, A.N.; Kelly, D.P. 2001: p38 mitogen-activated protein kinase activates peroxisome proliferator-activated receptor alpha: a potential role in the cardiac metabolic stress response. Journal of Biological Chemistry 276(48): 44495-44501
Le Panse, R.; Dubertret, L.; Coulomb, B. 2003: P38 mitogen-activated protein kinase activation by ultraviolet a radiation in human dermal fibroblasts. Photochemistry and Photobiology 78(2): 168-174
Maher, P. 1999: p38 mitogen-activated protein kinase activation is required for fibroblast growth factor-2-stimulated cell proliferation but not differentiation. Journal of Biological Chemistry 274(25): 17491-17498
Aiba, S.; Manome, H.; Nakagawa, S.; Mollah, Z.U.A.; Mizuashi, M.; Ohtani, T.; Yoshino, Y.; Tagami, H. 2003: p38 Mitogen-activated protein kinase and extracellular signal-regulated kinases play distinct roles in the activation of dendritic cells by two representative haptens, NiCl2 and 2,4-dinitrochlorobenzene. Journal of Investigative Dermatology 120(3): 390-399
Sundaresan, P.; Farndale, R.W. 2002: P38 mitogen-activated protein kinase dephosphorylation is regulated by protein phosphatase 2A in human platelets activated by collagen. FEBS Letters 528(1-3): 139-144
Nakamura, K.; Shirai, T.; Morishita, S.; Uchida, S.; Saeki-Miura, K.; Makishima, F. 1999: p38 mitogen-activated protein kinase functionally contributes to chondrogenesis induced by growth/differentiation factor-5 in ATDC5 cells. Experimental Cell Research 250(2): 351-363
Jin, S-Xue.; Zhuang, Z-Ye.; Woolf, C.J.; Ji, R-Rong. 2003: P38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. Journal of Neuroscience: the Official Journal of the Society for Neuroscience 23(10): 4017-4022
Waetzig, G.H.; Seegert, D.; Rosenstiel, P.; Nikolaus, S.; Schreiber, S. 2002: P38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. Journal of Immunology 168(10): 5342-5351
Hsu, S.C.; Gavrilin, M.A.; Tsai, M.H.; Han, J.; Lai, M.Z. 1999: P38 mitogen-activated protein kinase is involved in Fas ligand expression. Journal of Biological Chemistry 274(36): 25769-25776
Bakin, A.V.; Rinehart, C.; Tomlinson, A.K.; Arteaga, C.L. 2002: p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. Journal of Cell Science 115(Pt 15): 3193-3206
Zhuang, S.; Demirs, J.T.; Kochevar, I.E. 2000: p38 mitogen-activated protein kinase mediates bid cleavage, mitochondrial dysfunction, and caspase-3 activation during apoptosis induced by singlet oxygen but not by hydrogen peroxide. Journal of Biological Chemistry 275(34): 25939-25948
Liao, P.; Wang, S-Qiang.; Wang, S.; Zheng, M.; Zheng, M.; Zhang, S-Jun.; Cheng, H.; Wang, Y.; Xiao, R-Ping. 2002: P38 mitogen-activated protein kinase mediates a negative inotropic effect in cardiac myocytes. Circulation Research 90(2): 190-196
Deacon, K.; Mistry, P.; Chernoff, J.; Blank, J.L.; Patel, R. 2003: p38 Mitogen-activated protein kinase mediates cell death and p21-activated kinase mediates cell survival during chemotherapeutic drug-induced mitotic arrest. Molecular Biology of the Cell 14(5): 2071-2087
Zhu, Y.; Mao, X.Ou.; Sun, Y.; Xia, Z.; Greenberg, D.A. 2002: p38 Mitogen-activated protein kinase mediates hypoxic regulation of Mdm2 and p53 in neurons. Journal of Biological Chemistry 277(25): 22909-22914
Han, I.O.; Kim, K.-W.; Ryu, J.H.; Kim, W.-K. 2002: P38 mitogen-activated protein kinase mediates lipopolysaccharide, not interferon-gamma, -induced inducible nitric oxide synthase expression in mouse BV2 microglial cells. Neuroscience Letters 325(1): 9-12
Valladares, A.; Alvarez, A.M.; Ventura, J.J.; Roncero, C.; Benito, M.; Porras, A. 2000: p38 mitogen-activated protein kinase mediates tumor necrosis factor-alpha-induced apoptosis in rat fetal brown adipocytes. Endocrinology 141(12): 4383-4395
Yu, R.; Mandlekar, S.; Lei, W.; Fahl, W.E.; Tan, T.H.; Kong, A.N. 2000: P38 mitogen-activated protein kinase negatively regulates the induction of phase II drug-metabolizing enzymes that detoxify carcinogens. Journal of Biological Chemistry 275(4): 2322-2327
Zetser, A.; Gredinger, E.; Bengal, E. 1999: P38 mitogen-activated protein kinase pathway promotes skeletal muscle differentiation. Participation of the MEF2C transcription factor. Journal of Biological Chemistry 274(8): 5193-5200
Li, S-Ping.; Junttila, M.R.; Han, J.; Kähäri, V-Matti.; Westermarck, J. 2003: p38 Mitogen-activated protein kinase pathway suppresses cell survival by inducing dephosphorylation of mitogen-activated protein/extracellular signal-regulated kinase kinase1,2. Cancer Research 63(13): 3473-3477
Assefa, Z.; Vantieghem, A.; Garmyn, M.; Declercq, W.; Vandenabeele, P.; Vandenheede, J.R.; Bouillon, R.; Merlevede, W.; Agostinis, P. 2000: p38 mitogen-activated protein kinase regulates a novel, caspase-independent pathway for the mitochondrial cytochrome c release in ultraviolet B radiation-induced apoptosis. Journal of Biological Chemistry 275(28): 21416-21421
Rice, A.B.; Ingram, J.L.; Bonner, J.C. 2002: p38 mitogen-activated protein kinase regulates growth factor-induced mitogenesis of rat pulmonary myofibroblasts. American Journal of Respiratory Cell and Molecular Biology 27(6): 759-765
Pesu, M.; Aittomäki, S.; Takaluoma, K.; Lagerstedt, A.; Silvennoinen, O. 2002: p38 Mitogen-activated protein kinase regulates interleukin-4-induced gene expression by stimulating STAT6-mediated transcription. Journal of Biological Chemistry 277(41): 38254-38261
Yamagishi, S.; Yamada, M.; Ishikawa, Y.; Matsumoto, T.; Ikeuchi, T.; Hatanaka, H. 2000: p38 mitogen-activated protein kinase regulates low potassium-induced c-Jun phosphorylation and apoptosis in cultured cerebellar granule neurons. Journal of Biological Chemistry 276(7): 5129-5133
Hayashi, Y.; Sanada, K.; Hirota, T.; Shimizu, F.; Fukada, Y. 2003: p38 mitogen-activated protein kinase regulates oscillation of chick pineal circadian clock. Journal of Biological Chemistry 278(27): 25166-25171
He, Z.; Cho, Y-Yeon.; Liu, G.; Ma, W-Ya.; Bode, A.M.; Dong, Z. 2003: p38 Mitogen-activated protein kinase regulation of JB6 Cl41 cell transformation promoted by epidermal growth factor. Journal of Biological Chemistry 278(29): 26435-26442
Dean, J.L.E.; Sarsfield, S.J.; Tsounakou, E.; Saklatvala, J. 2003: p38 Mitogen-activated protein kinase stabilizes mRNAs that contain cyclooxygenase-2 and tumor necrosis factor AU-rich elements by inhibiting deadenylation. Journal of Biological Chemistry 278(41): 39470-39476
Xu, Q.; Yu, L.; Liu, L.; Cheung, C.Fung.; Li, X.; Yee, S-Pok.; Yang, X-Jiao.; Wu, Z. 2002: p38 Mitogen-activated protein kinase-, calcium-calmodulin-dependent protein kinase-, and calcineurin-mediated signaling pathways transcriptionally regulate myogenin expression. Molecular Biology of the Cell 13(6): 1940-1952
Westermarck, J.; Li, S.P.; Kallunki, T.; Han, J.; Kähäri, V.M. 2001: p38 mitogen-activated protein kinase-dependent activation of protein phosphatases 1 and 2A inhibits MEK1 and MEK2 activity and collagenase 1 (MMP-1) gene expression. Molecular and Cellular Biology 21(7): 2373-2383
Frevel, M.A.E.; Bakheet, T.; Silva, A.M.; Hissong, J.G.; Khabar, K.S.A.; Williams, B.R.G. 2003: P38 mitogen-activated protein kinase-dependent and -independent signaling of mRNA stability of AU-rich element-containing transcripts. Molecular and Cellular Biology 23(2): 425-436
Chou, T.T.; Trojanowski, J.Q.; Lee, V.M. 2001: p38 mitogen-activated protein kinase-independent induction of gadd45 expression in nerve growth factor-induced apoptosis in medulloblastomas. Journal of Biological Chemistry 276(44): 41120-41127
Irusen, E.; Matthews, J.G.; Takahashi, A.; Barnes, P.J.; Chung, K.F.; Adcock, I.M. 2002: P38 mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: Role in steroid-insensitive asthma. Journal of Allergy and Clinical Immunology 109(4): 649-657
Gao, N.; Jiang, B-Hua.; Leonard, S.S.; Corum, L.; Zhang, Z.; Roberts, J.R.; Antonini, J.; Zheng, J.Z.; Flynn, D.C.; Castranova, V.; Shi, X. 2002: p38 Signaling-mediated hypoxia-inducible factor 1alpha and vascular endothelial growth factor induction by Cr(VI) in DU145 human prostate carcinoma cells. Journal of Biological Chemistry 277(47): 45041-45048
Ganju, P.; Davis, A.; Patel, S.; Núñez, X.; Fox, A. 2001: P38 stress-activated protein kinase inhibitor reverses bradykinin B(1) receptor-mediated component of inflammatory hyperalgesia. European Journal of Pharmacology 421(3): 191-199
Zhao, T.C.; Taher, M.M.; Valerie, K.C.; Kukreja, R.C. 2001: p38 Triggers late preconditioning elicited by anisomycin in heart: involvement of NF-kappaB and iNOS. Circulation Research 89(10): 915-922
Schares, G.; Bärwald, A.; Staubach, C.; Söndgen, P.; Rauser, M.; Schröder, R.; Peters, M.; Wurm, R.; Selhorst, T.; Conraths, F.J. 2002: P38-avidity-ELISA: Examination of herds experiencing epidemic or endemic Neospora caninum-associated bovine abortion. Veterinary Parasitology 106(4): 293-305
Navarro, L.; David, M. 1999: p38-dependent activation of interferon regulatory factor 3 by lipopolysaccharide. Journal of Biological Chemistry 274(50): 35535-35538
Bellmann, K.; Burkart, V.; Bruckhoff, J.; Kolb, H.; Landry, J. 2000: p38-dependent enhancement of cytokine-induced nitric-oxide synthase gene expression by heat shock protein 70. Journal of Biological Chemistry 275(24): 18172-18179
Saccani, S.; Pantano, S.; Natoli, G. 2002: P38-dependent marking of inflammatory genes for increased NF-kappaB recruitment. Nature Immunology 3(1): 69-75
Schrantz, N.; Bourgeade, M.F.; Mouhamad, S.; Leca, G.; Sharma, S.; Vazquez, A. 2001: p38-mediated regulation of an Fas-associated death domain protein-independent pathway leading to caspase-8 activation during TGFbeta-induced apoptosis in human Burkitt lymphoma B cells BL41. Molecular Biology of the Cell 12(10): 3139-3151
Rolli-Derkinderen, M.; Gaestel, M. 2000: p38/SAPK2-dependent gene expression in Jurkat T cells. Biological Chemistry 381(3): 193-198
Sevier, C.S.; Machamer, C.E. 2001: p38: A novel protein that associates with the vesicular stomatitis virus glycoprotein. Biochemical and Biophysical Research Communications 287(2): 574-582
Li, S.; Liu, X.; Ascoli, M. 2000: P38JAB1 binds to the intracellular precursor of the lutropin/choriogonadotropin receptor and promotes its degradation. Journal of Biological Chemistry 275(18): 13386-13393
Murakami-Mori, K.; Mori, S.; Nakamura, S. 1999: p38MAP kinase is a negative regulator for ERK1/2-mediated growth of AIDS-associated Kaposi's sarcoma cells. Biochemical and Biophysical Research Communications 264(3): 676-682
Woods Ignatoski, K.M.; Grewal, N.K.; Markwart, S.; Livant, D.L.; Ethier, S.P. 2003: P38MAPK induces cell surface alpha4 integrin downregulation to facilitate erbB-2-mediated invasion. Neoplasia 5(2): 128-134
Mackova, M.; Man, J.R.; Chik, C.L.; Ho, A.K. 2000: p38MAPK inhibition enhances basal and norepinephrine-stimulated p42/44MAPK phosphorylation in rat pinealocytes. Endocrinology 141(11): 4202-4208
Sanz-Moreno, V.; Casar, B.; Crespo, P. 2003: P38alpha isoform Mxi2 binds to extracellular signal-regulated kinase 1 and 2 mitogen-activated protein kinase and regulates its nuclear activity by sustaining its phosphorylation levels. Molecular and Cellular Biology 23(9): 3079-3090
Guo, Y.L.; Kang, B.; Han, J.; Williamson, J.R. 2001: p38beta MAP kinase protects rat mesangial cells from TNF-alpha-induced apoptosis. Journal of Cellular Biochemistry 82(4): 556-565
Humbert, S.; Dhavan, R.; Tsai, L. 2000: p39 activates cdk5 in neurons, and is associated with the actin cytoskeleton. Journal of Cell Science 113: 975-983
Bouin, A.P.; Grandvaux, N.; Vignais, P.V.; Fuchs, A. 1998: P40(phox) is phosphorylated on threonine 154 and serine 315 during activation of the phagocyte NADPH oxidase. Implication of a protein kinase c-type kinase in the phosphorylation process. Journal of Biological Chemistry 273(46): 30097-30103
Cross, A.R. 2000: P40(phox) Participates in the activation of NADPH oxidase by increasing the affinity of p47(phox) for flavocytochrome b(558). Biochemical Journal 349(Pt 1): 113-117
Morita, A.; Suzuki, N.; Matsumoto, Y.; Hirano, K.; Enomoto, A.; Zhu, J.; Sakai, K. 2000: p41 as a possible marker for cell death is generated by caspase cleavage of p42/SETbeta in irradiated MOLT-4 cells. Biochemical and Biophysical Research Communications 278(3): 627-632
Gomez-Cambronero, J. 1999: P42-MAP kinase is activated in EGF-stimulated interphase but not in metaphase-arrested HeLa cells. FEBS Letters 443(2): 126-130
Engelman, J.A.; Zhang, X.L.; Razani, B.; Pestell, R.G.; Lisanti, M.P. 1999: P42/44 MAP kinase-dependent and -independent signaling pathways regulate caveolin-1 gene expression. Activation of Ras-MAP kinase and protein kinase a signaling cascades transcriptionally down-regulates caveolin-1 promoter activity. Journal of Biological Chemistry 274(45): 32333-32341
Varma, S.; Breslin, J.W.; Lal, B.K.; Pappas, P.J.; Hobson, R.W.; Durán, W.N. 2002: p42/44MAPK regulates baseline permeability and cGMP-induced hyperpermeability in endothelial cells. Microvascular Research 63(2): 172-178
Tokuda, H.; Kozawa, O.; Harada, A.; Uematsu, T. 1999: P42/p44 mitogen-activated protein kinase activation is involved in prostaglandin F2alpha-induced interleukin-6 synthesis in osteoblasts. Cellular Signalling 11(5): 325-330
Richard, D.E.; Berra, E.; Gothié, E.; Roux, D.; Pouysségur, J. 1999: p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. Journal of Biological Chemistry 274(46): 32631-32637
Kim, Y.H.; Kim, J.M.; Kim, S.N.; Kim, G.-S.; Baek, J.-H. 2003: P44/42 MAPK activation is necessary for receptor activator of nuclear factor-kappaB ligand induction by high extracellular calcium. Biochemical and Biophysical Research Communications 304(4): 729-735
Flamigni, F.; Facchini, A.; Capanni, C.; Stefanelli, C.; Tantini, B.; Caldarera, C.M. 1999: p44/42 mitogen-activated protein kinase is involved in the expression of ornithine decarboxylase in leukaemia L1210 cells. Biochemical Journal 341: 363-369
Seroz, T.; Perez, C.; Bergmann, E.; Bradsher, J.; Egly, J.M. 2000: p44/SSL1, the regulatory subunit of the XPD/RAD3 helicase, plays a crucial role in the transcriptional activity of TFIIH. Journal of Biological Chemistry 275(43): 33260-33266
Specht, M.C.; Barden, C.B.; Fahey, T.J. 2001: p44/p42-MAP kinase expression in papillary thyroid carcinomas. Surgery 130(6): 936-940
Li, Y.J.; Higgins, R.R.; Pak, B.J.; Shivdasani, R.A.; Ney, P.A.; Archer, M.; Ben-David, Y. 2000: p45(NFE2) is a negative regulator of erythroid proliferation which contributes to the progression of Friend virus-induced erythroleukemias. Molecular and Cellular Biology 21(1): 73-80
Barry-Lane, P.A.; Patterson, C.; van der Merwe, M.; Hu, Z.; Holland, S.M.; Yeh, E.T.; Runge, M.S. 2001: P47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice. Journal of Clinical Investigation 108(10): 1513-1522
Gu, Y.; Xu, Y.Cheng.; Wu, R.Feng.; Nwariaku, F.E.; Souza, R.F.; Flores, S.C.; Terada, L.S. 2003: p47phox participates in activation of RelA in endothelial cells. Journal of Biological Chemistry 278(19): 17210-17217
Nakao, K.; Nakata, K.; Yamashita, M.; Tamada, Y.; Hamasaki, K.; Ishikawa, H.; Kato, Y.; Eguchi, K.; Ishii, N. 1999: p48 (ISGF-3gamma) is involved in interferon-alpha-induced suppression of hepatitis B virus enhancer-1 activity. Journal of Biological Chemistry 274(40): 28075-28078
Tamada, Y.; Nakao, K.; Nagayama, Y.; Nakata, K.; Ichikawa, T.; Kawamata, Y.; Ishikawa, H.; Hamasaki, K.; Eguchi, K.; Ishii, N. 2002: P48 overexpression enhances interferon-mediated expression and activity of double-stranded RNA-dependent protein kinase in human hepatoma cells. Journal of Hepatology 37(4): 493-499
Obata, J.; Yano, M.; Mimura, H.; Goto, T.; Nakayama, R.; Mibu, Y.; Oka, C.; Kawaichi, M. 2001: p48 subunit of mouse PTF1 binds to RBP-Jkappa/CBF-1, the intracellular mediator of Notch signalling, and is expressed in the neural tube of early stage embryos. Genes to Cells: Devoted to Molecular and Cellular Mechanisms 6(4): 345-360
Cantoni, C.; Falco, M.; Pessino, A.; Moretta, A.; Moretta, L.; Biassoni, R. 1999: P49, a putative HLA-G1 specific inhibitory NK receptor belonging to the immunoglobulin Superfamily. Journal of Reproductive Immunology 43(2): 157-165
Scholz, G.; Hartson, S.D.; Cartledge, K.; Hall, N.; Shao, J.; Dunn, A.R.; Matts, R.L. 2000: P50(Cdc37) can buffer the temperature-sensitive properties of a mutant of Hck. Molecular and Cellular Biology 20(18): 6984-6995
Grammatikakis, N.; Lin, J.H.; Grammatikakis, A.; Tsichlis, P.N.; Cochran, B.H. 1999: P50(cdc37) acting in concert with Hsp90 is required for Raf-1 function. Molecular and Cellular Biology 19(3): 1661-1672
Hartson, S.D.; Irwin, A.D.; Shao, J.; Scroggins, B.T.; Volk, L.; Huang, W.; Matts, R.L. 2000: P50(cdc37) is a nonexclusive Hsp90 cohort which participates intimately in Hsp90-mediated folding of immature kinase molecules. Biochemistry 39(25): 7631-7644
Jawhari, A.; Lainé, J-Philippe.; Dubaele, S.; Lamour, Vérie.; Poterszman, A.; Coin, Fédéric.; Moras, D.; Egly, J-Marc. 2002: p52 Mediates XPB function within the transcription/repair factor TFIIH. Journal of Biological Chemistry 277(35): 31761-31767
Müller, M.; Wilder, S.; Bannasch, D.; Israeli, D.; Lehlbach, K.; Li-Weber, M.; Friedman, S.L.; Galle, P.R.; Stremmel, W.; Oren, M.; Krammer, P.H. 1998: P53 Activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. Journal of Experimental Medicine 188(11): 2033-2045
Miller, S.J.; Suthiphongchai, T.; Zambetti, G.P.; Ewen, M.E. 2000: P53 Binds selectively to the 5' untranslated region of cdk4, an RNA element necessary and sufficient for transforming growth factor beta- and p53-mediated translational inhibition of cdk4. Molecular and Cellular Biology 20(22): 8420-8431
Zotchev, S.B.; Protopopova, M.; Selivanova, G. 2000: P53 C-terminal interaction with DNA ends and gaps has opposing effect on specific DNA binding by the core. Nucleic Acids Research 28(20): 4005-4012
McLure, K.G.; Lee, P.W. 1999: p53 DNA binding can be modulated by factors that alter the conformational equilibrium. EMBO Journal 18(3): 763-770
Thanos, C.D.; Bowie, J.U. 1999: p53 Family members p63 and p73 are SAM domain-containing proteins. Protein Science: a Publication of the Protein Society 8(8): 1708-1710
Kawasaki, H.; Ogura, T.; Yokose, T.; Nagai, K.; Nishiwaki, Y.; Esumi, H. 2001: p53 gene alteration in atypical epithelial lesions and carcinoma in patients with idiopathic pulmonary fibrosis. Human Pathology 32(10): 1043-1049
Lang, S.; Marchesani, M.; Servomaa, K.; Kauppinen, L.; Jänne, J.; Rytömaa, T.; Wells, R.; Lun, M.; Elkind, M.M. 1999: P53 Gene mutations in neoplastic transformation of C3H 10T1/2 and severe combined immunodeficiency fibroblasts. Mutation Research 434(1): 61-65
Petmitr, S.; Makthiengtrong, S.; Sutinont, P.; Migasena, P. 1999: p53 gene mutations in non-small cell lung cancer from Thai patients. Journal of the Medical Association of Thailand 82(3): 250-255
Steiner, G.; Bierhoff, E.; Schmidt, D.; Leissner, J.; Wolf, H.K.; Albers, P. 2000: P53 immunoreactivity in biopsy specimens of T1G3 transitional cell carcinoma of the bladder--a helpful parameter in guiding the decision for or against cystectomy?. European Journal of Cancer 36(5): 610-614
Bachelder, R.E.; Ribick, M.J.; Marchetti, A.; Falcioni, R.; Soddu, S.; Davis, K.R.; Mercurio, A.M. 1999: P53 inhibits alpha 6 beta 4 integrin survival signaling by promoting the caspase 3-dependent cleavage of AKT/PKB. Journal of Cell Biology 147(5): 1063-1072
Quintanilla-Martinez, L.; Kremer, M.; Keller, G.; Nathrath, M.; Gamboa-Dominguez, A.; Meneses, A.; Luna-Contreras, L.; Cabras, A.; Hoefler, H.; Mohar, A.; Fend, F. 2001: p53 Mutations in nasal natural killer/T-cell lymphoma from Mexico: association with large cell morphology and advanced disease. American Journal of Pathology 159(6): 2095-2105
Navone, N.M.; Labate, M.E.; Troncoso, P.; Pisters, L.L.; Conti, C.J.; Von Eschenbach, A.C.; Logothetis, C.J. 1999: P53 Mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. Journal of Urology 161(1): 304-308
Chang, N.S.; Carey, G.; Pratt, N.; Chu, E.; Ou, M. 1998: P53 overexpression and downregulation of inter-alpha-inhibitor are associated with hyaluronidase enhancement of TNF cytotoxicity in L929 fibroblasts. Cancer Letters 131(1): 45-54
Vital, A.; Loiseau, H.; Kantor, G.; Daucourt, V.; Chene, G.; Cohadon, F.; Rougier, A.; Rivel, J.; Vital, C. 1999: p53 protein expression in grade II astrocytomas: immunohistochemical study of 100 cases with long-term follow-up. Pathology Research and Practice 194(12): 831-836
Aguiar, P.H.; Agner, C.; Simm, R.; Freitas, A.B.; Tsanaclis, A.M.C.; Plese, P. 2002: p53 Protein expression in meningiomas - a clinicopathologic study of 55 patients. Neurosurgical Review 25(4): 252-257
Goodrum, F.D.; Ornelles, D.A. 1998: P53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. Journal of Virology 72(12): 9479-9490
Xing, J.; Sheppard, H.M.; Corneillie, S.I.; Liu, X. 2001: p53 Stimulates TFIID-TFIIA-promoter complex assembly, and p53-T antigen complex inhibits TATA binding protein-TATA interaction. Molecular and Cellular Biology 21(11): 3652-3661
Schlechte, H.; Lenk, S.V.; Löning, T.; Schnorr, D.; Rudolph, B.D.; Ditscherlein, G.; Loening, S.A. 1998: p53 tumour suppressor gene mutations in benign prostatic hyperplasia and prostate cancer. European Urology 34(5): 433-440
Nichols, N.M.; Matthews, K.S. 2001: p53 unfolding detected by CD but not by tryptophan fluorescence. Biochemical and Biophysical Research Communications 288(1): 111-115
Gruszka-Westwood, A.M.; Hamoudi, R.A.; Matutes, E.; Tuset, E.; Catovsky, D. 2001: P53 abnormalities in splenic lymphoma with villous lymphocytes. Blood 97(11): 3552-3558
Sigurdsson, S.; Bödvarsdottir, S.K.; Anamthawat-Jonsson, K.; Steinarsdottir, M.; Jonasson, J.G.; Ogmundsdottir, H.M.; Eyfjörd, J.E. 2000: P53 abnormality and chromosomal instability in the same breast tumor cells. Cancer Genetics and Cytogenetics 121(2): 150-155
Borre, M.; Stausbol-Gron, B.; Overgaard, J. 2000: P53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting. Journal of Urology 164(3 Pt 1): 716-721
Bergan, A.; Gladhaug, I.P.; Schjolberg, A.; Bergan, A.B.; Clausen, O.P. 2000: P53 accumulation confers prognostic information in resectable adenocarcinomas with ductal but not with intestinal differentiation in the pancreatic head. International Journal of Oncology 17(5): 921-926
Gorgoulis, V.G.; Zacharatos, P.; Kotsinas, A.; Kletsas, D.; Mariatos, G.; Zoumpourlis, V.; Ryan, K.M.; Kittas, C.; Papavassiliou, A.G. 2003: p53 activates ICAM-1 (CD54) expression in an NF-kappaB-independent manner. EMBO Journal 22(7): 1567-1578
Regula, K.M.; Kirshenbaum, L.A. 2001: p53 activates the mitochondrial death pathway and apoptosis of ventricular myocytes independent of de novo gene transcription. Journal of Molecular and Cellular Cardiology 33(8): 1435-1445
Wang, X.; Michael, D.; de Murcia, G.; Oren, M. 2002: p53 Activation by nitric oxide involves down-regulation of Mdm2. Journal of Biological Chemistry 277(18): 15697-15702
Yahagi, N.; Shimano, H.; Matsuzaka, T.; Najima, Y.; Sekiya, M.; Nakagawa, Y.; Ide, T.; Tomita, S.; Okazaki, H.; Tamura, Y.; Iizuka, Y.; Ohashi, K.; Gotoda, T.; Nagai, R.; Kimura, S.; Ishibashi, S.; Osuga, J-Ichi.; Yamada, N. 2003: p53 Activation in adipocytes of obese mice. Journal of Biological Chemistry 278(28): 25395-25400
Brito-Babapulle, V.; Hamoudi, R.; Matutes, E.; Watson, S.; Kaczmarek, P.; Maljaie, H.; Catovsky, D. 2000: P53 allele deletion and protein accumulation occurs in the absence of p53 gene mutation in T-prolymphocytic leukaemia and Sezary syndrome. British Journal of Haematology 110(1): 180-187
Rodrigo, J.P.; Coto, E.; González, M.V.; Maldonado, M.; Suárez, C. 2001: P53 allelic loss and outcome in patients with squamous cell carcinoma of the head and neck. European Archives of Oto-Rhino-Laryngology: Official Journal of the European Federation of Oto-Rhino-Laryngological Societies: Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 258(5): 255-258
Cheng, L.; Leibovich, B.C.; Bergstralh, E.J.; Scherer, B.G.; Pacelli, A.; Ramnani, D.M.; Zincke, H.; Bostwick, D.G. 1999: P53 alteration in regional lymph node metastases from prostate carcinoma: A marker for progression?. Cancer 85(11): 2455-2459
van Nederveen, F.H.; Dannenberg, H.; Sleddens, H.F.B.M.; de Krijger, R.R.; Dinjens, W.N.M. 2003: p53 alterations and their relationship to SDHD mutations in parasympathetic paragangliomas. Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology Inc 16(9): 849-856
Arranz-Salas, I.; Sanz-Trelles, A.; Ojeda, D.Bautista. 2003: p53 alterations in porokeratosis. Journal of Cutaneous Pathology 30(7): 455-458
Ganly, I.; Soutar, D.S.; Brown, R.; Kaye, S.B. 2000: p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy. British Journal of Cancer 82(2): 392-398
Cabelguenne, A.; Blons, H.; de Waziers, I.; Carnot, F.; Houllier, A.M.; Soussi, T.; Brasnu, D.; Beaune, P.; Laccourreye, O.; Laurent-Puig, P. 2000: P53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: A prospective series. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 18(7): 1465-1473
Hong, T.M.; Chen, J.J.; Peck, K.; Yang, P.C.; Wu, C.W. 2000: p53 amino acids 339-346 represent the minimal p53 repression domain. Journal of Biological Chemistry 276(2): 1510-1515
Gottschlich, S.; Maune, S.; Preugschat, J.; Hoffmann, M.; Werner, J.A.; Maass, J.D.; Görögh, T.; Heidorn, K.; Rudert, H. 2000: p53 analysis of laryngeal cancer in exon 4 to 9. Anticancer Research 20(4): 2613-2616
Ishiyama, A.; Yamaoka, H.; Kohno, T.; Doi, T.; Shimada, H. 1998: P53 and BCA225 immunoreactions in breast cancer and their relationship to clinical and pathological features. Yokohama Medical Bulletin 46(5-6): 17-22
Zeng, Q.; Oakley, B. 1999: P53 and Bax: Putative death factors in taste cell turnover. Journal of Comparative Neurology 413(1): 168-180
Schwandner, O.; Schiedeck, T.H.; Bruch, H.P.; Duchrow, M.; Windhoevel, U.; Broll, R. 2000: P53 and Bcl-2 as significant predictors of recurrence and survival in rectal cancer. European Journal of Cancer 36(3): 348-356
A.Bozom, Issam, A. 2000: P53 and Bcl-2 oncoprotein expression in placentas with hydropic changes and partial and complete moles. APMIS 108(11): 756-760
Morgan, M.; Koorey, D.; Painter, D.; Findlay, M.; Newland, R.; Chapuis, P.; Solomon, M. 2003: p53 and DCC immunohistochemistry in curative rectal cancer surgery. International Journal of Colorectal Disease 18(3): 188-195
Yin, Y.; Stahl, B.C.; Dewolf, W.C.; Morgentaler, A. 2002: P53 and Fas are sequential mechanisms of testicular germ cell apoptosis. Journal of Andrology 23(1): 64-70
Gen, H.; Yamamoto, S.; Morimura, K.; Min, W.; Mitsuhashi, M.; Murai, T.; Mori, S.; Hosono, M.; Oohara, T.; Makino, S.; Wanibuchi, H.; Fukushima, S. 2001: p53 and H-ras mutations and microsatellite instability in renal pelvic carcinomas of NON / Shi mice treated with N-butyl-N-(4-hydroxybutyl)-nitrosamine: different genetic alteration from urinary bladder carcinoma. Japanese Journal of Cancer Research: Gann 92(12): 1278-1283
Grimberg, A. 2000: P53 and IGFBP-3: apoptosis and cancer protection. Molecular Genetics and Metabolism 70(2): 85-98
Tortola, S.; Marcuello, E.; González, I.; Reyes, G.; Arribas, R.; Aiza, G.; Sancho, F.J.; Peinado, M.A.; Capella, G. 1999: p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 17(5): 1375-1381
Servomaa, K.; Kiuru, A.; Kosma, V.M.; Hirvikoski, P.; Rytömaa, T. 2000: p53 and K-ras gene mutations in carcinoma of the rectum among Finnish women. Molecular Pathology: Mp 53(1): 24-30
Vähäkangas, K.H.; Bennett, W.P.; Castrén, K.; Welsh, J.A.; Khan, M.A.; Blömeke, B.; Alavanja, M.C.; Harris, C.C. 2001: P53 and K-ras mutations in lung cancers from former and never-smoking women. Cancer Research 61(11): 4350-4356
Couture, C.; Raybaud-Diogène, Hélène.; Têtu, B.; Bairati, I.; Murry, D.; Allard, Jée.; Fortin, Aé. 2002: P53 and Ki-67 as markers of radioresistance in head and neck carcinoma. Cancer 94(3): 713-722
Koelbl, O.; Rosenwald, A.; Haberl, M.; Müller, J.; Reuther, J.; Flentje, M. 2001: P53 and Ki-67 as predictive markers for radiosensitivity in squamous cell carcinoma of the oral cavity? An immunohistochemical and clinicopathologic study. International Journal of Radiation Oncology Biology Physics 49(1): 147-154
Testino, G.; Gada, D.; De Iaco, F.; Cornaggia, M. 2002: p53 and Ki-67 expression in epithelial gastric dysplasia and in gastric cancer. Panminerva Medica 44(4): 369-371
Bouzourene, H.; Gervaz, P.; Cerottini, J.P.; Benhattar, J.; Chaubert, P.; Saraga, E.; Pampallona, S.; Bosman, F.T.; Givel, J.C. 2000: P53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer. European Journal of Cancer 36(8): 1008-1015
Latonen, L.; Kurki, S.; Pitkanen, K.; Laiho, M. 2003: P53 and MDM2 are regulated by PI-3-kinases on multiple levels under stress induced by UV radiation and proteasome dysfunction. Cellular Signalling 15(1): 95-102
Ambrosch, P.; Ruschenburg, I. 2000: p53 and MDM2 protein expression in squamous cell carcinoma and neighboring dysplasia from the upper aerodigestive tract. Anticancer Research 20(5a): 3151-3155
Warnakulasuriya, S.; Jia, C.; Johnson, N.; Houghton, J. 2000: p53 and P-glycoprotein expression are significant prognostic markers in advanced head and neck cancer treated with chemo/radiotherapy. Journal of Pathology 191(1): 33-38
Seki, M.; Iwakawa, J.; Cheng, H.; Cheng, P-Wan. 2002: p53 and PTEN/MMAC1/TEP1 gene therapy of human prostate PC-3 carcinoma xenograft, using transferrin-facilitated lipofection gene delivery strategy. Human Gene Therapy 13(6): 761-773
Tabas, I. 2001: P53 and atherosclerosis. Circulation Research 88(8): 747-749
Oxley, J.D.; Winkler, M.H.; Parry, K.; Brewster, S.; Abbott, C.; Gillatt, D.A. 2002: P53 and bcl-2 immunohistochemistry in preoperative biopsies as predictors of biochemical recurrence after radical prostatectomy. BJU International 89(1): 27-32
Stackhouse, G.B.; Sesterhenn, I.A.; Bauer, J.J.; Mostofi, F.K.; Connelly, R.R.; Srivastava, S.K.; Moul, J.W. 1999: P53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. Journal of Urology 162(6): 2040-2045
Geisler, J.P.; Geisler, H.E.; Miller, G.A.; Wiemann, M.C.; Zhou, Z.; Crabtree, W. 2000: p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months. Gynecologic Oncology 77(2): 278-282
Walsh, S.V.; Loda, M.; Torres, C.M.; Antonioli, D.; Odze, R.D. 1999: P53 and beta catenin expression in chronic ulcerative colitis--associated polypoid dysplasia and sporadic adenomas: an immunohistochemical study. American Journal of Surgical Pathology 23(8): 963-969
Ziyaie, D.; Hupp, T.R.; Thompson, A.M. 2000: P53 and breast cancer. Breast 9(5): 239-246
Scherer, S.J.; Maier, S.M.; Seifert, M.; Hanselmann, R.G.; Zang, K.D.; Muller-Hermelink, H.K.; Angel, P.; Welter, C.; Schartl, M. 2000: p53 and c-Jun functionally synergize in the regulation of the DNA repair gene hMSH2 in response to UV. Journal of Biological Chemistry 275(48): 37469-37473
Chen, H.H.W.; Su, W-Chou.; Guo, H-Ran.; Chang, T-Wang.; Lee, W-Ying. 2002: P53 and c-erbB-2 but not bcl-2 are predictive of metastasis-free survival in breast cancer patients receiving post-mastectomy adjuvant radiotherapy in Taiwan. Japanese Journal of Clinical Oncology 32(9): 332-339
Kataki, A.; Sotirianakos, S.; Memos, N.; Karayiannis, M.; Messaris, E.; Leandros, E.; Manouras, A.; Androulakis, G. 2003: P53 and C-FOS overexpression in patients with thyroid cancer: an immunohistochemical study. Neoplasma 50(1): 26-30
Marcatili, A.; D'Isanto, M.; Vitiello, M.; Galdiero, R.; Galdiero, M. 2002: p53 and c-myc activation by Pasteurella haemolytica leukotoxin is correlated with bovine mononuclear cells apoptosis. New Microbiologica 25(2): 195-204
McGill, G.; Fisher, D.E. 1999: P53 and cancer therapy: a double-edged sword. Journal of Clinical Investigation 104(3): 223-225
North, S.; Hainaut, P. 2000: p53 and cell-cycle control: a finger in every pie. Pathologie-Biologie 48(3): 255-270
Castle, J.T.; Cardinali, M.; Kratochvil, F.J.; Abbondanzo, S.L.; Kessler, H.P.; Auclair, P.L.; Yeudall, W.A. 1999: P53 and cyclin D1 staining patterns of malignant and premalignant oral lesions in age-dependent populations. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics 88(3): 326-332
Sonoda, Y.; Saigo, P.E.; Boyd, J. 1999: P53 and genetic susceptibility to cervical cancer. Journal of the National Cancer Institute 91(6): 557
Aizu, W.; Guda, K.; Nambiar, P.; Xin, T.; Thibodeau, M.; Rosenberg, D.W.; Giardina, C. 2003: P53 and its co-activator p300 are inversely regulated in the mouse colon in response to carcinogen. Toxicology Letters 144(2): 213-224
Rodríguez-Alonso, Aés.; Pita-Fernández, S.; González-Carreró, Jín.; Nogueira-March, Jé.Luis. 2002: P53 and ki67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma. European Urology 41(2): 182-8; discussion 188-9
Solenthaler, M.; Matutes, E.; Brito-Babapulle, V.; Morilla, R.; Catovsky, D. 2002: p53 and mdm2 in mantle cell lymphoma in leukemic phase. Haematologica 87(11): 1141-1150
Reiher, F.; Ozer, O.; Pins, M.; Jovanovic, B.D.; Eggener, S.; Campbell, S.C. 2002: P53 and microvessel density in primary resection specimens of superficial bladder cancer. Journal of Urology 167(3): 1469-1474
Ashktorab, H.; Ahmed, A.; Littleton, G.; Wang, X.W.; Allen, C.R.; Tackey, R.; Walters, C.; Smoot, D.T. 2003: P53 and p14 increase sensitivity of gastric cells to H. pylori-induced apoptosis. Digestive Diseases and Sciences 48(7): 1284-1291
Gamieldien, W.; Victor, T.C.; Mugwanya, D.; Stepien, A.; Gelderblom, W.C.; Marasas, W.F.; Geiger, D.H.; van Helden, P.D. 1998: P53 and p16/CDKN2 gene mutations in esophageal tumors from a high-incidence area in South Africa. International Journal of Cancer 78(5): 544-549
Huang, L.W.; Chou, Y.Y.; Chao, S.L.; Chen, T.J.; Lee, T.T. 2001: p53 and p21 expression in precancerous lesions and carcinomas of the uterine cervix: overexpression of p53 predicts poor disease outcome. Gynecologic Oncology 83(2): 348-354
Minella, A.C.; Swanger, J.; Bryant, E.; Welcker, M.; Hwang, H.; Clurman, B.E. 2002: P53 and p21 form an inducible barrier that protects cells against cyclin E-cdk2 deregulation. Current Biology: Cb 12(21): 1817-1827
Zhao, B.; Kimura, W.; Futakawa, N.; Muto, T.; Kubota, K.; Harihara, Y.; Takayama, T.; Makuuchi, M. 1999: P53 and p21/Waf1 protein expression and K-ras codon 12 mutation in carcinoma of the papilla of Vater. American Journal of Gastroenterology 94(8): 2128-2134
Divan, A.; Lawry, J.; Dunsmore, I.R.; Parsons, M.A.; Royds, J.A. 2001: p53 and p21waf-1 expression correlates with apoptosis or cell survival in poorly differentiated, but not well-differentiated, retinoblastomas. Cancer Research 61(7): 3157-3163
Koistinen, P.; Siitonen, T.; Mäntymaa, P.; Savolainen, E.R. 2001: P53 and redox state in etoposide-induced acute myeloblastic leukemia cell death. Leukemia Research 25(12): 1099-1105
Adimoolam, S.; Ford, J.M. 2003: P53 and regulation of DNA damage recognition during nucleotide excision repair. DNA Repair 2(9): 947-954
Sengupta, P.S.; Mcgown, A.T.; Bajaj, V.; Blackhall, F.; Swindell, R.; Bromley, M.; Shanks, J.H.; Ward, T.; Buckley, C.H.; Reynolds, K.; Slade, R.J.; Jayson, G.C. 2000: P53 and related proteins in epithelial ovarian cancer. European Journal of Cancer 36(18): 2317-2328
Gentile, M.; Bergman Jungestrom, M.; Olsen, K.E.; Soderkvist, P.; Wingren, S. 1999: P53 and survival in early onset breast cancer: Analysis of gene mutations, loss of heterozygosity and protein accumulation. European Journal of Cancer 35(8): 1202-1207
Fulci, G.; Van Meir, E.G. 1999: p53 and the CNS: tumors and developmental abnormalities. Molecular Neurobiology 19(1): 61-77
Fernández-Salas, E.; Sagar, M.; Cheng, C.; Yuspa, S.H.; Weinberg, W.C. 1999: p53 and tumor necrosis factor alpha regulate the expression of a mitochondrial chloride channel protein. Journal of Biological Chemistry 274(51): 36488-36497
Linderholm, B.; Lindh, B.; Tavelin, B.; Grankvist, K.; Henriksson, R. 2000: P53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. International Journal of Cancer 89(1): 51-62
Soussi, T. 2000: p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Research 60(7): 1777-1788
Hill, K.A.; Sommer, S.S. 2002: P53 as a mutagen test in breast cancer. Environmental and Molecular Mutagenesis 39(2-3): 216-227
Lopes, A.; Bezerra, A.Licio.R.; Pinto, C.Antonio.Lopes.; Serrano, S.Vicente.; de MellO, C.Abdon.; Villa, L.Lina. 2002: P53 as a new prognostic factor for lymph node metastasis in penile carcinoma: Analysis of 82 patients treated with amputation and bilateral lymphadenectomy. Journal of Urology 168(1): 81-86
Sredni, S.T.; Zerbini, M.C.N.; Latorre, M.R.; Alves, V.A.F. 2003: P53 as a prognostic factor in adrenocortical tumors of adults and children. Brazilian Journal of Medical and Biological Research 36(1): 23-27
Makino, M.; Yamane, N.; Taniguchi, T.; Honboh, T.; Kurayoshi, K.; Kaibara, N. 2000: P53 as an indicator of lymph node metastases in invasive early colorectal cancer. Anticancer Research 20(3b): 2055-2059
Gottschlich, S.; Hoffmann, M.; Maass, J.D.; Görörgh, T.; Buhmann, V.; Hoffmann-Fazel, A.; Rudert, H.; Maune, S. 2003: P53 autoantibodies as tumor marker in head and neck squamous cell cancer. Anticancer Research 23(2a): 913-915
Regele, S.; Vogl, F.D.; Kohler, T.; Kreienberg, R.; Runnebaum, I.B. 2003: p53 autoantibodies can be indicative of the development of breast cancer relapse. Anticancer Research 23(1b): 761-764
Creaney, J.; McLaren, B.M.; Stevenson, S.; Musk, A.W.; de Klerk, N.; Robinson, B.W.; Lake, R.A. 2001: p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression. British Journal of Cancer 84(1): 52-56
Vogl, F.D.; Stickeler, E.; Weyermann, M.; Köhler, T.; Grill, H.J.; Negri, G.; Kreienberg, R.; Runnebaum, I.B. 1999: p53 autoantibodies in patients with primary ovarian cancer are associated with higher age, advanced stage and a higher proportion of p53-positive tumor cells. Oncology 57(4): 324-329
Lang, C.; Unteregger, G.; Kartarius, S.; Günther, J.; Bonkhoff, H.; Montenarh, M.; Zwergel, T. 1998: P53 autoantibodies in patients with urological tumours. British Journal of Urology 82(5): 721-726
Broll, R.; Duchrow, M.; Oevermann, E.; Wellm, C.; Schwandner, O.; Schimmelpenning, H.; Roblick, U.J.; Bruch, H.P.; Windhövel, U. 2001: P53 autoantibodies in sera of patients with a colorectal cancer and their association to p53 protein concentration and p53 immunohistochemistry in tumor tissue. International Journal of Colorectal Disease 16(1): 22-27
Ward, I.M.; Minn, K.; Van Deursen, J.; Chen, J. 2003: P53 binding protein 53BP1 is required for DNA damage responses and tumor suppression in mice. Molecular and Cellular Biology 23(7): 2556-2563
Tan, T.; Chu, G. 2002: P53 binds and activates the xeroderma pigmentosum DDB2 gene in humans but not mice. Molecular and Cellular Biology 22(10): 3247-3254
Stansel, R.M.; Subramanian, D.; Griffith, J.D. 2002: p53 binds telomeric single strand overhangs and t-loop junctions in vitro. Journal of Biological Chemistry 277(14): 11625-11628
Wetzel, C.C.; Berberich, S.J. 2001: P53 binds to cisplatin-damaged DNA. Biochimica et Biophysica Acta 1517(3): 392-397
Arora, D.S.; Ramsdale, J.; Lodge, J.P.; Wyatt, J.I. 1999: P53 but not bcl-2 is expressed by most cholangiocarcinomas: A study of 28 cases. Histopathology 34(6): 497-501
Morel, A.P.; Unsal, K.; Cagatay, T.; Ponchel, F.; Carr, B.; Ozturk, M. 2000: P53 but not p16INK4a induces growth arrest in retinoblastoma-deficient hepatocellular carcinoma cells. Journal of Hepatology 33(2): 254-265
Tweddle, D.A.; Malcolm, A.J.; Cole, M.; Pearson, A.D.; Lunec, J. 2001: p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells. American Journal of Pathology 158(6): 2067-2077
Giannoudis, A.; Graham, D.A.; Southern, S.A.; Herrington, C.S. 1999: P53 codon 72 Arg/Pro polymorphism is not related to HPV type or lesion grade in low- and high-grade squamous intra-epithelial lesions and invasive squamous carcinoma of the cervix. International Journal of Cancer 83(1): 66-69
Bonafè, M.; Salvioli, S.; Barbi, C.; Mishto, M.; Trapassi, C.; Gemelli, C.; Storci, G.; Olivieri, F.; Monti, D.; Franceschi, C. 2002: P53 codon 72 genotype affects apoptosis by cytosine arabinoside in blood leukocytes. Biochemical and Biophysical Research Communications 299(4): 539-541
Li, T.; Lu, Z-Ming.; Guo, M.; Wu, Q-Jiao.; Chen, K-Neng.; Xing, H-Ping.; Mei, Q.; Ke, Y. 2002: p53 codon 72 polymorphism (C/G) and the risk of human papillomavirus-associated carcinomas in China. Cancer 95(12): 2571-2576
O'Connor, D.P.; Kay, E.W.; Leader, M.; Atkins, G.J.; Murphy, G.M.; Mabruk, M.J. 2001: P53 codon 72 polymorphism and human papillomavirus associated skin cancer. Journal of Clinical Pathology 54(7): 539-542
Soulitzis, N.; Sourvinos, G.; Dokianakis, D.N.; Spandidos, D.A. 2002: P53 codon 72 polymorphism and its association with bladder cancer. Cancer Letters 179(2): 175-183
Lee, Y.H.; Kim, Y.R.; Ji, J.D.; Sohn, J.; Song, G.G. 2001: p53 codon 72 polymorphism and rheumatoid arthritis. Journal of Rheumatology 28(11): 2392-2394
Baek, W.K.; Cho, J.W.; Suh, S.I.; Suh, M.H.; Shin, D.H.; Cho, C.H.; Lee, T.S.; Cha, S.D. 2000: p53 codon 72 polymorphism and risk of cervical carcinoma in Korean women. Journal of Korean Medical Science 15(1): 65-67
Zehbe, I.; Voglino, G.; Wilander, E.; Delius, H.; Marongiu, A.; Edler, L.; Klimek, F.; Andersson, S.; Tommasino, M. 2001: p53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development. Cancer Research 61(2): 608-611
Dokianakis, D.N.; Spandidos, D.A. 2000: P53 codon 72 polymorphism as a risk factor in the development of HPV-associated cervical cancer. Molecular Cell Biology Research Communications: Mcbrc 3(2): 111-114
Dokianakis, D.N.; Koumantaki, E.; Billiri, K.; Spandidos, D.A. 2000: P53 codon 72 polymorphism as a risk factor in the development of HPV-associated non-melanoma skin cancers in immunocompetent hosts. International Journal of Molecular Medicine 5(4): 405-409
Papadakis, E.N.; Dokianakis, D.N.; Spandidos, D.A. 2000: p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Molecular Cell Biology Research Communications: Mcbrc 3(6): 389-392
Tenti, P.; Vesentini, N.; Rondo Spaudo, M.; Zappatore, R.; Migliora, P.; Carnevali, L.; Ranzani, G.N. 2000: p53 codon 72 polymorphism does not affect the risk of cervical cancer in patients from northern Italy. Cancer Epidemiology Biomarkers and Prevention: a Publication of the American Association for Cancer Research Cosponsored by the American Society of Preventive Oncology 9(4): 435-438
Manfredi, S.; Masetti, S.; Botto, N.; Colombo, M.Giovanna.; Terrazzi, M.; Vassalle, C.; Biagini, A.; Andreassi, M.Grazia. 2002: P53 codon 72 polymorphism in coronary artery disease: no evidence for association with increased risk or micronucleus frequency. Environmental and Molecular Mutagenesis 40(2): 110-115
Hiyama, T.; Tanaka, S.; Kitadai, Y.; Ito, M.; Sumii, M.; Yoshihara, M.; Shimamoto, F.; Haruma, K.; Chayama, K. 2002: p53 Codon 72 polymorphism in gastric cancer susceptibility in patients with Helicobacter pylori-associated chronic gastritis. International Journal of Cancer 100(3): 304-308
Rosenthal, A.N.; Ryan, A.; Hopster, D.; Jacobs, I.J. 2000: p53 codon 72 polymorphism in vulval cancer and vulval intraepithelial neoplasia. British Journal of Cancer 83(10): 1287-1290
Lloyd, D.R.; Hanawalt, P.C. 2002: p53 controls global nucleotide excision repair of low levels of structurally diverse benzo(g)chrysene-DNA adducts in human fibroblasts. Cancer Research 62(18): 5288-5294
Schwartz, D.; Goldfinger, N.; Kam, Z.; Rotter, V. 1999: p53 controls low DNA damage-dependent premeiotic checkpoint and facilitates DNA repair during spermatogenesis. Cell Growth and Differentiation: the Molecular Biology Journal of the American Association for Cancer Research 10(10): 665-675
Chang, P.Y.; Kanazawa, N.; Lutze-Mann, L.; Winegar, R.A.; Chang, P.Y. 2001: P53 deficiency alters the yield and spectrum of radiation-induced lacZ mutants in the brain of transgenic mice. Mutagenesis 16(1): 7-15
Baek, K-Hyuck.; Shin, H-Jin.; Yoo, J-Kwang.; Cho, J-Ho.; Choi, Y-Han.; Sung, Y-Chul.; McKeon, F.; Lee, C-Woo. 2003: P53 deficiency and defective mitotic checkpoint in proliferating T lymphocytes increase chromosomal instability through aberrant exit from mitotic arrest. Journal of Leukocyte Biology 73(6): 850-861
Mao, Y.; Okada, S.; Chang, L.S.; Muller, M.T. 2000: p53 dependence of topoisomerase I recruitment in vivo. Cancer Research 60(16): 4538-4543
Datta, K.; Babbar, P.; Srivastava, T.; Sinha, S.; Chattopadhyay, P. 2002: P53 dependent apoptosis in glioma cell lines in response to hydrogen peroxide induced oxidative stress. International Journal of Biochemistry and Cell Biology 34(2): 148-157
Heinze, T.; Greiner-Mai, E.; Lichtenegger, W. 1999: p53 determination in gynecological carcinomas: immunohistochemistry compared to luminometric immunoassay (LIA). Anticancer Research 19(4a): 2505-2508
Tang, W.; Willers, H.; Powell, S.N. 1999: p53 directly enhances rejoining of DNA double-strand breaks with cohesive ends in gamma-irradiated mouse fibroblasts. Cancer Research 59(11): 2562-2565
Ciciarello, M.; Mangiacasale, R.; Casenghi, M.; Zaira Limongi, M.; D'Angelo, M.; Soddu, S.; Lavia, P.; Cundari, E. 2001: p53 displacement from centrosomes and p53-mediated G1 arrest following transient inhibition of the mitotic spindle. Journal of Biological Chemistry 276(22): 19205-19213
Sablina, A.A.; Agapova, L.S.; Chumakov, P.M.; Kopnin, B.P. 1999: p53 does not control the spindle assembly cell cycle checkpoint but mediates G1 arrest in response to disruption of microtubule system. Cell Biology International 23(5): 323-334
Gottifredi, V.; Karni-Schmidt, O.; Shieh, S.S.; Prives, C. 2001: p53 down-regulates CHK1 through p21 and the retinoblastoma protein. Molecular and Cellular Biology 21(4): 1066-1076
Liu, G.; Schwartz, J.A.; Brooks, S.C. 1999: p53 down-regulates ER-responsive genes by interfering with the binding of ER to ERE. Biochemical and Biophysical Research Communications 264(2): 359-364
Yang, X.; Taylor, L.; Polgar, P. 2001: P53 down-regulates human bradykinin B1 receptor gene expression. Journal of Cellular Biochemistry 82(1): 38-45
Sun, Y.; Sun, Y.; Wenger, L.; Rutter, J.L.; Brinckerhoff, C.E.; Cheung, H.S. 1999: P53 down-regulates human matrix metalloproteinase-1 (collagenase-1) gene expression. Journal of Biological Chemistry 274(17): 11535-11540
Pettitt, A.R.; Sherrington, P.D.; Stewart, G.; Cawley, J.C.; Taylor, A.M.; Stankovic, T. 2001: P53 dysfunction in B-cell chronic lymphocytic leukemia: Inactivation of ATM as an alternative to TP53 mutation. Blood 98(3): 814-822
Hirose, Y.; Berger, M.S.; Pieper, R.O. 2001: P53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Research 61(5): 1957-1963
Pohl, U.; Wagenknecht, B.; Naumann, U.; Weller, M. 1999: P53 enhances BAK and CD95 expression in human malignant glioma cells but does not enhance CD95L-induced apoptosis. Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology Biochemistry and Pharmacology 9(1): 29-37
Marinone, C.; Martinetti, A.; Mestriner, M.; Seregni, E.; Geuna, M.; Ferrari, L.; Strola, G.; Bonardi, L.; Fea, E.; Bombardieri, E. 2001: P53 evaluation in gastric mucosa of patients with chronic Helicobacter pylori infection. Anticancer Research 21(2a): 1115-1118
Nio, Y.; Dong, M.; Uegaki, K.; Hirahara, N.; Minari, Y.; Sasaki, S.; Takamura, M.; Iguchi, C.; Tamura, K. 1998: P53 expression affects the efficacy of adjuvant chemotherapy after resection of invasive ductal carcinoma of the pancreas. Anticancer Research 18(5b): 3773-3779
Zalata, K.R.; Leech, S.H.; Ming, S-Chun.; Nasif, W.A.; Nada, N.A.; Mohamed, I.E.; Atallah, A.M.; Gad-el-Hak, N.A. 2002: P53 expression and DNA ploidy pattern in Egyptian colorectal carcinoma. Hepato-Gastroenterology 49(47): 1225-1229
Lennartsson, P.; Stenius, U.; Högberg, J. 1999: p53 expression and TGF-alpha-induced replication of hepatocytes isolated from rats exposed to the carcinogen diethylnitrosamine. Cell Biology and Toxicology 15(1): 31-39
Zhou-Jing-Jiao; Liu-Jian-Jun [author, Reprint-Author]; Xu-Shun-Xian; Liu-Jun; Wei-Yun 2003: P53 expression and genetic evidence for virus infection in cervical carcinoma. Virologica Sinica 18(3): 197-200
Dushku, N.; Hatcher, S.L.; Albert, D.M.; Reid, T.W. 1999: p53 expression and relation to human papillomavirus infection in pingueculae, pterygia, and limbal tumors. Archives of Ophthalmology 117(12): 1593-1599
Schmidt, M.; Bachhuber, A.; Victor, A.; Steiner, E.; Mahlke, M.; Lehr, H.A.; Pilch, H.; Weikel, W.; Knapstein, P.G. 2003: p53 expression and resistance against paclitaxel in patients with metastatic breast cancer. Journal of Cancer Research and Clinical Oncology 129(5): 295-302
Geisler, J.P.; Geisler, H.E.; Wiemann, M.C.; Zhou, Z.; Miller, G.A.; Crabtree, W. 1999: p53 expression as a prognostic indicator of 5-year survival in endometrial cancer. Gynecologic Oncology 74(3): 468-471
Di Bacco, A.M.A.; Cotter, T.G. 2002: P53 expression in K562 cells is associated with caspase-mediated cleavage of c-ABL and BCR-ABL protein kinases. British Journal of Haematology 117(3): 588-597
Isaksson, E.; Cline, J.M.; Skoog, L.; Söderqvist, G.; Wilking, N.; von Schoultz, E.; von Schoultz, B. 1999: P53 expression in breast and endometrium during estrogen and tamoxifen treatment of surgically postmenopausal cynomolgus macaques. Breast Cancer Research and Treatment 53(1): 61-67
Yoshida, M.; Kurisaka, M.; Mori, K. 1998: P53 expression in congenital experimental hydrocephalus induced by rat kidney antiserum. Medical Electron Microscopy 31(3): 121-127
Ljungberg, B.; Bozoky, B.; Kovacs, G.; Stattin, P.; Farrelly, E.; Nylander, K.; Landberg, G. 2001: P53 expression in correlation to clinical outcome in patients with renal cell carcinoma. Scandinavian Journal of Urology and Nephrology 35(1): 15-20
Galietti, F.; Bollo, E.; Cappia, S.; Dondo, A.; Pregel, P.; Nicali, R.; Pozzi, E. 2001: p53 expression in cultured blood human monocytes infected with mycobacterial strains. Panminerva Medica 43(4): 249-255
Rosen, A.C.; Ausch, C.; Klein, M.; Graf, A.H.; Metzenbauer, M.; Philipp, K.; Reiner, A. 2000: P53 expression in fallopian tube carcinomas. Cancer Letters 156(1): 1-7
Al-Bozom, I.A. 2001: P53 expression in gastrointestinal stromal tumors. Pathology International 51(7): 519-523
Marijnen, C.A.M.; Kapiteijn, E.; Nagtegaal, I.D.; Mulder-Stapel, A.A.; van de Velde, C.J.H.; Schrier, P.I.; Peltenburg, L.T.C.; van Krieken, J.Han.J.M. 2002: P53 expression in human rectal tissue after radiotherapy: Upregulation in normal mucosa versus functional loss in rectal carcinomas. International Journal of Radiation Oncology Biology Physics 52(3): 720-728
Lassaletta, L.; Brandáriz, J.A.; Benito, A.; de la Cruz, J.; Gómez, C.; Ballestín, C.; Hitt, R.; Colomer, R.; Alvarez-Vicent, J.J. 1999: P53 expression in locally advanced pharyngeal squamous cell carcinoma. Archives of Otolaryngology--Head and Neck Surgery 125(12): 1356-1359
Skacel, M.; Petras, R.E.; Rybicki, L.A.; Gramlich, T.L.; Richter, J.E.; Falk, G.W.; Goldblum, J.R. 2002: p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression. American Journal of Gastroenterology 97(10): 2508-2513
Ayhan, A.; Tuncer, Z.S.; Ayhan, A. 1998: p53 expression in ovarian carcinoma with regard to second-look findings. European Journal of Gynaecological Oncology 19(5): 501-502
Kalogeraki, A.; Panayiotides, J.; Tamiolakis, D.; Tzardi, M.; Chaniotis, V.; Chalkiadakis, G.; Melissas, J.; Stiftsis, D.; Kanavaros, P.; Delides, G.S. 2000: P53 expression in patients with malignant and benign breast diseases. Anticancer Research 20(3a): 1801-1805
Yasuda, M.; Kuwano, H.; Watanabe, M.; Toh, Y.; Ohno, S.; Sugimachi, K. 2000: P53 expression in squamous dysplasia associated with carcinoma of the oesophagus: evidence for field carcinogenesis. British Journal of Cancer 83(8): 1033-1038
Satoh, K.; Kihira, K.; Kawata, H.; Tokumaru, K.; Kumakura, Y.; Ishino, Y.; Kawakami, S.; Inoue, K.; Kojima, T.; Satoh, Y.; Mutoh, H.; Sugano, K. 2001: P53 expression in the gastric mucosa before and after eradication of Helicobacter pylori. Helicobacter 6(1): 31-36
Pokroy, R.; Tendler, Y.; Pollack, A.; Zinder, O.; Weisinger, G. 2002: p53 expression in the normal murine eye. IOVS Investigative Ophthalmology and Visual Science 43(6): 1736-1741
Maciel, M.do.Socorro.; Viegas, L.C.; Nonogaki, S.; Nishimoto, Iês.N.; Abrão, F.S.; Mourão Neto, Mário.; Brentani, M.Mitzi. 2002: P53 expression is a factor for prognostic assessment in breast sarcoma. Breast Cancer Research and Treatment 71(3): 193-202
Pizzi, C.; Panico, L.; De Marchis, L.; Mastranzo, P.; Di Maio, M.; D'Amico, C.; Limite, G.; Pettinato, G.; Cocozza, S.; Bianco, A.Raffaele.; Contegiacomo, A. 2002: P53 expression is decreased in primary breast carcinomas with microsatellite instability. Breast Cancer Research and Treatment 73(3): 257-266
Llopis, J.; Alcaraz, A.; Ribal, M.J.; Solé, M.; Ventura, P.J.; Barranco, M.A.; Rodriguez, A.; Corral, J.M.; Carretero, P. 2000: p53 expression predicts progression and poor survival in T1 bladder tumours. European Urology 37(6): 644-653
Auepemkiate, S.; Boonyaphiphat, P.; Thongsuksai, P. 2002: P53 expression related to the aggressive infiltrative histopathological feature of basal cell carcinoma. Histopathology 40(6): 568-573
Hiyama, T.; Tanaka, S.; Masuda, H.; Shima, H.; Kose, K.; Tuncel, H.; Ito, M.; Kitadai, Y.; Sumii, M.; Uemura, N.; Yoshihara, M.; Shimamoto, F.; Haruma, K.; Chayama, K. 2003: P53 expression, K-ras gene mutation and microsatellite instability in gastric B-cell lymphomas. Journal of Gastroenterology and Hepatology 18(9): 1047-1053
Burton, J.L.; Stewart, R.L.; Heatley, M.K.; Royds, J.A.; Wells, M. 1999: P53 expression, p21 expression and the apoptotic index in endometrioid endometrial adenocarcinoma. Histopathology 35(3): 221-229
Chang, K.W.; Sarraj, S.; Lin, S.C.; Tsai, P.I.; Solt, D. 2000: P53 expression, p53 and Ha-ras mutation and telomerase activation during nitrosamine-mediated hamster pouch carcinogenesis. Carcinogenesis 21(7): 1441-1451
Chowdhury, I.H.; Radonovich, M.; Mahieux, R.; Pise-Masison, C.; Muralidhar, S.; Brady, J.N. 2003: P53 facilitates degradation of human T-cell leukaemia virus type I Tax-binding protein through a proteasome-dependent pathway. Journal of General Virology 84(Pt 4): 897-906
Irwin, M.S.; Kaelin, W.G. 2001: P53 family update: p73 and p63 develop their own identities. Cell Growth and Differentiation: the Molecular Biology Journal of the American Association for Cancer Research 12(7): 337-349
Blagosklonny, M.V. 2000: p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect. FASEB Journal 14(13): 1901-1907
Medina, D.; Kittrell, F.S. 2003: p53 function is required for hormone-mediated protection of mouse mammary tumorigenesis. Cancer Research 63(19): 6140-6143
Camplejohn, R.S.; Rutherford, J. 2001: P53 functional assays: Detecting p53 mutations in both the germline and in sporadic tumours. Cell Proliferation 34(1): 1-14
Pezeshki, A.M.; Farjadian, S.; Talei, A.; Vasei, M.; Gharesi-Fard, B.; Doroudchi, M.; Ghaderi, A. 2001: P53 gene alteration and protein expression in Iranian women with infiltrative ductal breast carcinoma. Cancer Letters 169(1): 69-75
Chen, Y-Wen.; Jeng, Y-Ming.; Yeh, S-Hwei.; Chen, P-Jer. 2002: P53 gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia. Hepatology 36(4 Pt 1): 927-935
Vallianatou, K.; Brito-Babapulle, V.; Matutes, E.; Atkinson, S.; Catovsky, D. 1999: P53 gene deletion and trisomy 12 in hairy cell leukemia and its variant. Leukemia Research 23(11): 1041-1045
Paunesku, T.; Zhang, Y.; Gemmell, M.A.; Woloschak, G.E. 2000: P53 gene deletions in paraffin-preserved lymphoid tumors from irradiated mice. Leukemia Research 24(6): 511-517
Lan, Q.; Feng, Z.; Tian, D.; He, X.; Rothman, N.; Tian, L.; Lu, X.; Terry, M.B.; Mumford, J.L. 2001: P53 gene expression in relation to indoor exposure to unvented coal smoke in Xuan Wei, China. Journal of Occupational and Environmental Medicine 43(3): 226-230
Gao Zifen; Jiang Fen; Pan Zenggang 1999: P53 gene mutation and Epstein - Barr virus associated nasopharyngeal T - cell lymphomas. Zhongguo Zhongliu Linchuang 26(6): 429-432
Jiao, Y-Fei.; Nakamura, S-Ichi.; Sugai, T.; Habano, W.; Uesugi, N.; Oikawa, M.; Sato, T. 2002: P53 gene mutation and MDM2 overexpression in a case of primary malignant fibrous histiocytoma of the jejunum. Apmis: Acta Pathologica Microbiologica et Immunologica Scandinavica 110(2): 165-171
Fujiki, T.; Haraoka, S.; Yoshioka, S.; Ohshima, K.; Iwashita, A.; Kikuchi, M. 2002: P53 gene mutation and genetic instability in superficial multifocal esophageal squamous cell carcinoma. International Journal of Oncology 20(4): 669-679
Elsaleh, H.; Powell, B.; Soontrapornchai, P.; Joseph, D.; Goria, F.; Spry, N.; Iacopetta, B. 2000: P53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma. Oncology 58(1): 52-59
Angelopoulou, K.; Yu, H.; Bharaj, B.; Giai, M.; Diamandis, E.P. 2000: P53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer. Clinical Biochemistry 33(1): 53-62
Yoneda, K.; Yokoyama, T.; Yamamoto, T.; Hatabe, T.; Osaki, T. 1999: p53 gene mutations and p21 protein expression induced independently of p53, by TGF-beta and gamma-rays in squamous cell carcinoma cells. European Journal of Cancer 35(2): 278-283
Chen, P.M.; Chiou, T.J.; Hsieh, R.K.; Fan, F.S.; Chu, C.J.; Lin, C.Z.; Chiang, H.; Yen, C.C.; Wang, W.S.; Liu, J.H. 1999: P53 gene mutations and rearrangements in non-Hodgkin's lymphoma. Cancer 85(3): 718-724
Lee, H.J.; Kim, J.S.; Ha, S.J.; Roh, K.Y.; Seo, E.J.; Park, W.S.; Lee, J.Y.; Park, K.S.; Kim, J.W. 2000: P53 gene mutations in Bowen's disease in Koreans: Clustering in exon 5 and multiple mutations. Cancer Letters 158(1): 27-33
Liu, B.C.; Fu, D.C.; Miao, Q.; Wang, H.H.; You, B.R. 1998: p53 gene mutations in asbestos associated cancers. Biomedical and Environmental Sciences: Bes 11(3): 226-232
Radig, K.; Schneider-Stock, R.; Haeckel, C.; Neumann, W.; Roessner, A. 1998: p53 gene mutations in osteosarcomas of low-grade malignancy. Human Pathology 29(11): 1310-1316
Kusafuka, T.; Kuroda, S.; Inoue, M.; Ara, T.; Yoneda, A.; Oue, T.; Udatsu, Y.; Osugi, Y.; Okada, A. 2002: P53 gene mutations in pleuropulmonary blastomas. Pediatric Hematology and Oncology 19(2): 117-128
Shahnavaz, S.A.; Regezi, J.A.; Bradley, G.; Dubé, I.D.; Jordan, R.C. 2000: p53 gene mutations in sequential oral epithelial dysplasias and squamous cell carcinomas. Journal of Pathology 190(4): 417-422
Lam, V.; McPherson, J.P.; Salmena, L.; Lees, J.; Chu, W.; Sexsmith, E.; Hedley, D.W.; Freedman, M.H.; Reed, J.C.; Malkin, D.; Goldenberg, G.J. 1999: P53 gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to adriamycin. Leukemia Research 23(10): 871-880
Veloso, M.; Wrba, F.; Kaserer, K.; Heinze, G.; Magalhães, A.; Herbst, F.; Teleky, B. 2000: P53 gene status and expression of p53, mdm2, and p21Waf1/Cip1 proteins in colorectal cancer. Virchows Archiv: An International Journal of Pathology 437(3): 241-247
Lavarino, C.; Pilotti, S.; Oggionni, M.; Gatti, L.; Perego, P.; Bresciani, G.; Pierotti, M.A.; Scambia, G.; Ferrandina, G.; Fagotti, A.; Mangioni, C.; Lucchini, V.; Vecchione, F.; Bolis, G.; Scarfone, G.; Zunino, F. 2000: p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 18(23): 3936-3945
Vogt, U.; Zaczek, A.; Klinke, F.; Granetzny, A.; Bielawski, K.; Falkiewicz, B. 2002: p53 Gene status in relation to ex vivo chemosensitivity of non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology 128(3): 141-147
Shimada, H.; Matsubara, H.; Ochiai, T. 2002: P53 gene therapy for esophageal cancer. Journal of Gastroenterology 37(Suppl 14): 87-91
Scheinman, M.; Ascher, E.; Levi, G.S.; Hingorani, A.; Shirazian, D.; Seth, P. 1999: P53 gene transfer to the injured rat carotid artery decreases neointimal formation. Journal of Vascular Surgery 29(2): 360-369
Wu, X.; Zhao, H.; Amos, C.I.; Shete, S.; Makan, N.; Hong, W.K.; Kadlubar, F.F.; Spitz, M.R. 2002: P53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. Journal of the National Cancer Institute 94(9): 681-690
Pötzsch, C.; Voigtländer, T.; Lübbert, M. 2002: p53 Germline mutation in a patient with Li-Fraumeni Syndrome and three metachronous malignancies. Journal of Cancer Research and Clinical Oncology 128(8): 456-460
Ide, F.; Kitada, M.; Sakashita, H.; Kusama, K.; Tanaka, K.; Ishikawa, T. 2003: p53 haploinsufficiency profoundly accelerates the onset of tongue tumors in mice lacking the xeroderma pigmentosum group A gene. American Journal of Pathology 163(5): 1729-1733
Mihara, M.; Erster, S.; Zaika, A.; Petrenko, O.; Chittenden, T.; Pancoska, P.; Moll, U.M. 2003: P53 has a direct apoptogenic role at the mitochondria. Molecular Cell 11(3): 577-590
Boley, S.E.; Wong, V.A.; French, J.E.; Recio, L. 2002: P53 heterozygosity alters the mRNA expression of p53 target genes in the bone marrow in response to inhaled benzene. Toxicological Sciences: An Official Journal of the Society of Toxicology 66(2): 209-215
Nishi, H.; Senoo, M.; Nishi, K.H.; Murphy, B.; Rikiyama, T.; Matsumura, Y.; Habu, S.; Johnson, A.C. 2001: p53 Homologue p63 represses epidermal growth factor receptor expression. Journal of Biological Chemistry 276(45): 41717-41724
Cruz, I.B.; Meijer, C.J.; Snijders, P.J.; Snow, G.B.; Walboomers, J.M.; van Der Waal, I. 2000: p53 immunoexpression in non-malignant oral mucosa adjacent to oral squamous cell carcinoma: potential consequences for clinical management. Journal of Pathology 191(2): 132-137
Cheah, P-Leng.; Looi, L-Meng. 2002: P53 immunohistochemical expression: Messages in cervical carcinogenesis. Pathology 34(4): 326-331
Schmitz-Dräger, B.J.; Goebell, P.J.; Ebert, T.; Fradet, Y. 2000: p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists?. European Urology 38(6): 691-9;discussion 700
Ponticiello, A.; Barra, E.; Giani, U.; Bocchino, M.; Sanduzzi, A. 2000: P53 immunohistochemistry can identify bronchial dysplastic lesions proceeding to lung cancer: a prospective study. European Respiratory Journal 15(3): 547-552
Pindzola, J.A.; Kovatich, A.J.; Bibbo, M. 2000: p53 immunohistochemistry for distinguishing reactive mesothelium from low grade ovarian carcinoma. Acta Cytologica 44(1): 31-36
Sato, A.; Machinami, R. 1999: P53 immunohistochemistry of ulcerative colitis-associated with dysplasia and carcinoma. Pathology International 49(10): 858-868
Khurana, K.K.; Ramzy, I.; Truong, L.D. 1999: p53 immunolocalization in cell block preparations of squamous lesions of the neck: an adjunct to fine-needle aspiration diagnosis of malignancy. Archives of Pathology and Laboratory Medicine 123(5): 421-425
D'Angelo, M.F.; Kausik, S.J.; Sebo, T.J.; Rathbun, S.R.; Kramer, S.A.; Husmann, D.A. 2003: p53 immunopositivity in histologically favorable Wilms tumor is not related to stage at presentation or to biological aggression. Journal of Urology 169(5): 1815-1817
Tolbert, D.M.; Noffsinger, A.E.; Miller, M.A.; DeVoe, G.W.; Stemmermann, G.N.; Macdonald, J.S.; Fenoglio-Preiser, C.M. 1999: p53 immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status. Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology Inc 12(1): 54-60
Cooper, L.S.; Gillett, C.E.; Hanby, A.M.; Barnes, D.M. 1998: P53 immunoreactivity in breast cancer tissues does not deteriorate in stored paraffin sections. Breast 7(5): 260-264
Quddus, M.R.; Sung, C.J.; Zheng, W.; Lauchlan, S.C. 1999: P53 immunoreactivity in endometrial metaplasia with dysfunctional uterine bleeding. Histopathology 35(1): 44-49
Zheng, W.; Khurana, R.; Farahmand, S.; Wang, Y.; Zhang, Z.F.; Felix, J.C. 1998: p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma. American Journal of Surgical Pathology 22(12): 1463-1473
Matsuda, K.; Yokoyama, T.; Shinozaki, M.; Suzuki, K.; Watanabe, T.; Masaki, T.; Muto, T. 1998: P53 immunostaining in diagnosing UC-associated carcinoma. Journal of the Japan Society of Coloproctology 51(10): 1101-1108
Technau, A.; Wolff, A.; Sauder, C.; Birkner, N.; Brandner, G. 2001: P53 in SV40-transformed DNA-damaged human cells binds to its cognate sequence but fails to transactivate target genes. International Journal of Oncology 18(2): 281-286
Choi, J.; Donehower, L.A. 1999: P53 in embryonic development: Maintaining a fine balance. Cellular and Molecular Life Sciences: Cmls 55(1): 38-47
Tanaka, M.; Nonogaki, S.; Alberti, V.N.; Forones, N.M. 1999: p53 in epidermoid cancer of the esophagus. Hepato-Gastroenterology 46(27): 1765-1768
Simpson, J.F.; Page, D.L.; Edgerton, M.E. 2001: P53 in mammary ductal carcinoma in situ, mutations in high-grade lesions only?. Journal of the National Cancer Institute 93(9): 666-667
Kurtkaya-Yapicier, O.; Scheithauer, B.W.; Hebrink, D.; James, C.D. 2002: P53 in nonneoplastic central nervous system lesions: An immunohistochemical and genetic sequencing study. Neurosurgery 51(5): 1246-54; discussion 1254-5
Horn, L.C.; Fischer, U.; Hänel, C.; Kuhn, H.; Raptis, G.; Bilek, K. 2001: p53 in surgically treated and pathologically staged cervical cancer: correlation with local tumor progression, but not with lymphatic spread. Pathology Research and Practice 197(9): 605-609
Gong, Z.Y.; Wong, K.W.; Li, Y.; Mao, Y.R.; Lung, M.L. 2000: p53 inactivating mutations in chinese breast carcinomas. Oncology Reports 7(2): 381-385
Campana, A.L.M.; Rondi-Reig, L.; Tobin, C.; Lohof, A.M.; Picquet, F.; Falempin, M.; Weitzman, J.B.; Mariani, J. 2003: P53 inactivation leads to impaired motor synchronization in mice. European Journal of Neuroscience 17(10): 2135-2146
Nemoto, T.; Kamei, S.; Seyama, Y.; Kubota, S. 2001: P53 independent G(1) arrest induced by DL-alpha-difluoromethylornithine. Biochemical and Biophysical Research Communications 280(3): 848-854
Turner, T.T.; Riley, T.A. 1999: p53 independent, region-specific epithelial apoptosis is induced in the rat epididymis by deprivation of luminal factors. Molecular Reproduction and Development 53(2): 188-197
Schuler, M.; Bossy-Wetzel, E.; Goldstein, J.C.; Fitzgerald, P.; Green, D.R. 2000: P53 induces apoptosis by caspase activation through mitochondrial cytochrome c release. Journal of Biological Chemistry 275(10): 7337-7342
Kartasheva, N.N.; Contente, A.; Lenz Stoeppler, C.; Roth, J.; Dobbelstein, M. 2002: P53 induces the expression of its antagonist p73DELTAN, establishing an autoregulatory feedback loop. Oncogene 21(31): 4715-4727, 18 July
Ongusaha, P.P.; Kim, J-il.; Fang, L.; Wong, T.W.; Yancopoulos, G.D.; Aaronson, S.A.; Lee, S.W. 2003: p53 induction and activation of DDR1 kinase counteract p53-mediated apoptosis and influence p53 regulation through a positive feedback loop. EMBO Journal 22(6): 1289-1301
Kemp, C.J.; Sun, S.; Gurley, K.E. 2001: p53 induction and apoptosis in response to radio- and chemotherapy in vivo is tumor-type-dependent. Cancer Research 61(1): 327-332
Duerksen-Hughes, P.J.; Yang, J.; Ozcan, O. 1999: p53 induction as a genotoxic test for twenty-five chemicals undergoing in vivo carcinogenicity testing. Environmental Health Perspectives 107(10): 805-812
Davenport, V.; Morris, J.F.; Motazed, R.; Chu, A.C. 1999: p53 induction in normal human skin in vitro following exposure to solar simulated UV and UV-B irradiation. Journal of Photochemistry and Photobiology. B Biology 49(2-3): 177-186
Fang, L.; Li, G.; Liu, G.; Lee, S.W.; Aaronson, S.A. 2001: p53 induction of heparin-binding EGF-like growth factor counteracts p53 growth suppression through activation of MAPK and PI3K/Akt signaling cascades. EMBO Journal 20(8): 1931-1939
Moyret-Lalle, C.; Duriez, C.; Van Kerckhove, J.; Gilbert, C.; Wang, Q.; Puisieux, A. 2001: p53 induction prevents accumulation of aberrant transcripts in cancer cells. Cancer Research 61(2): 486-488
Komarova, E.A.; Neznanov, N.; Komarov, P.G.; Chernov, M.V.; Wang, K.; Gudkov, A.V. 2003: p53 inhibitor pifithrin alpha can suppress heat shock and glucocorticoid signaling pathways. Journal of Biological Chemistry 278(18): 15465-15468
Duan, W.; Zhu, X.; Ladenheim, B.; Yu, Q-sheng.; Guo, Z.; Oyler, J.; Cutler, R.G.; Cadet, J.Lud.; Greig, N.H.; Mattson, M.P. 2002: p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Annals of Neurology 52(5): 597-606
Shao, J.; Teraishi, F.; Katsuda, K.; Tanaka, N.; Fujiwara, T. 2002: p53 inhibits adriamycin-induced down-regulation of cyclin D1 expression in human cancer cells. Biochemical and Biophysical Research Communications 290(3): 1101-1107
Linke, S.P.; Sengupta, S.; Khabie, N.; Jeffries, B.A.; Buchhop, S.; Miska, S.; Henning, W.; Pedeux, R.; Wang, X.W.; Hofseth, L.J.; Yang, Q.; Garfield, S.H.; Stürzbecher, H-Werner.; Harris, C.C. 2003: p53 interacts with hRAD51 and hRAD54, and directly modulates homologous recombination. Cancer Research 63(10): 2596-2605
Lin, X.; Ramamurthi, K.; Mishima, M.; Kondo, A.; Howell, S.B. 2000: P53 interacts with the DNA mismatch repair system to modulate the cytotoxicity and mutagenicity of hydrogen peroxide. Molecular Pharmacology 58(6): 1222-1229
Bromidge, T.; Lowe, C.; Prentice, A.; Johnson, S. 2000: P53 intronic point mutation, aberrant splicing and telomeric associations in a case of B-chronic lymphocytic leukaemia. British Journal of Haematology 111(1): 223-229
Botchkarev, V.A.; Komarova, E.A.; Siebenhaar, F.; Botchkareva, N.V.; Sharov, A.A.; Komarov, P.G.; Maurer, M.; Gudkov, A.V.; Gilchrest, B.A. 2001: p53 Involvement in the control of murine hair follicle regression. American Journal of Pathology 158(6): 1913-1919
Rubbi, C.P.; Milner, J. 2003: p53 is a chromatin accessibility factor for nucleotide excision repair of DNA damage. EMBO Journal 22(4): 975-986
Fraser, M.; Leung, B.M.; Yan, X.; Dan, H.C.; Cheng, J.Q.; Tsang, B.K. 2003: P53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Research 63(21): 7081-7088
Aranda-Anzaldo, A.; Orozco-Velasco, F.; García-Villa, E.; Gariglio, P. 1999: P53 is a rate-limiting factor in the repair of higher-order DNA structure. Biochimica et Biophysica Acta 1446(3): 181-192
Chen, S-Liang.; Wu, Y-Shin.; Shieh, H-Ying.; Yen, C-Che.; Shen, J-Jong.; Lin, K-Huei. 2003: P53 is a regulator of the metastasis suppressor gene Nm23-H1. Molecular Carcinogenesis 36(4): 204-214
Ruiz-Lozano, P.; Hixon, M.L.; Wagner, M.W.; Flores, A.I.; Ikawa, S.; Baldwin, A.S.; Chien, K.R.; Gualberto, A. 1999: p53 is a transcriptional activator of the muscle-specific phosphoglycerate mutase gene and contributes in vivo to the control of its cardiac expression. Cell Growth and Differentiation: the Molecular Biology Journal of the American Association for Cancer Research 10(5): 295-306
Martin, L.J. 2000: p53 is abnormally elevated and active in the CNS of patients with amyotrophic lateral sclerosis. Neurobiology of Disease 7(6 Pt B): 613-622
Al-Mohanna, M.A.; Al-Khodairy, F.M.; Krezolek, Z.; Bertilsson, P.A.; Al-Houssein, K.A.; Aboussekhra, A. 2001: P53 is dispensable for UV-induced cell cycle arrest at late G(1) in mammalian cells. Carcinogenesis 22(4): 573-578
Uberti, D.; Piccioni, L.; Cadei, M.; Grigolato, P.; Rotter, V.; Memo, M. 2001: P53 is dispensable for apoptosis but controls neurogenesis of mouse dentate gyrus cells following gamma-irradiation. Brain Research. Molecular Brain Research 93(1): 81-89
Botchkarev, V.A.; Komarova, E.A.; Siebenhaar, F.; Botchkareva, N.V.; Komarov, P.G.; Maurer, M.; Gilchrest, B.A.; Gudkov, A.V. 2000: p53 is essential for chemotherapy-induced hair loss. Cancer Research 60(18): 5002-5006
Ma, P.; Magut, M.; Chen, X.; Chen, C-Yan. 2002: P53 is necessary for the apoptotic response mediated by a transient increase of Ras activity. Molecular and Cellular Biology 22(9): 2928-2938
Duddy, S.K.; Parker, R.F.; Bleavins, M.R.; Gough, A.W.; Rowse, P.E.; Gorospe, S.; Dethloff, L.A.; de la Iglesia, F.A. 1999: p53 is not inactivated in B6C3F1 mouse vascular tumors arising spontaneously or associated with long-term administration of the thiazolidinedione troglitazone. Toxicology and Applied Pharmacology 156(2): 106-112
Gilman, C.P.; Chan, S.L.; Guo, Z.; Zhu, X.; Greig, N.; Mattson, M.P. 2003: P53 is present in synapses where it mediates mitochondrial dysfunction and synaptic degeneration in response to DNA damage, and oxidative and excitotoxic insults. Neuromolecular Medicine 3(3): 159-172
Polek, T.C.; Stewart, L.V.; Ryu, E.J.; Cohen, M.B.; Allegretto, E.A.; Weigel, N.L. 2002: p53 Is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells. Endocrinology 144(1): 50-60
Hensel, M.; Schneeweiss, A.; Sinn, H-Peter.; Egerer, G.; Solomayer, E.; Haas, R.; Bastert, G.; Ho, A.D. 2002: P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support. International Journal of Cancer 100(3): 290-296
Yakovleva, T.; Pramanik, A.; Kawasaki, T.; Tan-No, K.; Gileva, I.; Lindegren, H.; Langel, U.; Ekstrom, T.J.; Rigler, R.; Terenius, L.; Bakalkin, G. 2001: p53 Latency. C-terminal domain prevents binding of p53 core to target but not to nonspecific DNA sequences. Journal of Biological Chemistry 276(19): 15650-15658
Yakovleva, T.; Pramanik, A.; Terenius, L.; Ekström, T.J.; Bakalkin, G. 2002: P53 latency--out of the blind alley. Trends in Biochemical Sciences 27(12): 612-618
Werner, F.; Zoelzer, F.; Streffer, C. 2001: P53 levels, cell cycle kinetics and radiosensitivity in two SV40 transformed Wi38VA13 fibroblast strains. Strahlentherapie und Onkologie 177(12): 662-669
Brusa, G.; Benvenuti, M.; Mazzacurati, L.; Mancini, M.; Pattacini, L.; Martinelli, G.; Barbieri, E.; Greenberger, J.S.; Baccarani, M.; Santucci, M.Alessandra. 2003: p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase. Haematologica 88(6): 622-630
Chen-Gang; Xu-Liangzhong; He-Kailing; Zhu-Xiongzeng 1999: P53 mRNA expression in non-Hodgkin's lymphomas. Journal of Shanghai Medical University 26(6): 428-430
Inoue, Y.; Tomiya, T.; Yanase, M.; Arai, M.; Ikeda, H.; Tejima, K.; Ogata, I.; Kimura, S.; Omata, M.; Fujiwara, K. 2002: p53 May positively regulate hepatocyte proliferation in rats. Hepatology 36(2): 336-344
Cui, H.; Schroering, A.; Ding, H.-F. 2002: P53 mediates DNA damaging drug-induced apoptosis through a caspase-9-dependent pathway in SH-SY5Y neuroblastoma cells. Molecular Cancer Therapeutics 1(9): 679-686
Unnikrishnan, I.; Radfar, A.; Jenab-Wolcott, J.; Rosenberg, N. 1999: P53 mediates apoptotic crisis in primary Abelson virus-transformed pre-B cells. Molecular and Cellular Biology 19(7): 4825-4831
Wu, K.; Jiang, S-Wen.; Couch, F.J. 2003: p53 mediates repression of the BRCA2 promoter and down-regulation of BRCA2 mRNA and protein levels in response to DNA damage. Journal of Biological Chemistry 278(18): 15652-15660
Mousses, S.; Gokgoz, N.; Wunder, J.S.; Ozcelik, H.; Bull, S.; Bell, R.S.; Andrulis, I.L. 2001: P53 missense but not truncation mutations are associated with low levels of p21(CIP1/WAF1) mRNA expression in primary human sarcomas. British Journal of Cancer 84(12): 1635-1639
Done, S.J.; Eskandarian, S.; Bull, S.; Redston, M.; Andrulis, I.L. 2001: P53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast. Journal of the National Cancer Institute 93(9): 700-704
Offer, H.; Zurer, I.; Banfalvi, G.; Reha'k, M.; Falcovitz, A.; Milyavsky, M.; Goldfinger, N.; Rotter, V. 2001: p53 modulates base excision repair activity in a cell cycle-specific manner after genotoxic stress. Cancer Research 61(1): 88-96
Lin, X.; Ramamurthi, K.; Mishima, M.; Kondo, A.; Christen, R.D.; Howell, S.B. 2001: P53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Research 61(4): 1508-1516
Brosh, R.M.; Karmakar, P.; Sommers, J.A.; Yang, Q.; Wang, X.W.; Spillare, E.A.; Harris, C.C.; Bohr, V.A. 2001: p53 Modulates the exonuclease activity of Werner syndrome protein. Journal of Biological Chemistry 276(37): 35093-35102
Soussi, T. 2003: P53 mutantes et resistance a la chimiotherapie: Un coup dans le dos de p73?. Bulletin du Cancer (Montrouge) 90(5): 383-386
Aurelio, O.N.; Kong, X.T.; Gupta, S.; Stanbridge, E.J. 2000: P53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines. Molecular and Cellular Biology 20(3): 770-778
Chène, P.; Bechter, E. 1999: p53 mutants without a functional tetramerisation domain are not oncogenic. Journal of Molecular Biology 286(5): 1269-1274
van Rens, M.Th.M.; Eijken, E.J.E.; Elbers, J.R.J.; Lammers, J-W.J.; Tilanus, M.G.J.; Slootweg, P.J. 2002: P53 mutation analysis for definite diagnosis of multiple primary lung carcinoma. Cancer 94(1): 188-196
Taylor, A.C.; Shu, L.; Danks, M.K.; Poquette, C.A.; Shetty, S.; Thayer, M.J.; Houghton, P.J.; Harris, L.C. 2000: P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Medical and Pediatric Oncology 35(2): 96-103
Yamamoto, H.; Oda, Y.; Saito, T.; Sakamoto, A.; Miyajima, K.; Tamiya, S.; Tsuneyoshi, M. 2003: P53 mutation and MDM2 amplification in inflammatory myofibroblastic tumours. Histopathology 42(5): 431-439
Kohno, H.; Hiroshima, K.; Toyozaki, T.; Fujisawa, T.; Ohwada, H. 1999: P53 mutation and allelic loss of chromosome 3p, 9p of preneoplastic lesions in patients with nonsmall cell lung carcinoma. Cancer 85(2): 341-347
Yoon, K.S.; Lee, M.C.; Kang, S.S.; Kim, J.H.; Jung, S.; Kim, Y.J.; Lee, J.H.; Ahn, K.Y.; Lee, J.S.; Cheon, J.Y. 2001: P53 mutation and epidermal growth factor receptor overexpression in glioblastoma. Journal of Korean Medical Science 16(4): 481-488
Tarapore, P.; Fukasawa, K. 2000: P53 mutation and mitotic infidelity. Cancer Investigation 18(2): 148-155
Khan, Z.A.; Jonas, S.K.; Feldmann, K.A.; Patel, H.; Wharton, R.Q.; Tarragona, A.; Ivison, A.; Allen-Mersh, T.G. 2001: P53 mutation and response to hepatic arterial floxuridine in patients with colorectal liver metastases. Journal of Cancer Research and Clinical Oncology 127(11): 675-680
de Cremoux, P.; Salomon, A.V.; Liva, S.; Dendale, R.; Bouchind'homme, B.; Martin, E.; Sastre-Garau, X.; Magdelenat, H.; Fourquet, A.; Soussi, T. 1999: P53 mutation as a genetic trait of typical medullary breast carcinoma. Journal of the National Cancer Institute 91(7): 641-643
Mueller, J.; Gansauge, S.; Mattfeldt, T. 2003: P53 mutation but not p16/MTS1 mutation occurs in intraductal papillary mucinous tumors of the pancreas. Hepato-Gastroenterology 50(50): 541-544
Bradford, C.R.; Zhu, S.; Ogawa, H.; Ogawa, T.; Ubell, M.; Narayan, A.; Johnson, G.; Wolf, G.T.; Fisher, S.G.; Carey, T.E. 2003: P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head and Neck 25(8): 654-661
Maebayashi, K.; Mitsuhashi, N.; Takahashi, T.; Sakurai, H.; Niibe, H. 1999: P53 mutation decreased radiosensitivity in rat yolk sac tumor cell lines. International Journal of Radiation Oncology Biology Physics 44(3): 677-682
Fallows, S.; Price, J.; Atkinson, R.J.; Johnston, P.G.; Hickey, I.; Russell, S.E. 2001: P53 mutation does not affect prognosis in ovarian epithelial malignancies. Journal of Pathology 194(1): 68-75
Okubo, R.; Masuda, H.; Nemoto, N. 2001: P53 mutation found to be a significant prognostic indicator in distal colorectal cancer. Oncology Reports 8(3): 509-514
Megha, T.; Ferrari, F.; Benvenuto, A.; Bellan, C.; Lalinga, A.V.; Lazzi, S.; Bartolommei, S.; Cevenini, G.; Leoncini, L.; Tosi, P. 2002: p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin. Journal of Clinical Pathology 55(6): 461-466
Date, K.; Watanabe, H.; Ajioka, Y.; Shirai, Y.; Yokoyama, N.; Yoshikawa, T.; Kasuya, K.; Koyanagi, Y.; Hatakeyama, K. 2002: P53 mutation in gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Acta Medica et Biologica 50(2): 83-90
Stern, R.S.; Bolshakov, S.; Nataraj, A.J.; Ananthaswamy, H.N. 2002: p53 mutation in nonmelanoma skin cancers occurring in psoralen ultraviolet a-treated patients: evidence for heterogeneity and field cancerization. Journal of Investigative Dermatology 119(2): 522-526
Ho, E.S.; Lai, C.R.; Hsieh, Y.T.; Chen, J.T.; Lin, A.J.; Hung, M.H.; Liu, F.S. 2001: p53 mutation is infrequent in clear cell carcinoma of the ovary. Gynecologic Oncology 80(2): 189-193
Kubicka, S.; Claas, C.; Staab, S.; Kühnel, F.; Zender, L.; Trautwein, C.; Wagner, S.; Rudolph, K.Lenhard.; Manns, M. 2002: P53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: Relation to histological subtypes, Helicobacter pylori infection, and prognosis. Digestive Diseases and Sciences 47(1): 114-121
Shiraishi, K.; Eguchi, S.; Mohri, J.; Kamiryo, Y. 2003: P53 mutation predicts intravesical adriamycin instillation failure in superficial transitional cell carcinoma of bladder. Anticancer Research 23(4): 3475-3478
Hussain, S.P.; Harris, C.C. 1999: P53 mutation spectrum and load: The generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer. Mutation Research 428(1-2): 23-32
Pfeifer, G.P. 2000: P53 mutational spectra and the role of methylated CpG sequences. Mutation Research 450(1-2): 155-166
Ostwald, C.; Gogacz, P.; Hillmann, T.; Schweder, J.; Gundlach, K.; Kundt, G.; Barten, M. 2000: P53 mutational spectra are different between squamous-cell carcinomas of the lip and the oral cavity. International Journal of Cancer 88(1): 82-86
Gudlaugsdottir, S.; Sigurdardottir, V.; Snorradottir, M.; Jonasson, J.G.; Ogmundsdottir, H.; Eyfjord, J.E. 2000: P53 mutations analysis in benign and malignant breast lesions: Using needle rinses from fine-needle aspirations. Diagnostic Cytopathology 22(5): 268-274
Popp, W.; Vahrenholz, C.; Schuster, H.; Wiesner, B.; Bauer, P.; Täuscher, F.; Plogmann, H.; Morgenroth, K.; Konietzko, N.; Norpoth, K. 1999: P53 mutations and codon 213 polymorphism of p53 in lung cancers of former uranium miners. Journal of Cancer Research and Clinical Oncology 125(5): 309-312
Husgafvel-Pursiainen, K.; Boffetta, P.; Kannio, A.; Nyberg, F.; Pershagen, G.; Mukeria, A.; Constantinescu, V.; Fortes, C.; Benhamou, S. 2000: p53 mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer. Cancer Research 60(11): 2906-2911
Lukas, J.; Niu, N.; Press, M.F. 2000: p53 mutations and expression in breast carcinoma in situ. American Journal of Pathology 156(1): 183-191
Wen, W.H.; Reles, A.; Runnebaum, I.B.; Sullivan-Halley, J.; Bernstein, L.; Jones, L.A.; Felix, J.C.; Kreienberg, R.; el-Naggar, A.; Press, M.F. 1999: P53 mutations and expression in ovarian cancers: correlation with overall survival. International Journal of Gynecological Pathology: Official Journal of the International Society of Gynecological Pathologists 18(1): 29-41
Keshelava, N.; Zuo, J.J.; Waidyaratne, N.S.; Triche, T.J.; Reynolds, C.P. 2000: P53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma. Medical and Pediatric Oncology 35(6): 563-568
Kim, S.Soo.; Bhang, C.Sang.; Min, K.Ouk.; Chae, H.Suk.; Choi, S.Wook.; Lee, C.Don.; Lim, K.Woo.; Chung, I.Sik.; Park, D.Ho. 2002: p53 mutations and microsatellite instabilities in the subtype of intestinal metaplasia of the stomach. Journal of Korean Medical Science 17(4): 490-496
Buller, R.E.; Shahin, M.S.; Holmes, R.W.; Hatterman, M.; Kirby, P.A.; Sood, A.K. 2001: p53 Mutations and microsatellite instability in ovarian cancer: Yin and yang. American Journal of Obstetrics and Gynecology 184(5): 891-902; Discussion 902-3
Okuda, T.; Otsuka, J.; Sekizawa, A.; Saito, H.; Makino, R.; Kushima, M.; Farina, A.; Kuwano, Y.; Okai, T. 2003: P53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer. Gynecologic Oncology 88(3): 318-325
Yang Yang; Xia Qiong; Lian Fangjie 1999: P53 mutations and protein overexpression in primary colorectal cancer and its liver metastasis. Zhonghua Zhongliu Zazhi 21(2): 114-118
Ahrendt, S.A.; Hu, Y.; Buta, M.; Mcdermott, M.P.; Benoit, N.; Yang, S.C.; Wu, L.; Sidransky, D. 2003: P53 mutations and survival in stage I non-small-cell lung cancer: Results of a prospective study. Journal of the National Cancer Institute 95(13): 961-970
Jansson, A.; Gentile, M.; Sun, X.F. 2001: P53 mutations are present in colorectal cancer with cytoplasmic p53 accumulation. International Journal of Cancer 92(3): 338-341
Denk, C.; Butz, K.; Schneider, A.; Dürst, M.; Hoppe-Seyler, F. 2001: P53 mutations are rare events in recurrent cervical cancer. Journal of Molecular Medicine 79(5-6): 283-288
Phillips, H.A.; Howard, G.C.; Miller, W.R. 2000: p53 mutations as a marker of malignancy in bladder washing samples from patients with bladder cancer. British Journal of Cancer 82(1): 136-141
Dillon, D.A.; Hipolito, E.; Zheng, K.; Rimm, D.L.; Costa, Jé.C. 2002: p53 mutations as tumor markers in fine needle aspirates of palpable breast masses. Acta Cytologica 46(5): 841-847
King, T.C.; Akerley, W.; Fan, A.C.; Moore, T.; Mangray, S.; Hsiu Chen, M.; Safran, H. 2000: P53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma. Cancer 89(4): 769-773
Monti, P.; Inga, A.; Aprile, A.; Campomenosi, P.; Menichini, P.; Ottaggio, L.; Viaggi, S.; Ghigliotti, G.; Abbondandolo, A.; Fronza, G. 2000: P53 mutations experimentally induced by 8-methoxypsoralen plus UVA (PUVA) differ from those found in human skin cancers in PUVA-treated patients. Mutagenesis 15(2): 127-132
Vautier, G.; Bomford, A.B.; Portmann, B.C.; Metivier, E.; Williams, R.; Ryder, S.D. 1999: P53 mutations in British patients with hepatocellular carcinoma: Clustering in genetic hemochromatosis. Gastroenterology 117(1): 154-160
Russo, A.; Migliavacca, M.; Zanna, I.; Valerio, M.R.; Latteri, M.A.; Grassi, N.; Pantuso, G.; Salerno, S.; Dardanoni, G.; Albanese, I.; La Farina, M.; Tomasino, R.M.; Gebbia, N.; Bazan, V. 2002: P53 mutations in L3-loop zinc-binding domain, DNA-ploidy, and S phase fraction are independent prognostic indicators in colorectal cancer: a prospective study with a five-year follow-up. Cancer Epidemiology Biomarkers and Prevention: a Publication of the American Association for Cancer Research Cosponsored by the American Society of Preventive Oncology 11(11): 1322-1331
Schroeder, J.C.; Conway, K.; Li, Y.; Mistry, K.; Bell, D.A.; Taylor, J.A. 2003: p53 mutations in bladder cancer: evidence for exogenous versus endogenous risk factors. Cancer Research 63(21): 7530-7538
Pfister, C.; Flaman, J.M.; Dunet, F.; Grise, P.; Frebourg, T. 1999: P53 mutations in bladder tumors inactivate the transactivation of the p21 and Bax genes, and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy. Journal of Urology 162(1): 69-73
Forslund, A.; Kressner, U.; Lönnroth, C.; Andersson, M.; Lindmark, G.; Lundholm, K. 2002: P53 mutations in colorectal cancer assessed in both genomic DNA and cDNA as compared to the presence of p53 LOH. International Journal of Oncology 21(2): 409-415
Laframboise, S.; Chapman, W.; McLaughlin, J.; Andrulis, I.L. 2000: p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance. Cancer Journal 6(5): 302-308
Yngveson, A.; Williams, C.; Hjerpe, A.; Lundeberg, J.; Söderkvist, P.; Pershagen, G. 1999: P53 Mutations in lung cancer associated with residential radon exposure. Cancer Epidemiology Biomarkers and Prevention: a Publication of the American Association for Cancer Research Cosponsored by the American Society of Preventive Oncology 8(5): 433-438
Yang, Y.; Forslund, A.; Remotti, H.; Lönnroth, C.; Andersson, M.; Brevinge, H.; Svanberg, E.; Lindnér, P.; Hafström, L.; Naredi, P.; Lundholm, K. 2001: P53 mutations in primary tumors and subsequent liver metastases are related to survival in patients with colorectal carcinoma who undergo liver resection. Cancer 91(4): 727-736
Takayama, H.; Shin, M.; Nonomura, N.; Okuyama, A.; Aozasa, K. 2000: p53 mutations in prostatic intraepithelial neoplasia and concurrent carcinoma: analysis of laser capture microdissected specimens from non-transition and transition zones. Japanese Journal of Cancer Research: Gann 91(9): 941-947
Iwamoto, K.S.; Fujii, S.; Kurata, A.; Suzuki, M.; Hayashi, T.; Ohtsuki, Y.; Okada, Y.; Narita, M.; Takahashi, M.; Hosobe, S.; Doishita, K.; Manabe, T.; Hata, S.; Murakami, I.; Hata, S.; Itoyama, S.; Akatsuka, S.; Ohara, N.; Iwasaki, K.; Akabane, H.; Fujihara, M.; Seyama, T.; Mori, T. 1999: P53 mutations in tumor and non-tumor tissues of Thorotrast recipients: A model for cellular selection during radiation carcinogenesis in the liver. Carcinogenesis 20(7): 1283-1291
Gamble, S.C.; Cook, M.C.; Riches, A.C.; Herceg, Z.; Bryant, P.E.; Arrand, J.E. 1999: P53 mutations in tumors derived from irradiated human thyroid epithelial cells. Mutation Research 425(2): 231-238
Berggren, P.; Steineck, G.; Adolfsson, J.; Hansson, J.; Jansson, O.; Larsson, P.; Sandstedt, B.; Wijkström, H.; Hemminki, K. 2001: p53 mutations in urinary bladder cancer. British Journal of Cancer 84(11): 1505-1511
Matsuzoe, D.; Hideshima, T.; Kimura, A.; Inada, K.; Watanabe, K.; Akita, Y.; Kawahara, K.; Shirakusa, T. 1999: P53 mutations predict non-small cell lung carcinoma response to radiotherapy. Cancer Letters 135(2): 189-194
Khaliq, S.; Hameed, A.; Khaliq, T.; Ayub, Q.; Qamar, R.; Mohyuddin, A.; Mazhar, K.; Qasim-Mehdi, S. 2000: P53 mutations, polymorphisms, and haplotypes in Pakistani ethnic groups and breast cancer patients. Genetic Testing 4(1): 23-29
Yun, J.; Chae, H.D.; Choy, H.E.; Chung, J.; Yoo, H.S.; Han, M.H.; Shin, D.Y. 1999: P53 negatively regulates cdc2 transcription via the CCAAT-binding NF-Y transcription factor. Journal of Biological Chemistry 274(42): 29677-29682
Sturm, A.; Itoh, J.; Jacobberger, J.W.; Fiocchi, C. 2002: P53 negatively regulates intestinal immunity by delaying mucosal T cell cycling. Journal of Clinical Investigation 109(11): 1481-1492
Buglioni, S.; D'Agnano, I.; Vasselli, S.; Perrone Donnorso, R.; D'Angelo, C.; Brenna, A.; Benevolo, M.; Cosimelli, M.; Zupi, G.; Mottolese, M. 2001: p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected stage II colorectal cancers independent of fluorouracil-based adjuvant therapy. American Journal of Clinical Pathology 116(3): 360-368
Kim, Y.Y.; Kim, J.I.; Kim, J.; Yook, J.I.; Kim, T.H.; Son, Y.S. 2001: P53 nuclear accumulation as a possible biomarker for biological radio-dosimetry in oral mucosal epithelial cells. Journal of Biochemistry and Molecular Biology 34(2): 123-129
Fleshner, N.; Kapusta, L.; Ezer, D.; Herschorn, S.; Klotz, L. 2000: P53 nuclear accumulation is not associated with decreased disease-free survival in patients with node positive transitional cell carcinoma of the bladder. Journal of Urology 164(4): 1177-1182
Osugi, H.; Morimura, K.; Okuda, E.; Takemura, M.; Higashino, M.; Takada, N.; Kinoshita, H. 2002: P53 null mutations detected by a p53 yeast functional assay predict a poor outcome in young esophageal carcinoma patients. International Journal of Oncology 21(3): 637-641
Hashimoto, T.; Tokuchi, Y.; Hayashi, M.; Kobayashi, Y.; Nishida, K.; Hayashi, S.; Ishikawa, Y.; Tsuchiya, S.; Nakagawa, K.; Hayashi, J.; Tsuchiya, E. 1999: p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas. Cancer Research 59(21): 5572-5577
Voskuil, D.W.; Kampman, E.; van Kraats, A.A.; Balder, H.F.; van Muijen, G.N.; Goldbohm, R.A.; van't Veer, P. 1999: P53 over-expression and p53 mutations in colon carcinomas: Relation to dietary risk factors. International Journal of Cancer 81(5): 675-681
Pescarmona, E.; Pignoloni, P.; Puopolo, M.; Martelli, M.; Addesso, M.; Guglielmi, C.; Baroni, C.D. 2001: p53 over-expression identifies a subset of nodal peripheral T-cell lymphomas with a distinctive biological profile and poor clinical outcome. Journal of Pathology 195(3): 361-366
Saito, K.; Arai, K.; Mori, M. 2000: P53 overexpression and K-ras codon 12 mutations in submucosal invasive depressed-type colorectal cancer. Oncology Reports 7(4): 741-744
Niwa, K.; Murase, T.; Morishita, S.; Hashimoto, M.; Itoh, N.; Tamaya, T. 1999: p53 overexpression and mutation in endometrial carcinoma: inverted relation with estrogen and progesterone receptor status. Cancer Detection and Prevention 23(2): 147-154
Ozalp, S.; Yalcin, O.T.; Tanir, H.Mete.; Kabukcuoglu, S.; Erol, G. 2003: p53 overexpression as a prognostic indicator in endometrial carcinoma. European Journal of Gynaecological Oncology 24(3-4): 275-278
Elghetany, M.T. 2000: P53 overexpression in bone marrow biopsies in refractory anemia and aplastic anemia: Impact of antibody selection. Leukemia Research 24(11): 975-977
Campani, D.; Boggi, U.; Cecchetti, D.; Esposito, I.; Ceccarelli, F.; D'Antonio, L.; De Negri, F.; Mosca, F.; Bevilacqua, G.; Fornaciari, G. 1999: P53 overexpression in lymph node metastases predicts clinical outcome in ductal pancreatic cancer. Pancreas 19(1): 26-32
van Oijen, M.G.; van de Craats, J.G.; Slootweg, P.J. 1999: p53 overexpression in oral mucosa in relation to smoking. Journal of Pathology 187(4): 469-474
Tak, P.P.; Smeets, T.J.; Boyle, D.L.; Kraan, M.C.; Shi, Y.; Zhuang, S.; Zvaifler, N.J.; Breedveld, F.C.; Firestein, G.S. 1999: p53 overexpression in synovial tissue from patients with early and longstanding rheumatoid arthritis compared with patients with reactive arthritis and osteoarthritis. Arthritis and Rheumatism 42(5): 948-953
Narayana, A.; Vaughan, A.T.; Kathuria, S.; Fisher, S.G.; Walter, S.A.; Reddy, S.P. 2000: P53 overexpression is associated with bulky tumor and poor local control in T1 glottic cancer. International Journal of Radiation Oncology Biology Physics 46(1): 21-26
Leung, S.Y.; Chau, K.Y.; Yuen, S.T.; Chu, K.M.; Branicki, F.J.; Chung, L.P. 1998: p53 overexpression is different in Epstein-Barr virus-associated and Epstein-Barr virus-negative carcinoma. Histopathology 33(4): 311-317
Liang, J-Tung.; Huang, K-Chin.; Cheng, Y-Ming.; Hsu, H-Chi.; Cheng, A-Lii.; Hsu, C-Hung.; Yeh, K-Huei.; Wang, S-Ming.; Chang, K-Jen. 2002: P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection. International Journal of Cancer 97(4): 451-457
Buschmann, T.; Adler, V.; Matusevich, E.; Fuchs, S.Y.; Ronai, Z. 2000: p53 phosphorylation and association with murine double minute 2, c-Jun NH2-terminal kinase, p14ARF, and p300/CBP during the cell cycle and after exposure to ultraviolet irradiation. Cancer Research 60(4): 896-900
Parra, M.; Jardí, M.; Koziczak, M.; Nagamine, Y.; Muñoz-Cánoves, P. 2001: p53 Phosphorylation at serine 15 is required for transcriptional induction of the plasminogen activator inhibitor-1 (PAI-1) gene by the alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine. Journal of Biological Chemistry 276(39): 36303-36310
Yoshida, Y.; Izumi, H.; Torigoe, T.; Ishiguchi, H.; Itoh, H.; Kang, D.; Kohno, K. 2003: P53 physically interacts with mitochondrial transcription factor A and differentially regulates binding to damaged DNA. Cancer Research 63(13): 3729-3734
Goh, H.S.; Elnatan, J.; Low, C.H.; Smith, D.R. 1999: P53 point mutation and survival in colorectal cancer patients: Effect of disease dissemination and tumour location. International Journal of Oncology 15(3): 491-498
Wong, Y.F.; Chung, T.K.; Cheung, T.H.; Nobori, T.; Hampton, G.M.; Wang, V.W.; Li, Y.F.; Chang, A.M. 2000: P53 polymorphism and human papillomavirus infection in Hong Kong women with cervical cancer. Gynecologic and Obstetric Investigation 50(1): 60-63
Cenci, M.; French, D.; Pisani, T.; Alderisio, M.; Lombardi, A.Maria.; Marchese, R.; Colelli, F.; Vecchione, A. 2003: p53 polymorphism at codon 72 is not a risk factor for cervical carcinogenesis in central Italy. Anticancer Research 23(2b): 1385-1387
Kawaguchi, H.; Ohno, S.; Araki, K.; Miyazaki, M.; Saeki, H.; Watanabe, M.; Tanaka, S.; Sugimachi, K. 2000: P53 polymorphism in human papillomavirus-associated esophageal cancer. Cancer Research 60(11): 2753-2755
Bergamaschi, D.; Gasco, M.; Hiller, L.; Sullivan, A.; Syed, N.; Trigiante, G.; Yulug, I.; Merlano, M.; Numico, G.; Comino, A.; Attard, M.; Reelfs, O.; Gusterson, B.; Bell, A.K.; Heath, V.; Tavassoli, M.; Farrell, P.J.; Smith, P.; Lu, X.; Crook, T. 2003: P53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3(4): 387-402
Summersgill, K.F.; Smith, E.M.; Kirchner, H.L.; Haugen, T.H.; Turek, L.P. 2000: p53 polymorphism, human papillomavirus infection in the oral cavity, and oral cancer. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics 90(3): 334-339
Maecker, H.L.; Koumenis, C.; Giaccia, A.J. 2000: p53 promotes selection for Fas-mediated apoptotic resistance. Cancer Research 60(16): 4638-4644
Dmitrieva, N.; Michea, L.; Burg, M. 2001: P53 Protects renal inner medullary cells from hypertonic stress by restricting DNA replication. American Journal of Physiology. Renal Physiology 281(3): F522-F530
Shin, D.M.; Charuruks, N.; Lippman, S.M.; Lee, J.J.; Ro, J.Y.; Hong, W.K.; Hittelman, W.N. 2001: p53 protein accumulation and genomic instability in head and neck multistep tumorigenesis. Cancer Epidemiology Biomarkers and Prevention: a Publication of the American Association for Cancer Research Cosponsored by the American Society of Preventive Oncology 10(6): 603-609
Kandel, R.; Li, S.Q.; Ozcelik, H.; Rohan, T. 2000: P53 protein accumulation and mutations in normal and benign breast tissue. International Journal of Cancer 87(1): 73-78
Saeki, H.; Ohno, S.; Miyazaki, M.; Araki, K.; Egashira, A.; Kawaguchi, H.; Watanabe, M.; Morita, M.; Sugimachi, K. 2002: P53 protein accumulation in multiple oesophageal squamous cell carcinoma: relationship to risk factors. Oncology 62(2): 175-179
Done, S.J.; Arneson, C.R.; Ozçelik, H.; Redston, M.; Andrulis, I.L. 2001: P53 protein accumulation in non-invasive lesions surrounding p53 mutation positive invasive breast cancers. Breast Cancer Research and Treatment 65(2): 111-118
Liu, Y.; Kulesz-Martin, M. 2001: P53 protein at the hub of cellular DNA damage response pathways through sequence-specific and non-sequence-specific DNA binding. Carcinogenesis 22(6): 851-860
Brys, M.; Semczuk, A.; Wojcik, M.; Krajewska, W.M.; Jakowicki, J.A. 1999: P53 protein detection by the Western blotting technique in normal and neoplastic specimens of human endometrium. Cancer Letters 148(2): 197-205
Gatalica, Z.; Finkelstein, S.; Lucio, E.; Tawfik, O.; Palazzo, J.; Hightower, B.; Eyzaguirre, E. 2001: p53 protein expression and gene mutation in phyllodes tumors of the breast. Pathology Research and Practice 197(3): 183-187
Zheng-Meilian; Ou-Baoxiang; Long-Jiangbin 1999: P53 protein expression and its clinical significance in human nasopharyngeal carcinoma. Zhongguo Zhongliu Linchuang 26(11): 829-831
Ahn, M.J.; Kim, H.; Kim, I.S.; Park, J.K.; Ki, M.R.; Park, C.K. 2000: p53 protein expression and its prognostic importance in patients with nodal non-Hodgkin's lymphoma. Journal of Korean Medical Science 15(1): 59-64
Ioakim-Liossi, A.; Pantazopoulos, D.; Karakitsos, P.; Athanassiadou, P.; Aroni, K.; Giahnaki, A.E.; Athanassiades, P. 2000: p53 protein expression and proliferative activity in imprints of superficial transitional cell carcinoma of the bladder. Analytical and Quantitative Cytology and Histology 22(3): 223-228
Sironi, G.; Riccaboni, P.; Mertel, L.; Cammarata, G.; Brooks, D., E. 2000: P53 protein expression in conjunctival squamous cell carcinomas of domestic animals. Veterinary Ophthalmology 2(4): 227-231
Testino, G.; Cornaggia, M. 2002: P53 protein expression in epithelial high-grade dysplasia from the stomach. Scandinavian Journal of Gastroenterology 37(3): 370-371
Koníková, E.; Kusenda, J. 2001: P53 protein expression in human leukemia and lymphoma cells. Neoplasma 48(4): 290-298
Kawahira, H.; Kobayashi, S.; Kaneko, K.; Asano, T.; Ochiai, T. 2000: p53 protein expression in intraductal papillary mucinous tumors (IPMT) of the pancreas as an indicator of tumor malignancy. Hepato-Gastroenterology 47(34): 973-977
Chyczewski, L.; Kozłowski, M.; Nikliński, J.; Szyszko, J.; Laudański, J.; Niklińska, W. 1999: p53 protein expression in resected invasive esophageal cancer. Neoplasma 46(3): 150-155
Scheistrøen, M.; Tropé, C.; Pettersen, E.O.; Nesland, J.M. 1999: p53 protein expression in squamous cell carcinoma of the vulva. Cancer 85(5): 1133-1138
Gafa, R.; Lanza, G. 1998: P53 protein expression in the colorectal adenoma-carcinoma sequence. Pathologica (Genoa) 90(4): 351-356
Soong, R.; Knowles, S.; Hammond, I.G.; Michael, C.; Iacopetta, B.J. 1999: P53 protein overexpression and gene mutation in mixed Müllerian tumors of the uterus. Cancer Detection and Prevention 23(1): 8-12
Elghetany, M.Tarek.; Alter, B.P. 2002: p53 protein overexpression in bone marrow biopsies of patients with Shwachman-Diamond syndrome has a prevalence similar to that of patients with refractory anemia. Archives of Pathology and Laboratory Medicine 126(4): 452-455
Weston, A.P.; Banerjee, S.K.; Sharma, P.; Tran, T.M.; Richards, R.; Cherian, R. 2001: P53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: Immunohistochemical marker predictive of progression. American Journal of Gastroenterology 96(5): 1355-1362
Cheng, L.; Sebo, T.J.; Cheville, J.C.; Pisansky, T.M.; Slezak, J.; Bergstralh, E.J.; Pacelli, A.; Neumann, R.M.; Zincke, H.; Bostwick, D.G. 1999: P53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy. Cancer 85(6): 1293-1299
Bancher-Todesca, D.; Gitsch, G.; Williams, K.E.; Kohlberger, P.; Neunteufel, W.; Obermair, A.; Heinze, G.; Breitenecker, G.; Hacker, N.F. 1998: p53 protein overexpression: a strong prognostic factor in uterine papillary serous carcinoma. Gynecologic Oncology 71(1): 59-63
Wu, H.H.; Thomas, J.A.; Momand, J. 2000: P53 protein oxidation in cultured cells in response to pyrrolidine dithiocarbamate: A novel method for relating the amount of p53 oxidation in vivo to the regulation of p53-responsive genes. Biochemical Journal 351(Pt 1): 87-93
Tanooka, H.; Sasaki, H.; Shiroishi, T.; Moriwaki, K. 2001: P53 pseudogene dating: Identification of the origin of laboratory mice. Gene 270(1-2): 153-159
Giebler, H.A.; Lemasson, I.; Nyborg, J.K. 2000: P53 recruitment of CREB binding protein mediated through phosphorylated CREB: A novel pathway of tumor suppressor regulation. Molecular and Cellular Biology 20(13): 4849-4858
Li, Y.; Schlamp, C.L.; Poulsen, G.L.; Jackson, M.W.; Griep, A.E.; Nickells, R.W. 2002: p53 regulates apoptotic retinal ganglion cell death induced by N-methyl-D-aspartate. Molecular Vision 8: 341-350
Singh, B.; Reddy, P.G.; Goberdhan, A.; Walsh, C.; Dao, S.; Ngai, I.; Chou, T.Chao.; O-Charoenrat, P.; Levine, A.J.; Rao, P.H.; Stoffel, A. 2002: p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes and Development 16(8): 984-993
Li, P.F.; Dietz, R.; von Harsdorf, R. 1999: p53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent apoptosis blocked by Bcl-2. EMBO Journal 18(21): 6027-6036
Porrello, A.; Cerone, M.A.; Coen, S.; Gurtner, A.; Fontemaggi, G.; Cimino, L.; Piaggio, G.; Sacchi, A.; Soddu, S. 2000: P53 regulates myogenesis by triggering the differentiation activity of pRb. Journal of Cell Biology 151(6): 1295-1304
Zou, Z.; Gao, C.; Nagaich, A.K.; Connell, T.; Saito, S.; Moul, J.W.; Seth, P.; Appella, E.; Srivastava, S. 2000: P53 regulates the expression of the tumor suppressor gene maspin. Journal of Biological Chemistry 275(9): 6051-6054
Smith, M.L.; Seo, Y.R. 2002: P53 regulation of DNA excision repair pathways. Mutagenesis 17(2): 149-156
Flatt, P.M.; Tang, L.J.; Scatena, C.D.; Szak, S.T.; Pietenpol, J.A. 2000: P53 regulation of G(2) checkpoint is retinoblastoma protein dependent. Molecular and Cellular Biology 20(12): 4210-4223
Kubicka, S.; Kühnel, F.; Zender, L.; Rudolph, K.L.; Plümpe, J.; Manns, M.; Trautwein, C. 1999: P53 represses CAAT enhancer-binding protein (C/EBP)-dependent transcription of the albumin gene. A molecular mechanism involved in viral liver infection with implications for hepatocarcinogenesis. Journal of Biological Chemistry 274(45): 32137-32144
Crighton, D.; Woiwode, A.; Zhang, C.; Mandavia, N.; Morton, J.P.; Warnock, L.J.; Milner, J.; White, R.J.; Johnson, D.L. 2003: p53 represses RNA polymerase III transcription by targeting TBP and inhibiting promoter occupancy by TFIIIB. EMBO Journal 22(11): 2810-2820
Shenk, J.L.; Fisher, C.J.; Chen, S.Y.; Zhou, X.F.; Tillman, K.; Shemshedini, L. 2001: p53 represses androgen-induced transactivation of prostate-specific antigen by disrupting hAR amino- to carboxyl-terminal interaction. Journal of Biological Chemistry 276(42): 38472-38479
Rocha, S.; Martin, A.M.; Meek, D.W.; Perkins, N.D. 2003: p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1. Molecular and Cellular Biology 23(13): 4713-4727
Fitch, M.E.; Cross, I.V.; Ford, J.M. 2003: P53 responsive nucleotide excision repair gene products p48 and XPC, but not p53, localize to sites of UV-irradiation-induced DNA damage, in vivo. Carcinogenesis 24(5): 843-850
Vollmer, C.M.; Ribas, A.; Butterfield, L.H.; Dissette, V.B.; Andrews, K.J.; Eilber, F.C.; Montejo, L.D.; Chen, A.Y.; Hu, B.; Glaspy, J.A.; McBride, W.H.; Economou, J.S. 1999: p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma. Cancer Research 59(17): 4369-4374
Biroš, E.; Kalina, I.; Salagovic, J.; Habalová, V.; Hriv ák, M.; Valanský, L. 2000: p53 single nucleotide polymorphisms and bladder cancer. Neoplasma 47(5): 303-306
Liu, L.; Scolnick, D.M.; Trievel, R.C.; Zhang, H.B.; Marmorstein, R.; Halazonetis, T.D.; Berger, S.L. 1999: P53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Molecular and Cellular Biology 19(2): 1202-1209
Magnusson, K.P.; Sandström, M.; Ståhlberg, M.; Larsson, M.; Flygare, J.; Hellgren, D.; Wiman, K.G.; Ljungquist, S. 2000: P53 splice acceptor site mutation and increased HsRAD51 protein expression in Bloom's syndrome GM1492 fibroblasts. Gene 246(1-2): 247-254
Takemoto, S.; Trovato, R.; Cereseto, A.; Nicot, C.; Kislyakova, T.; Casareto, L.; Waldmann, T.; Torelli, G.; Franchini, G. 2000: P53 stabilization and functional impairment in the absence of genetic mutation or the alteration of the p14(ARF)-MDM2 loop in ex vivo and cultured adult T-cell leukemia/lymphoma cells. Blood 95(12): 3939-3944
Tergaonkar, V.; Pando, M.; Vafa, O.; Wahl, G.; Verma, I. 2002: P53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy. Cancer Cell 1(5): 493-503
Ozsaran, A.A.; Türker, S.; Dikmen, Y.; Erhan, Y.; Itil, I.; Terek, C.; Ozdemir, N. 1999: p53 staining as a prognostic indicator in endometrial carcinoma. European Journal of Gynaecological Oncology 20(2): 156-159
Allamane, S.; Ratel, D.; Jourdes, P.; Berger, F.; Benabid, A.L.; Wion, D. 2001: p53 Status and gene transfer experiments using CMV enhancer/promoter. Biochemical and Biophysical Research Communications 280(1): 45-47
Limpaiboon, T.; Pooart, J.; Bhattarakosol, P.; Niruthisard, S.; Chantratita, W.; Lulitanond, V. 2000: p53 status and human papillomavirus infection in Thai women with cervical carcinoma. Southeast Asian Journal of Tropical Medicine and Public Health 31(1): 66-71
Bergqvist, M.; Brattström, D.; Gullbo, J.; Hesselius, P.; Brodin, O.; Wagenius, G. 2003: p53 status and its in vitro relationship to radiosensitivity and chemosensitivity in lung cancer. Anticancer Research 23(2b): 1207-1212
Xinarianos, G.; Liloglou, T.; Prime, W.; Sourvinos, G.; Karachristos, A.; Gosney, J.R.; Spandidos, D.A.; Field, J.K. 2002: p53 status correlates with the differential expression of the DNA mismatch repair protein MSH2 in non-small cell lung carcinoma. International Journal of Cancer 101(3): 248-252
Yamamoto, S.; Tada, M.; Lee, C.C.; Masuda, C.; Wanibuchi, H.; Yoshimura, R.; Wada, S.; Yamamoto, K.; Kishimoto, T.; Fukushima, S. 2000: p53 status in multiple human urothelial cancers: assessment for clonality by the yeast p53 functional assay in combination with p53 immunohistochemistry. Japanese Journal of Cancer Research: Gann 91(2): 181-189
Tanaka, F.; Yanagihara, K.; Ohtake, Y.; Miyahara, R.; Kawano, Y.; Fukuse, T.; Hitomi, S.; Wada, H. 1999: p53 status predicts the efficacy of postoperative oral administration of tegafur for completely resected non-small cell lung cancer. Japanese Journal of Cancer Research: Gann 90(4): 432-438
Ng, C.E.; Banerjee, S.K.; Pavliv, M.; Wang, G.; Raaphorst, G.P.; Aubin, R.A. 1999: P53 status, cellular recovery and cell cycle arrest as prognosticators of in vitro radiosensitivity in human pancreatic adenocarcinoma cell lines. International Journal of Radiation Biology 75(11): 1365-1376
Adell, G.; Sun, X.F.; Stål, O.; Klintenberg, C.; Sjödahl, R.; Nordenskjöld, B. 1999: P53 status: An indicator for the effect of preoperative radiotherapy of rectal cancer. RadioTherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology 51(2): 169-174
Budhram-Mahadeo, V.; Morris, P.J.; Smith, M.D.; Midgley, C.A.; Boxer, L.M.; Latchman, D.S. 1999: P53 suppresses the activation of the Bcl-2 promoter by the Brn-3a POU family transcription factor. Journal of Biological Chemistry 274(21): 15237-15244
Tanikawa, J.; Ichikawa-Iwata, E.; Kanei-Ishii, C.; Nakai, A.; Matsuzawa, S.; Reed, J.C.; Ishii, S. 2000: p53 suppresses the c-Myb-induced activation of heat shock transcription factor 3. Journal of Biological Chemistry 275(20): 15578-15585
Ogden, S.K.; Lee, K.C.; Wernke-Dollries, K.; Stratton, S.A.; Aronow, B.; Barton, M.C. 2001: p53 targets chromatin structure alteration to repress alpha-fetoprotein gene expression. Journal of Biological Chemistry 276(45): 42057-42062
Schwartz, K.A.; Lanciloti, N.J.; Moore, M.K.; Campione, A.L.; Chandar, N. 1999: P53 transactivity during in vitro osteoblast differentiation in a rat osteosarcoma cell line. Molecular Carcinogenesis 25(2): 132-138
Chao, C.; Saito, S.; Kang, J.; Anderson, C.W.; Appella, E.; Xu, Y. 2000: p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage. EMBO Journal 19(18): 4967-4975
Livengood, J.A.; Scoggin, K.E.S.; Van Orden, K.; McBryant, S.J.; Edayathumangalam, R.S.; Laybourn, P.J.; Nyborg, J.K. 2002: p53 Transcriptional activity is mediated through the SRC1-interacting domain of CBP/p300. Journal of Biological Chemistry 277(11): 9054-9061
Hegi, M.E.; Klein, M.A.; Rüedi, D.; Chène, P.; Hamou, M.F.; Aguzzi, A. 2000: p53 transdominance but no gain of function in mouse brain tumor model. Cancer Research 60(11): 3019-3024
Marrogi, A.J.; Khan, M.A.; Vonderheid, E.C.; Wood, G.S.; Mcburney, E. 1999: P53 tumor suppressor gene mutations in transformed cutaneous T-cell lymphoma: A study of 12 cases. Journal of Cutaneous Pathology 26(8): 369-378
Kahlenberg, M.S.; Stoler, D.L.; Rodriguez-Bigas, M.A.; Weber, T.K.; Driscoll, D.L.; Anderson, G.R.; Petrelli, N.J. 2000: P53 tumor suppressor gene mutations predict decreased survival of patients with sporadic colorectal carcinoma. Cancer 88(8): 1814-1819
Cutilli, T.; Papola, F.; Di Emidio, P.; Corbacelli, A. 1998: p53 tumor suppressor protein and H-RAS oncogene in maxillofacial tumors: immunohistochemical and genetic investigation, induction chemotherapy response and prognosis evaluation. Journal of ChemoTherapy 10(5): 411-417
Junker, K.; Wiethege, T.; Müller, K.M.; Thomas, M. 2000: P53 tumour-suppressor gene in non-small-cell lung cancer with neoadjuvant therapy. Journal of Cancer Research and Clinical Oncology 126(4): 238-245
Soussi, T.; Dehouche, K.; Béroud, C. 1999: p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Human Mutation 15(1): 105-113
Chipuk, J.E.; Green, D.R. 2003: P53's believe it or not: Lessons on transcription-independent death. Journal of Clinical Immunology 23(5): 355-361
Storer, R.D.; French, J.E.; Haseman, J.; Hajian, G.; LeGrand, E.K.; Long, G.G.; Mixson, L.A.; Ochoa, R.; Sagartz, J.E.; Soper, K.A. 2001: P53+/- hemizygous knockout mouse: Overview of available data. Toxicologic Pathology 29(Suppl): 30-50
Denis, G.; Humblet, C.; Verlaet, M.; Boniver, J.; Defresne, M.P. 1998: p53, Bax and Bcl-2 in vivo expression in the murine thymus after apoptogenic treatments. Anticancer Research 18(5a): 3315-3321
Vahteristo, P.; Tamminen, A.; Karvinen, P.; Eerola, H.; Eklund, C.; Aaltonen, L.A.; Blomqvist, C.; Aittomäki, K.; Nevanlinna, H. 2001: P53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Research 61(15): 5718-5722
Pagnano, K.B.; Vassallo, J.; Lorand-Metze, I.; Costa, F.F.; Saad, S.T. 2001: p53, Mdm2, and c-Myc overexpression is associated with a poor prognosis in aggressive non-Hodgkin's lymphomas. American Journal of Hematology 67(2): 84-92
Miyauchi, M.; Higashikawa, K.; Sugiyama, M.; Harada, T.; Sasaki, N.; Ishikawa, T. 2000: P53, bcl-2 and bax abnormalities in non-Hodgkin's lymphomas of the head and neck. Journal of Oral Pathology and Medicine: Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 29(4): 180-185
Kikuyama, S.; Inada, T.; Shimizu, K.; Miyakita, M.; Ogata, Y. 2001: p53, bcl-2 and thymidine phosphorylase as predictive markers of chemotherapy in patients with advanced and recurrent gastric cancer. Anticancer Research 21(3c): 2149-2153
Murakami, K.; Mitomi, H.; Yamashita, K.; Tanabe, S.; Saigenji, K.; Okayasu, I. 2001: p53, but not c-Ki-ras, mutation and down-regulation of p21WAF1/CIP1 and cyclin D1 are associated with malignant transformation in gastric hyperplastic polyps. American Journal of Clinical Pathology 115(2): 224-234
Werness, B.A.; Afify, A.M.; Eltabbakh, G.H.; Huelsman, K.; Piver, M.S.; Paterson, J.M. 1999: P53, c-erbB, and Ki-67 expression in ovaries removed prophylactically from women with a family history of ovarian cancer. International Journal of Gynecological Pathology: Official Journal of the International Society of Gynecological Pathologists 18(4): 338-343
Anreder, M.B.; Freeman, S.M.; Merogi, A.; Halabi, S.; Marrogi, A.J. 1999: P53, c-erbB2, and PCNA status in benign, proliferative and malignant ovarian surface epithelial neoplasms: a study of 75 cases. Archives of Pathology and Laboratory Medicine 123(4): 310-316
Fabbrocini, G.; Russo, N.; Pagliuca, M.C.; Delfino, M.; Staibano, S.; Molea, G.; Mancini, A.; Virgili, A.; Valente, M.G.; Bratina, G.; Galbiati, S.; Marzaduri, A.; Orlandi, K.; Bottoni, U.; Calvieri, S.; Di Landro, A.; Cainelli, T.; Delfino, S.; De Rosa, G. 2000: P53, cyclin-D1, PCNA, AgNOR expression in squamous cell cancer of the lip: A multicenter study. Photodermatology Photoimmunology and Photomedicine 16(4): 172-177
Stark, A.M.; Witzel, P.; Strege, R.J.; Hugo, H-H.; Mehdorn, H.M. 2003: P53, mdm2, EGFR, and msh2 expression in paired initial and recurrent glioblastoma multiforme. Journal of Neurology Neurosurgery and Psychiatry 74(6): 779-783
Yanamoto, S.; Kawasaki, G.; Yoshitomi, I.; Mizuno, A. 2002: P53, mdm2, and p21 expression in oral squamous cell carcinomas: Relationship with clinicopathologic factors. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics 94(5): 593-600
Kato, T.; Kameoka, S.; Kimura, T.; Tanaka, S.; Nishikawa, T.; Kobayashi, M. 2002: P53, mitosis, apoptosis and necrosis as prognostic indicators of long-term survival in breast cancer. Anticancer Research 22(2b): 1105-1112
Lee, W.A.; Woo, D.K.; Kim, Y.I.; Kim, W.H. 1999: p53, p16 and RB expression in adenosquamous and squamous cell carcinomas of the stomach. Pathology Research and Practice 195(11): 747-752
Røtterud, R.; Berner, A.; Holm, R.; Skovlund, E.; Fosså, S.D. 2001: P53, p21 and mdm2 expression vs the response to radiotherapy in transitional cell carcinoma of the bladder. BJU International 88(3): 202-208
Kapranos, N.; Stathopoulos, G.P.; Manolopoulos, L.; Kokka, E.; Papadimitriou, C.; Bibas, A.; Yiotakis, J.; Adamopoulos, G. 2001: P53, p21 and p27 protein expression in head and neck cancer and their prognostic value. Anticancer Research 21(1b): 521-528
Hsieh, J.K.; Kletsas, D.; Clunn, G.; Hughes, A.D.; Schachter, M.; Demoliou-Mason, C. 2000: P53, p21(WAF1/CIP1), and MDM2 involvement in proliferation and apoptosis in an in vitro model of conditionally immortalized human vascular smooth muscle cells. Arteriosclerosis Thrombosis and Vascular Biology 20(3): 636-644
Hsieh, J.K.; Kletsas, D.; Clunn, G.; Hughes, A.D.; Schachter, M.; Demoliou-Mason, C. 2000: P53, p21(WAF1/CIP1), and MDM2 involvement in the proliferation and apoptosis in an in vitro model of conditionally immortalized human vascular smooth muscle cells. Arteriosclerosis Thrombosis and Vascular Biology 20(4): 973-981
Moll, U.M.; Erster, S.; Zaika, A. 2001: P53, p63, and p73: Solos, alliances and feuds among family members. Biochimica et Biophysica Acta 1552(2): 47-59, 28 December
Villunger, A.; Michalak, E.M.; Coultas, L.; Müllauer, F.; Böck, G.; Ausserlechner, M.J.; Adams, J.M.; Strasser, A. 2003: p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 302(5647): 1036-1038
El-Mahdy, M.A.; Hamada, F.M.; Wani, M.A.; Zhu, Q.; Wani, A.A. 2000: P53-Degradation by HPV-16 E6 preferentially affects the removal of cyclobutane pyrimidine dimers from non-transcribed strand and sensitizes mammary epithelial cells to UV-irradiation. Mutation Research 459(2): 135-145
Li, G.; Bush, J.A.; Ho, V.C. 2000: p53-dependent apoptosis in melanoma cells after treatment with camptothecin. Journal of Investigative Dermatology 114(3): 514-519
He, A.W.; Cory, J.G. 1999: P53-independent anisomycin induced G1 arrest and apoptosis in L1210 cell lines. Anticancer Research 19(1a): 421-428
Casenghi, M.; Mangiacasale, R.; Tuynder, M.; Caillet-Fauquet, P.; Elhajouji, A.; Lavia, P.; Mousset, S.; Kirsch-Volders, M.; Cundari, E. 1999: p53-independent apoptosis and p53-dependent block of DNA rereplication following mitotic spindle inhibition in human cells. Experimental Cell Research 250(2): 339-350
Peterson, E.J.; Bögler, O.; Taylor, S.M. 2003: p53-mediated repression of DNA methyltransferase 1 expression by specific DNA binding. Cancer Research 63(20): 6579-6582
Fortuño, M.A.; Zalba, G.; Ravassa, S.; D'Elom, E.; Beaumont, F.J.; Fortuño, A.; Díez, J. 1999: P53-mediated upregulation of BAX gene transcription is not involved in Bax-alpha protein overexpression in the left ventricle of spontaneously hypertensive rats. Hypertension 33(6): 1348-1352
Gila, L.; Elena, N.; Yechezkel, S.; Mary, B. 2003: P53-associated 3'fwdarw5' exonuclease activity in nuclear and cytoplasmic compartments of cells. Oncogene 22(2): 233-245, 16 January
Fedier, Aé.; Moawad, A.; Haller, U.; Fink, D. 2003: P53-deficient cells display increased sensitivity to anthracyclines after loss of the catalytic subunit of the DNA-dependent protein kinase. International Journal of Oncology 23(5): 1431-1437
Badie, C.; Bourhis, J.; Sobczak-Thépot, J.; Haddada, H.; Chiron, M.; Janicot, M.; Janot, F.; Tursz, T.; Vassal, G. 2000: p53-dependent G2 arrest associated with a decrease in cyclins A2 and B1 levels in a human carcinoma cell line. British Journal of Cancer 82(3): 642-650
Scoggins, C.R.; Meszoely, I.M.; Wada, M.; Means, A.L.; Yang, L.; Leach, S.D. 2000: P53-dependent acinar cell apoptosis triggers epithelial proliferation in duct-ligated murine pancreas. American Journal of Physiology. Gastrointestinal and Liver Physiology 279(4): G827-G836
Morrison, R.S.; Kinoshita, Y.; Johnson, M.D.; Guo, W.; Garden, G.A. 2003: P53-dependent cell death signaling in neurons. Neurochemical Research 28(1): 15-27
Xu, D.; Falke, D.; Juliano, R.L. 2003: P53-dependent cell-killing by selective repression of thymidine kinase and reduced prodrug activation. Molecular Pharmacology 64(2): 289-297
Flatt, P.M.; Polyak, K.; Tang, L.J.; Scatena, C.D.; Westfall, M.D.; Rubinstein, L.A.; Yu, J.; Kinzler, K.W.; Vogelstein, B.; Hill, D.E.; Pietenpol, J.A. 2000: P53-dependent expression of PIG3 during proliferation, genotoxic stress, and reversible growth arrest. Cancer Letters 156(1): 63-72
Tomasini, R.; Samir, A.Azizi.; Pebusque, M-Josèphe.; Calvo, E.L.; Totaro, S.; Dagorn, J.Charles.; Dusetti, N.J.; Iovanna, J.L. 2002: P53-dependent expression of the stress-induced protein (SIP). European Journal of Cell Biology 81(5): 294-301
Takahashi, A.; Ota, I.; Tamamoto, T.; Asakawa, I.; Nagata, Y.; Nakagawa, H.; Kondo, N.; Ohnishi, K.; Furusawa, Y.; Matsumoto, H.; Ohnishi, T. 2003: P53-dependent hyperthermic enhancement of tumour growth inhibition by X-ray or carbon-ion beam irradiation. International Journal of Hyperthermia: the Official Journal of European Society for Hyperthermic Oncology North American Hyperthermia Group 19(2): 145-153
Gao, C.; Zou, Z.; Xu, L.; Moul, J.; Seth, P.; Srivastava, S. 2000: P53-dependent induction of heat shock protein 27 (hsp27) expression. International Journal of Cancer 88(2): 191-194
Helt, C.E.; Rancourt, R.C.; Staversky, R.J.; O'reilly, M.A. 2001: P53-dependent induction of p21(Cip1/WAF1/Sdi1) protects against oxygen-induced toxicity. Toxicological Sciences: An Official Journal of the Society of Toxicology 63(2): 214-222
Concin, N.; Zeillinger, C.; Stimpfel, M.; Schiebel, I.; Tong, D.; Wolff, U.; Reiner, A.; Leodolter, S.; Zeillinger, R. 2000: P53-dependent radioresistance in ovarian carcinoma cell lines. Cancer Letters 150(2): 191-199
Quenneville, L.A.; Trotter, M.J.; Maeda, T.; Tron, V.A. 2002: P53-dependent regulation of heat shock protein 72. British Journal of Dermatology 146(5): 786-791
Sun, P.; Dong, P.; Dai, K.; Hannon, G.J.; Beach, D. 1998: P53-independent role of MDM2 in TGF-beta1 resistance. Science 282(5397): 2270-2272
Zhang, D.; Cao, D.; Russell, R.; Pizzorno, G. 2001: p53-dependent suppression of uridine phosphorylase gene expression through direct promoter interaction. Cancer Research 61(18): 6899-6905
Takahashi, A.; Ohnishi, K.; Ota, I.; Asakawa, I.; Tamamoto, T.; Furusawa, Y.; Matsumoto, H.; Ohnishi, T. 2001: p53-dependent thermal enhancement of cellular sensitivity in human squamous cell carcinomas in relation to LET. International Journal of Radiation Biology 77(10): 1043-1051
Jaiswal, A.S.; Narayan, S. 2001: p53-dependent transcriptional regulation of the APC promoter in colon cancer cells treated with DNA alkylating agents. Journal of Biological Chemistry 276(21): 18193-18199
Kwun, H.Jin.; Jung, E.Young.; Ahn, J.Young.; Lee, M.Nam.; Jang, K.Lib. 2001: P53-dependent transcriptional repression of p21(waf1) by hepatitis C virus NS3. Journal of General Virology 82(Pt 9): 2235-2241
Phelps, M.; Darley, M.; Primrose, J.N.; Blaydes, J.P. 2003: P53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells. Cancer Research 63(10): 2616-2623
Harada, J.N.; Berk, A.J. 1999: P53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. Journal of Virology 73(7): 5333-5344
Kumlin, T.; Heikkinen, Päivi.; Kosma, V-Matti.; Alhonen, L.; Jänne, J.; Juutilainen, J. 2002: P53-independent apoptosis in UV-irradiated mouse skin: Possible inhibition by 50 Hz magnetic fields. Radiation and Environmental Biophysics 41(2): 155-158
Gottifredi, V.; Peschiaroli, A.; Fimia, G.M.; Maione, R. 1999: P53-independent apoptosis induced by muscle differentiation stimuli in polyomavirus large T-expressing myoblasts. Journal of Cell Science 112: 2397-2407
Tsuji, K.; Mizumoto, K.; Sudo, H.; Kouyama, K.; Ogata, E.; Matsuoka, M. 2002: P53-independent apoptosis is induced by the p19ARF tumor suppressor. Biochemical and Biophysical Research Communications 295(3): 621-629
Abeysinghe, R.D.; Greene, B.T.; Haynes, R.; Willingham, M.C.; Turner, J.; Planalp, R.P.; Brechbiel, M.W.; Torti, F.M.; Torti, S.V. 2001: P53-independent apoptosis mediated by tachpyridine, an anti-cancer iron chelator. Carcinogenesis 22(10): 1607-1614
Yuan, R.; Meng, Q.; Hu, H.; Goldberg, I.D.; Rosen, E.M.; Fan, S. 2001: P53-independent downregulation of p73 in human cancer cells treated with Adriamycin. Cancer Chemotherapy and Pharmacology 47(2): 161-169
Park, J.W.; Jang, M.A.; Lee, Y.H.; Passaniti, A.; Kwon, T.K. 2001: p53-independent elevation of p21 expression by PMA results from PKC-mediated mRNA stabilization. Biochemical and Biophysical Research Communications 280(1): 244-248
Sato, T.; Koseki, T.; Yamato, K.; Saiki, K.; Konishi, K.; Yoshikawa, M.; Ishikawa, I.; Nishihara, T. 2002: P53-independent expression of p21(CIP1/WAF1) in plasmacytic cells during G(2) cell cycle arrest induced by Actinobacillus actinomycetemcomitans cytolethal distending toxin. Infection and Immunity 70(2): 528-534
Meng, Raymond, D.; Phillips, Peter; El-Deiry, Wafik, S. 1999: P53-independent increase in E2F-1 expression enhances the cytotoxic effects of etoposide and of adriamycin. International Journal of Oncology 14(1): 5-14
Kim, S.Gon.; Ravi, G.; Hoffmann, C.; Jung, Y.Jin.; Kim, M.; Chen, A.; Jacobson, K.A. 2002: p53-Independent induction of Fas and apoptosis in leukemic cells by an adenosine derivative, Cl-IB-MECA. Biochemical Pharmacology 63(5): 871-880
Choi, Y.H.; Lee, W.H.; Park, K.Y.; Zhang, L. 2000: p53-independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Japanese Journal of Cancer Research: Gann 91(2): 164-173
Petit, T.; Bearss, D.J.; Troyer, D.A.; Munoz, R.M.; Windle, J.J. 2003: p53-independent response to cisplatin and oxaliplatin in MMTV-ras mouse salivary tumors. Molecular Cancer Therapeutics 2(2): 165-171
Katano, H.; Masago, A.; Taki, H.; Nakatsuka, M.; Fuse, T.; Yamada, K. 2000: P53-independent transient p21(WAF1/CIP1) mRNA induction in the rat brain following experimental traumatic injury. Neuroreport 11(10): 2073-2078
Meng, R.D.; El-Deiry, W.S. 2001: p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma. Experimental Cell Research 262(2): 154-169
Asker, C.; Wiman, K.G.; Selivanova, G. 1999: p53-induced apoptosis as a safeguard against cancer. Biochemical and Biophysical Research Communications 265(1): 1-6
Liang, X-Qui.; Cao, E-Hua.; Zhang, Y.; Qin, J-Fen. 2003: P53-induced gene 11 (PIG11) involved in arsenic trioxide-induced apoptosis in human gastric cancer MGC-803 cells. Oncology Reports 10(5): 1265-1269
Takekawa, M.; Adachi, M.; Nakahata, A.; Nakayama, I.; Itoh, F.; Tsukuda, H.; Taya, Y.; Imai, K. 2000: p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. EMBO Journal 19(23): 6517-6526
Smith, M.L.; Ford, J.M.; Hollander, M.C.; Bortnick, R.A.; Amundson, S.A.; Seo, Y.R.; Deng, C.X.; Hanawalt, P.C.; Fornace, A.J. 2000: P53-mediated DNA repair responses to UV radiation: Studies of mouse cells lacking p53, p21, and/or gadd45 genes. Molecular and Cellular Biology 20(10): 3705-3714
Robles, A., I.; Harris, C., C. 2001: P53-mediated apoptosis and genomic instability diseases. Acta Oncologica (Stockholm) 40(6): 696-701
Chylicki, K.; Ehinger, M.; Svedberg, H.; Bergh, G.; Olsson, I.; Gullberg, U. 2000: p53-mediated differentiation of the erythroleukemia cell line K562. Cell Growth and Differentiation: the Molecular Biology Journal of the American Association for Cancer Research 11(6): 315-324
Cummings, M.; Siitonen, T.; Higginbottom, K.; Newland, A.C.; Allen, P.D. 2002: P53-mediated downregulation of Chk1 abrogates the DNA damage-induced G2M checkpoint in K562 cells, resulting in increased apoptosis. British Journal of Haematology 116(2): 421-428
Han, J.A.; Kim, J-Il.; Ongusaha, P.P.; Hwang, D.H.; Ballou, L.R.; Mahale, A.; Aaronson, S.A.; Lee, S.W. 2002: P53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-induced apoptosis. EMBO Journal 21(21): 5635-5644
Johnsen, J.I.; Aurelio, O.N.; Kwaja, Z.; Jörgensen, G.E.; Pellegata, N.S.; Plattner, R.; Stanbridge, E.J.; Cajot, J.F. 2000: P53-mediated negative regulation of stathmin/Op18 expression is associated with G(2)/M cell-cycle arrest. International Journal of Cancer 88(5): 685-691
Lee, K.C.; Crowe, A.J.; Barton, M.C. 1999: P53-mediated repression of alpha-fetoprotein gene expression by specific DNA binding. Molecular and Cellular Biology 19(2): 1279-1288
Prevo, L.J.; Sanchez, C.A.; Galipeau, P.C.; Reid, B.J. 1999: p53-mutant clones and field effects in Barrett's esophagus. Cancer Research 59(19): 4784-4787
Kasper, H.U.; Schneider-Stock, R.; Mellin, W.; Günther, T.; Roessner, A. 2000: P53-protein accumulation and MDM2-protein overexpression in gastric carcinomas. No apparent correlation with survival. Pathology Research and Practice 195(12): 815-820
Higashiyama, M.; Miyoshi, Y.; Kodama, K.; Yokouchi, H.; Takami, K.; Nishijima, M.; Nakayama, T.; Kobayashi, H.; Minamigawa, K.; Nakamura, Y. 2000: P53-regulated GML gene expression in non-small cell lung cancer. a promising relationship to cisplatin chemosensitivity. European Journal of Cancer 36(4): 489-495
Papavassiliou, A.G. 2000: P53-Targeted drugs: intelligent weapons in the tumor-suppressing arsenal. Journal of Cancer Research and Clinical Oncology 126(2): 117-118
Wang, Q.M.; Studzinski, G.P.; Chen, F.; Coffman, F.D.; Harrison, L.E. 2000: p53/56(lyn) antisense shifts the 1,25-dihydroxyvitamin D3-induced G1/S block in HL60 cells to S phase. Journal of Cellular Physiology 183(2): 238-246
Narayanan, B.A.; Geoffroy, O.; Willingham, M.C.; Re, G.G.; Nixon, D.W. 1999: P53/p21(WAF1/CIP1) expression and its possible role in G1 arrest and apoptosis in ellagic acid treated cancer cells. Cancer Letters 136(2): 215-221
Huang, S.; Liu, L.N.; Hosoi, H.; Dilling, M.B.; Shikata, T.; Houghton, P.J. 2001: P53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin. Cancer Research 61(8): 3373-3381
Chikamatsu, K.; Albers, A.; Stanson, J.; Kwok, W.W.; Appella, E.; Whiteside, T.L.; DeLeo, A.B. 2003: P53(110-124)-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells. Cancer Research 63(13): 3675-3681
Moore, B.E.; Banner, B.F.; Gokden, M.; Woda, B.; Liu, Y.; Ayala, A.; Jiang, Z. 2001: P53: A good diagnostic marker for intratubular germ cell neoplasia, unclassified. Applied Immunohistochemistry and Molecular Morphology: Aimm 9(3): 203-206
Blagosklonny, M.V. 2002: P53: An ubiquitous target of anticancer drugs. International Journal of Cancer 98(2): 161-166
Dahm-Daphi, J. 2000: P53: Biology and role for cellular radiosensitivity. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft . 176(6): 278-285
Soddu, S.; Sacchi, A. 1998: p53: prospects for cancer gene therapy. Cytokines Cellular and Molecular Therapy 4(3): 177-185
Matsuda, K.; Yoshida, K.; Taya, Y.; Nakamura, K.; Nakamura, Y.; Arakawa, H. 2002: p53AIP1 regulates the mitochondrial apoptotic pathway. Cancer Research 62(10): 2883-2889
Oda, K.; Arakawa, H.; Tanaka, T.; Matsuda, K.; Tanikawa, C.; Mori, T.; Nishimori, H.; Tamai, K.; Tokino, T.; Nakamura, Y.; Taya, Y. 2000: P53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102(6): 849-862
Tan, M.; Bian, J.; Guan, K.; Sun, Y. 2001: P53CP is p51/p63, the third member of the p53 gene family: Partial purification and characterization. Carcinogenesis 22(2): 295-300
Okamura, S.; Arakawa, H.; Tanaka, T.; Nakanishi, H.; Ng, C.C.; Taya, Y.; Monden, M.; Nakamura, Y. 2001: P53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis. Molecular Cell 8(1): 85-94
Yamaguchi, T.; Matsuda, K.; Sagiya, Y.; Iwadate, M.; Fujino, M.A.; Nakamura, Y.; Arakawa, H. 2001: p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint. Cancer Research 61(22): 8256-8262
Ishitani, K.; Yoshida, T.; Kitagawa, H.; Ohta, H.; Nozawa, S.; Kato, S. 2003: P54nrb acts as a transcriptional coactivator for activation function 1 of the human androgen receptor. Biochemical and Biophysical Research Communications 306(3): 660-665
Meyer, P.; Janin, J.; Baudet-Nessler, S. 1999: P55-hGRF, a short natural form of the Ras-GDP exchange factor high yield production and characterization. European Journal of Biochemistry 263(3): 806-816
Lin, M.L.; Sakamoto, K.M. 2001: p55Cdc/cdc20 overexpression promotes early g1/s transition in myeloid cells. Stem Cells 19(3): 205-211
Suzu, S.; Tanaka-Douzono, M.; Nomaguchi, K.; Yamada, M.; Hayasawa, H.; Kimura, F.; Motoyoshi, K. 2000: p56(dok-2) as a cytokine-inducible inhibitor of cell proliferation and signal transduction. EMBO Journal 19(19): 5114-5122
Broadbridge, R.J.; Sharma, R.P. 1999: P56lck SH2 domain binding motifs from bead binding screening of peptide libraries containing phosphotyrosine surrogates. Letters in Peptide Science 6(5-6): 335-341
Goldmann, W.H. 2002: P56(lck) Controls phosphorylation of filamin (ABP-280) and regulates focal adhesion kinase (pp125(FAK)). Cell Biology International 26(6): 567-571
Ouellet, M.; Barbeau, B.; Tremblay, M.J. 1999: P56(lck), ZAP-70, SLP-76, and calcium-regulated effectors are involved in NF-kappaB activation by bisperoxovanadium phosphotyrosyl phosphatase inhibitors in human T cells. Journal of Biological Chemistry 274(49): 35029-35036
Nijjar, T.; Wigington, D.; Garbe, J.C.; Waha, A.; Stampfer, M.R.; Yaswen, P. 1999: P57KIP2 expression and loss of heterozygosity during immortal conversion of cultured human mammary epithelial cells. Cancer Research 59(20): 5112-5118
Kassem, S.A.; Ariel, I.; Thornton, P.S.; Hussain, K.; Smith, V.; Lindley, K.J.; Aynsley-Green, A.; Glaser, B. 2001: P57(KIP2) expression in normal islet cells and in hyperinsulinism of infancy. Diabetes 50(12): 2763-2769
Hartmann, W.; Waha, A.; Koch, A.; Goodyer, C.G.; Albrecht, S.; von Schweinitz, D.; Pietsch, T. 2000: p57(KIP2) is not mutated in hepatoblastoma but shows increased transcriptional activity in a comparative analysis of the three imprinted genes p57(KIP2), IGF2, and H19. American Journal of Pathology 157(4): 1393-1403
Kochilas, L.K.; Li, J.; Jin, F.; Buck, C.A.; Epstein, J.A. 1999: p57Kip2 expression is enhanced during mid-cardiac murine development and is restricted to trabecular myocardium. Pediatric Research 45(5 Part 1): 635-642
Urano, T.; Yashiroda, H.; Muraoka, M.; Tanaka, K.; Hosoi, T.; Inoue, S.; Ouchi, Y.; Toyoshima, H. 1999: P57(Kip2) is degraded through the proteasome in osteoblasts stimulated to proliferation by transforming growth factor beta1. Journal of Biological Chemistry 274(18): 12197-12200
Dyer, M.A.; Cepko, C.L. 2000: P57(Kip2) regulates progenitor cell proliferation and amacrine interneuron development in the mouse retina. Development 127(16): 3593-3605
Reynaud, E.G.; Pelpel, K.; Guillier, M.; Leibovitch, M.P.; Leibovitch, S.A. 1999: P57(Kip2) stabilizes the MyoD protein by inhibiting cyclin E-Cdk2 kinase activity in growing myoblasts. Molecular and Cellular Biology 19(11): 7621-7629
Samuelsson, M.K.; Pazirandeh, A.; Davani, B.; Okret, S. 1999: p57Kip2, a glucocorticoid-induced inhibitor of cell cycle progression in HeLa cells. Molecular Endocrinology 13(11): 1811-1822
Jun, S-Y.; Ro, J.Y.; Kim, K-R. 2003: P57kip2 is useful in the classification and differential diagnosis of complete and partial hydatidiform moles. Histopathology 43(1): 17-25
Carréno, Sébastien.; Caron, E.; Cougoule, Céline.; Emorine, L.J.; Maridonneau-Parini, I. 2002: p59Hck isoform induces F-actin reorganization to form protrusions of the plasma membrane in a Cdc42- and Rac-dependent manner. Journal of Biological Chemistry 277(23): 21007-21016
Chang, S.; Kim, J.H.; Shin, J. 2002: P62 forms a ternary complex with PKCzeta and PAR-4 and antagonizes PAR-4-induced PKCzeta inhibition. Febs Letters 510(1-2): 57-61
Sudo, T.; Maruyama, M.; Osada, H. 2000: p62 functions as a p38 MAP kinase regulator. Biochemical and Biophysical Research Communications 269(2): 521-525
Zatloukal, K.; Stumptner, C.; Fuchsbichler, A.; Heid, H.; Schnoelzer, M.; Kenner, L.; Kleinert, R.; Prinz, M.; Aguzzi, A.; Denk, H. 2002: p62 Is a common component of cytoplasmic inclusions in protein aggregation diseases. American Journal of Pathology 160(1): 255-263
Filippini, D.; Bozzoni, I.; Caffarelli, E. 2000: p62, a novel Xenopus laevis component of box C/D snoRNPs. Rna 6(3): 391-401
Joung, I. 2001: P62, a phosphotyrosine independent ligand of SH2 domain of p56lck, is cleaved by caspase-3 during apoptosis in Jurkat cells. Korean Journal of Biological Sciences 5(2): 145-151
Di Cristofano, A.; Niki, M.; Zhao, M.; Karnell, F.G.; Clarkson, B.; Pear, W.S.; Van Aelst, L.; Pandolfi, P.P. 2001: P62(dok), a negative regulator of Ras and mitogen-activated protein kinase (MAPK) activity, opposes leukemogenesis by p210(bcr-abl). Journal of Experimental Medicine 194(3): 275-284
De Laurenzi, V.; Rossi, A.; Terrinoni, A.; Barcaroli, D.; Levrero, M.; Costanzo, A.; Knight, R.A.; Guerrieri, P.; Melino, G. 2000: p63 and p73 transactivate differentiation gene promoters in human keratinocytes. Biochemical and Biophysical Research Communications 273(1): 342-346
Ince, T.A.; Cviko, A.P.; Quade, B.J.; Yang, A.; McKeon, F.D.; Mutter, G.L.; Crum, C.P. 2002: p63 Coordinates anogenital modeling and epithelial cell differentiation in the developing female urogenital tract. American Journal of Pathology 161(4): 1111-1117
Tsujita-Kyutoku, M.; Kiuchi, K.; Danbara, N.; Yuri, T.; Senzaki, H.; Tsubura, A. 2003: P63 expression in normal human epidermis and epidermal appendages and their tumors. Journal of Cutaneous Pathology 30(1): 11-17
Reis-Filho, J.S.; Torio, B.; Albergaria, Aé.; Schmitt, F.C. 2002: P63 expression in normal skin and usual cutaneous carcinomas. Journal of Cutaneous Pathology 29(9): 517-523
Reis-Filho, J.S.; Preto, A.; Soares, P.; Ricardo, S.; Cameselle-Teijeiro, Jé.; Sobrinho-Simões, M. 2003: p63 expression in solid cell nests of the thyroid: further evidence for a stem cell origin. Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology Inc 16(1): 43-48
Suliman, Y.; Opitz, O.G.; Avadhani, A.; Burns, T.C.; El-Deiry, W.; Wong, D.T.; Rustgi, A.K. 2001: p63 expression is associated with p53 loss in oral-esophageal epithelia of p53-deficient mice. Cancer Research 61(17): 6467-6473
Pelosi, G.; Pasini, F.; Olsen Stenholm, C.; Pastorino, U.; Maisonneuve, P.; Sonzogni, A.; Maffini, F.; Pruneri, G.; Fraggetta, F.; Cavallon, A.; Roz, E.; Iannucci, A.; Bresaola, E.; Viale, G. 2002: p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas?. Journal of Pathology 198(1): 100-109
Pruneri, G.; Pignataro, L.; Manzotti, M.; Carboni, N.; Ronchetti, D.; Neri, A.; Cesana, B.Mario.; Viale, G. 2002: P63 in laryngeal squamous cell carcinoma: Evidence for a role of TA-p63 down-regulation in tumorigenesis and lack of prognostic implications of p63 immunoreactivity. Laboratory Investigation; a Journal of Technical Methods and Pathology 82(10): 1327-1334
Wang, B.Y.; Gil, J.; Kaufman, D.; Gan, L.; Kohtz, D.Stave.; Burstein, D.E. 2002: P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. Human Pathology 33(9): 921-926
Signoretti, S.; Waltregny, D.; Dilks, J.; Isaac, B.; Lin, D.; Garraway, L.; Yang, A.; Montironi, R.; McKeon, F.; Loda, M. 2000: p63 is a prostate basal cell marker and is required for prostate development. American Journal of Pathology 157(6): 1769-1775
Bilal, H.; Handra-Luca, A.; Bertrand, J-Charles.; Fouret, P.J. 2003: P63 is expressed in basal and myoepithelial cells of human normal and tumor salivary gland tissues. Journal of Histochemistry and Cytochemistry: Official Journal of the Histochemistry Society 51(2): 133-139
Parsons, J.K.; Gage, W.R.; Nelson, W.G.; De Marzo, A.M. 2001: P63 protein expression is rare in prostate adenocarcinoma: Implications for cancer diagnosis and carcinogenesis. Urology 58(4): 619-624
Reis-Filho, J.S.; Milanezi, F.; Amendoeira, I.; Albergaria, A.; Schmitt, F.C. 2002: P63 staining of myoepithelial cells in breast fine needle aspirates: A study of its role in differentiating in situ from invasive ductal carcinomas of the breast. Journal of Clinical Pathology 55(12): 936-939
Barbareschi, M.; Pecciarini, L.; Cangi, M.G.; Macrì, E.; Rizzo, A.; Viale, G.; Doglioni, C. 2001: P63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. American Journal of Surgical Pathology 25(8): 1054-1060
Espinosa, Lís.; Santos, S.; Inglés-Esteve, J.; Muñoz-Canoves, P.; Bigas, A. 2002: p65-NFkappaB synergizes with Notch to activate transcription by triggering cytoplasmic translocation of the nuclear receptor corepressor N-CoR. Journal of Cell Science 115(Pt 6): 1295-1303
Ito, K.; Jazrawi, E.; Cosio, B.; Barnes, P.J.; Adcock, I.M. 2001: p65-activated histone acetyltransferase activity is repressed by glucocorticoids: mifepristone fails to recruit HDAC2 to the p65-HAT complex. Journal of Biological Chemistry 276(32): 30208-30215
Purdom, S.; Chen, Q.M. 2003: P66(Shc): at the crossroad of oxidative stress and the genetics of aging. Trends in Molecular Medicine 9(5): 206-210
Cho, S.Y.; Jeon, J.W.; Lee, S.H.; Park, S.S. 2000: P67 isoform of mouse disabled 2 protein acts as a transcriptional activator during the differentiation of F9 cells. Biochemical Journal 352 Pt 3: 645-650
Liu, Z-Ren. 2002: P68 RNA helicase is an essential human splicing factor that acts at the U1 snRNA-5' splice site duplex. Molecular and Cellular Biology 22(15): 5443-5450
Seufert, D.W.; Kos, R.; Erickson, C.A.; Swalla, B.J. 2000: P68, a DEAD-box RNA helicase, is expressed in chordate embryo neural and mesodermal tissues. Journal of Experimental Zoology 288(3): 193-204
Canicio, J.; Gallardo, E.; Illa, I.; Testar, X.; Palacín, M.; Zorzano, A.; Kaliman, P. 1998: p70 S6 kinase activation is not required for insulin-like growth factor-induced differentiation of rat, mouse, or human skeletal muscle cells. Endocrinology 139(12): 5042-5049
Romanelli, A.; Martin, K.A.; Toker, A.; Blenis, J. 1999: p70 S6 kinase is regulated by protein kinase Czeta and participates in a phosphoinositide 3-kinase-regulated signalling complex. Molecular and Cellular Biology 19(4): 2921-2928
Viñals, F.; Chambard, J.C.; Pouysségur, J. 1999: p70 S6 kinase-mediated protein synthesis is a critical step for vascular endothelial cell proliferation. Journal of Biological Chemistry 274(38): 26776-26782
Schwab, M.S.; Kim, S.H.; Terada, N.; Edfjäll, C.; Kozma, S.C.; Thomas, G.; Maller, J.L. 1999: P70(S6K) controls selective mRNA translation during oocyte maturation and early embryogenesis in Xenopus laevis. Molecular and Cellular Biology 19(4): 2485-2494
Brennan, P.; Babbage, J.W.; Thomas, G.; Cantrell, D. 1999: P70(s6k) integrates phosphatidylinositol 3-kinase and rapamycin-regulated signals for E2F regulation in T lymphocytes. Molecular and Cellular Biology 19(7): 4729-4738
Davison, T.S.; Vagner, C.; Kaghad, M.; Ayed, A.; Caput, D.; Arrowsmith, C.H. 1999: P73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53. Journal of Biological Chemistry 274(26): 18709-18714
Matos, P.; Isidro, G.; Vieira, E.; Lacerda, A.F.; Martins, A.G.; Boavida, M.G. 2001: P73 expression in neuroblastoma: a role in the biology of advanced tumors?. Pediatric Hematology and Oncology 18(1): 37-46
Di Como, C.J.; Gaiddon, C.; Prives, C. 1999: P73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Molecular and Cellular Biology 19(2): 1438-1449
El-Naggar, A.K.; Lai, S.; Clayman, G.L.; Mims, B.; Lippman, S.M.; Coombes, M.; Luna, M.A.; Lozano, G. 2001: P73 gene alterations and expression in primary oral and laryngeal squamous carcinomas. Carcinogenesis 22(5): 729-735
Pilozzi, E.; Talerico, C.; Platt, A.; Fidler, C.; Ruco, L. 2003: p73 gene mutations in gastric adenocarcinomas. Molecular Pathology: Mp 56(1): 60-62
Loiseau, H.; Arsaut, J.; Demotes-Mainard, J. 1999: P73 gene transcripts in human brain tumors: Overexpression and altered splicing in ependymomas. Neuroscience Letters 263(2-3): 173-176
Stiewe, T.; Pützer, B.M. 2001: P73 in apoptosis. Apoptosis: An International Journal on Programmed Cell Death 6(6): 447-452
Hackzell, A.; Uramoto, H.; Izumi, H.; Kohno, K.; Funa, K. 2002: p73 independent of c-Myc represses transcription of platelet-derived growth factor beta-receptor through interaction with NF-Y. Journal of Biological Chemistry 277(42): 39769-39776
Uramoto, H.; Izumi, H.; Ise, T.; Tada, M.; Uchiumi, T.; Kuwano, M.; Yasumoto, K.; Funa, K.; Kohno, K. 2002: p73 Interacts with c-Myc to regulate Y-box-binding protein-1 expression. Journal of Biological Chemistry 277(35): 31694-31702
Weiss, R.H.; Howard, L.L. 2001: p73 is a growth-regulated protein in vascular smooth muscle cells and is present at high levels in human atherosclerotic plaque. Cellular Signalling 13(10): 727-733
Rödicker, F.; Pützer, B.M. 2003: p73 is effective in p53-null pancreatic cancer cells resistant to wild-type TP53 gene replacement. Cancer Research 63(11): 2737-2741
Ichimiya, S.; Kojima, T.; Momota, H.; Kondo, N.; Ozaki, T.; Nakagawara, A.; Toribio, Mía.Luisa.; Imamura, M.; Sato, N. 2002: P73 is expressed in human thymic epithelial cells. Journal of Histochemistry and Cytochemistry: Official Journal of the Histochemistry Society 50(4): 455-462
Yamamoto, T.; Oda, K.; Miyazaki, K.; Ichigotani, Y.; Takenouchi, Y.; Kamei, T.; Shirafuji, N.; Nimura, Y.; Hamaguchi, M.; Matsuda, S. 2001: P73 is highly expressed in myoepithelial cells and in carcinomas with metaplasia. International Journal of Oncology 19(2): 271-276
Nozaki, M.; Tada, M.; Kashiwazaki, H.; Hamou, M.F.; Diserens, A.C.; Shinohe, Y.; Sawamura, Y.; Iwasaki, Y.; de Tribolet, N.; Hegi, M.E. 2001: P73 is not mutated in meningiomas as determined with a functional yeast assay but p73 expression increases with tumor grade. Brain Pathology 11(3): 296-305
Pozniak, C.D.; Barnabé-Heider, F.; Rymar, V.V.; Lee, A.F.; Sadikot, A.F.; Miller, F.D. 2002: p73 is required for survival and maintenance of CNS neurons. Journal of Neuroscience: the Official Journal of the Society for Neuroscience 22(22): 9800-9809
Herath, N.I.; Kew, M.C.; Whitehall, V.L.; Walsh, M.D.; Jass, J.R.; Khanna, K.K.; Young, J.; Powell, L.W.; Leggett, B.A.; Macdonald, G.A. 2000: p73 is up-regulated in a subset of hepatocellular carcinomas. Hepatology 31(3): 601-605
Guan, M.; Peng, H-Xia.; Yu, B.; Lu, Y. 2003: P73 overexpression and angiogenesis in human colorectal carcinoma. Japanese Journal of Clinical Oncology 33(5): 215-220
Zemel, R.; Koren, C.; Bachmatove, L.; Avigad, S.; Kaganovsky, E.; Okon, E.; Ben-Ari, Z.; Grief, F.; Ben-Yehoyada, M.; Shaul, Y.; Tur-Kaspa, R. 2002: P73 overexpression and nuclear accumulation in hepatitis C virus-associated hepatocellular carcinoma. Digestive Diseases and Sciences 47(4): 716-722
Frasca, F.; Vella, V.; Aloisi, A.; Mandarino, A.; Mazzon, E.; Vigneri, R.; Vigneri, P. 2003: p73 tumor-suppressor activity is impaired in human thyroid cancer. Cancer Research 63(18): 5829-5837
Shinbo, J.; Ozaki, T.; Nakagawa, T.; Watanabe, K-ichi.; Nakamura, Y.; Yamazaki, M.; Moriya, H.; Nakagawara, A.; Sakiyama, S. 2002: P73-dependent expression of DAN during cisplatin-induced cell death and osteoblast differentiation. Biochemical and Biophysical Research Communications 295(2): 501-507
Gonzalez, S.; Prives, C.; Cordon-Cardo, C. 2003: p73alpha regulation by Chk1 in response to DNA damage. Molecular and Cellular Biology 23(22): 8161-8171
Ren, J.; Datta, R.; Shioya, H.; Li, Y.; Oki, E.; Biedermann, V.; Bharti, A.; Kufe, D. 2002: p73beta is regulated by protein kinase Cdelta catalytic fragment generated in the apoptotic response to DNA damage. Journal of Biological Chemistry 277(37): 33758-33765
Ueda, Y.; Hijikata, M.; Takagi, S.; Takada, R.; Takada, S.; Chiba, T.; Shimotohno, K. 2001: p73beta, a variant of p73, enhances Wnt/beta-catenin signaling in Saos-2 cells. Biochemical and Biophysical Research Communications 283(2): 327-333
Gatzinsky, K.P.; Haugland, R.P.; Thrasivoulou, C.; Orike, N.; Budi-Santoso, A.W.; Cowen, T. 2001: P75 and TrkA receptors are both required for uptake of NGF in adult sympathetic neurons: Use of a novel fluorescent NGF conjugate. Brain Research 920(1-2): 226-238
Zaccaro, M.C.; Ivanisevic, L.; Perez, P.; Meakin, S.O.; Saragovi, H.U. 2001: p75 Co-receptors regulate ligand-dependent and ligand-independent Trk receptor activation, in part by altering Trk docking subdomains. Journal of Biological Chemistry 276(33): 31023-31029
Bentley, C.A.; Lee, K.F. 2000: p75 is important for axon growth and schwann cell migration during development. Journal of Neuroscience: the Official Journal of the Society for Neuroscience 20(20): 7706-7715
Eggert, A.; Sieverts, H.; Ikegaki, N.; Brodeur, G.M. 2000: P75 mediated apoptosis in neuroblastoma cells is inhibited by expression of TrkA. Medical and Pediatric Oncology 35(6): 573-576
Roux, P.P.; Colicos, M.A.; Barker, P.A.; Kennedy, T.E. 1999: p75 neurotrophin receptor expression is induced in apoptotic neurons after seizure. Journal of Neuroscience: the Official Journal of the Society for Neuroscience 19(16): 6887-6896
Bui, N.Truc.; König, H-Georg.; Culmsee, C.; Bauerbach, E.; Poppe, M.; Krieglstein, J.; Prehn, J.H.M. 2002: P75 neurotrophin receptor is required for constitutive and NGF-induced survival signalling in PC12 cells and rat hippocampal neurones. Journal of Neurochemistry 81(3): 594-605
Zhang, Y.; Hong, Y.; Bounhar, Y.; Blacker, M.; Roucou, X.; Tounekti, O.; Vereker, E.; Bowers, W.J.; Federoff, H.J.; Goodyer, C.G.; LeBlanc, A. 2003: P75 neurotrophin receptor protects primary cultures of human neurons against extracellular amyloid beta peptide cytotoxicity. Journal of Neuroscience: the Official Journal of the Society for Neuroscience 23(19): 7385-7394
Dobrowsky, R.T.; Carter, B.D. 2000: P75 neurotrophin receptor signaling: Mechanisms for neurotrophic modulation of cell stress?. Journal of Neuroscience Research 61(3): 237-243
Coulson, E.J.; Reid, K.; Barrett, G.L.; Bartlett, P.F. 1999: P75 neurotrophin receptor-mediated neuronal death is promoted by Bcl-2 and prevented by Bcl-xL. Journal of Biological Chemistry 274(23): 16387-16391
Vesa, J.; Kruttgen, A.; Shooter, E.M. 2000: p75 reduces TrkB tyrosine autophosphorylation in response to brain-derived neurotrophic factor and neurotrophin 4/5. Journal of Biological Chemistry 275(32): 24414-24420
Hamanoue, M.; Middleton, G.; Wyatt, S.; Jaffray, E.; Hay, R.T.; Davies, A.M. 1999: P75-mediated NF-kappaB activation enhances the survival response of developing sensory neurons to nerve growth factor. Molecular and Cellular Neurosciences 14(1): 28-40
Kume, T.; Nishikawa, H.; Tomioka, H.; Katsuki, H.; Akaike, A.; Kaneko, S.; Maeda, T.; Kihara, T.; Shimohama, S. 2000: P75-mediated neuroprotection by NGF against glutamate cytotoxicity in cortical cultures. Brain Research 852(2): 279-289
Yan, C.; Liang, Y.; Nylander, K.D.; Wong, J.; Rudavsky, R.M.; Saragovi, H.Uri.; Schor, N.Felice. 2002: P75-nerve growth factor as an antiapoptotic complex: Independence versus cooperativity in protection from enediyne chemotherapeutic agents. Molecular Pharmacology 61(4): 710-719
Ward, N.L.; Hagg, T. 1999: P75(NGFR) and cholinergic neurons in the developing forebrain: a re-examination. Brain Research. Developmental Brain Research 118(1-2): 79-91
Dougherty, K.D.; Milner, T.A. 1999: P75NTR immunoreactivity in the rat dentate gyrus is mostly within presynaptic profiles but is also found in some astrocytic and postsynaptic profiles. Journal of Comparative Neurology 407(1): 77-91
Pérez-Pérez, M.; García-Suárez, O.; Esteban, I.; Germanà, A.; Fariñas, I.; Naves, F.J.; Vega, J.A. 2003: p75NTR in the spleen: age-dependent changes, effect of NGF and 4-methylcatechol treatment, and structural changes in p75NTR-deficient mice. Anatomical Record. Part A Discoveries in Molecular Cellular and Evolutionary Biology 270(2): 117-128
Wang, S.; Bray, P.; McCaffrey, T.; March, K.; Hempstead, B.L.; Kraemer, R. 2000: p75(NTR) mediates neurotrophin-induced apoptosis of vascular smooth muscle cells. American Journal of Pathology 157(4): 1247-1258
Perry, M.E.; Mendrysa, S.M.; Saucedo, L.J.; Tannous, P.; Holubar, M. 2000: P76(MDM2) inhibits the ability of p90(MDM2) to destabilize p53. Journal of Biological Chemistry 275(8): 5733-5738
Motoo, Y.; Iovanna, J.L.; Mallo, G.V.; Su, S.B.; Xie, M.J.; Sawabu, N. 2001: P8 Expression is induced in acinar cells during chronic pancreatitis. Digestive Diseases and Sciences 46(8): 1640-1646
Vasseur, S.; Hoffmeister, A.; Garcia, S.; Bagnis, C.; Dagorn, J-Charles.; Iovanna, J.Lucio. 2002: p8 is critical for tumour development induced by rasV12 mutated protein and E1A oncogene. Embo Reports 3(2): 165-170
Leung, T.; Ng, Y.; Cheong, A.; Ng, C.Han.; Tan, I.; Hall, C.; Lim, L. 2002: p80 ROKalpha binding protein is a novel splice variant of CRMP-1 which associates with CRMP-2 and modulates RhoA-induced neuronal morphology. Febs Letters 532(3): 445-449
Zhang, S.; Broxmeyer, H.E. 1999: p85 subunit of PI3 kinase does not bind to human Flt3 receptor, but associates with SHP2, SHIP, and a tyrosine-phosphorylated 100-kDa protein in Flt3 ligand-stimulated hematopoietic cells. Biochemical and Biophysical Research Communications 254(2): 440-445
Gonda, K.; Numata, O. 2002: p85 binds to G-actin in a Ca(2+)/calmodulin-dependent manner, thus regulating the initiation of cytokinesis in tetrahymena. Biochemical and Biophysical Research Communications 292(4): 1098-1103
Funaki, M.; Katagiri, H.; Kanda, A.; Anai, M.; Nawano, M.; Ogihara, T.; Inukai, K.; Fukushima, Y.; Ono, H.; Yazaki, Y.; Kikuchi, M.; Oka, Y.; Asano, T. 1999: P85/p110-type phosphatidylinositol kinase phosphorylates not only the D-3, but also the D-4 position of the inositol ring. Journal of Biological Chemistry 274(31): 22019-22024
De Mesquita, D.D.; Zhan, Q.; Crossley, L.; Badwey, J.A. 2001: p90-RSK and Akt may promote rapid phosphorylation/inactivation of glycogen synthase kinase 3 in chemoattractant-stimulated neutrophils. FEBS Letters 502(3): 84-88
Tan, Y.; Ruan, H.; Demeter, M.R.; Comb, M.J. 1999: P90(RSK) blocks bad-mediated cell death via a protein kinase C-dependent pathway. Journal of Biological Chemistry 274(49): 34859-34867
Takahashi, E.; Abe, J.; Gallis, B.; Aebersold, R.; Spring, D.J.; Krebs, E.G.; Berk, B.C. 1999: p90(RSK) is a serum-stimulated Na+/H+ exchanger isoform-1 kinase. Regulatory phosphorylation of serine 703 of Na+/H+ exchanger isoform-1. Journal of Biological Chemistry 274(29): 20206-20214
Yamada, T.; Okuhara, K.; Iwamatsu, A.; Seo, H.; Ohta, K.; Shibata, T.; Murofushi, H. 2000: P97 ATPase, an ATPase involved in membrane fusion, interacts with DNA unwinding factor (DUF) that functions in DNA replication. FEBS Letters 466(2-3): 287-291
Ujiie, M.; Dickstein, D.L.; Jefferies, W.A. 2002: p97 as a biomarker for Alzheimer disease. Frontiers in Bioscience: a Journal and Virtual Library 7: E42-E47
McAleer, M.A.; Breen, M.A.; White, N.L.; Matthews, N. 1999: pABC11 (also known as MOAT-C and MRP5), a member of the ABC family of proteins, has anion transporter activity but does not confer multidrug resistance when overexpressed in human embryonic kidney 293 cells. Journal of Biological Chemistry 274(33): 23541-23548
Fujimoto, S.; Ike, Y. 2001: pAM401-based shuttle vectors that enable overexpression of promoterless genes and one-step purification of tag fusion proteins directly from Enterococcus faecalis. Applied and Environmental Microbiology 67(3): 1262-1267
Moraes, M.P.; Mayr, G.A.; Grubman, M.J. 2001: pAd5-Blue: direct ligation system for engineering recombinant adenovirus constructs. Biotechniques 31(5): 1050 1052 1054-6
Mccormac, A.C.; Elliott, M.C.; Chen, D.F. 1999: PBECKS2000: a novel plasmid series for the facile creation of complex binary vectors, which incorporates "clean-gene" facilities. Molecular and General Genetics: Mgg 261(2): 226-235
Le Borgne, S.; Palmeros, B.; Valle, F.; Bolivar, F.; Gosset, G. 1998: PBRINT-Ts: A plasmid family with a temperature-sensitive replicon, designed for chromosomal integration into the lacZ gene of Escherichia coli. Gene 223(1-2): 213-219
Loewen, M.E.; Bekar, L.K.; Gabriel, S.E.; Walz, W.; Forsyth, G.W. 2002: PCLCA1 becomes a cAMP-dependent chloride conductance mediator in Caco-2 cells. Biochemical and Biophysical Research Communications 298(4): 531-536
Meggio, F.; Ruzzene, M.; Sarno, S.; Pagano, M.A.; Pinna, L.A. 2000: pCMB treatment reveals the essential role of cysteinyl residues in conferring functional competence to the regulatory subunit of protein kinase CK2. Biochemical and Biophysical Research Communications 267(1): 427-432
Mclean, J.H.; Harley, C.W.; Darby King, A.; Yuan, Q. 1999: PCREB in the neonate rat olfactory bulb is selectively and transiently increased by odor preference-conditioned training. Learning and Memory (Cold Spring Harbor) 6(6): 608-618
Pandjaitan, B.; Eibensteiner, P.B.; Vrtala, S.; Hayek, B.; Grote, M.; Reichelt, R.; Rumpold, H.; Valenta, R.; Spitzauer, S. 1999: PET-prof, a plasmid for high-level expression of recombinant peptides fused to a birch profilin-derived hexadecapeptide tag: A system for the detection and presentation of recombinant antigens. Gene 237(2): 333-342
Scrittori, L.; Hans, F.; Angelov, D.; Charra, M.; Prigent, C.; Dimitrov, S. 2001: pEg2 aurora-A kinase, histone H3 phosphorylation, and chromosome assembly in Xenopus egg extract. Journal of Biological Chemistry 276(32): 30002-30010
Sanna, P.P.; Samson, M.E.; Moon, J.S.; Rozenshteyn, R.; De Logu, A.; Williamson, R.A.; Burton, D.R. 1999: pFab-CMV, a single vector system for the rapid conversion of recombinant Fabs into whole IgG1 antibodies. Immunotechnology: An International Journal of Immunological Engineering 4(3-4): 185-188
Liu, J.; Voutilainen, R.; Heikkilä, P.; Kahri, A.I. 1999: PG2 gene expression and its regulation in human adrenocortical and medullary tumors. European Journal of Endocrinology 140(6): 590-596
Mizutani, T.; Osaka, T.; Ito, Y.; Kanou, M.; Usui, T.; Sone, Y.; Totsuka, T. 2002: PGp as the main product of bovine tRNA kinase. Molecular Biology Reports 29(3): 293-300
Hellens, R.P.; Edwards, E.A.; Leyland, N.R.; Bean, S.; Mullineaux, P.M. 2000: PGreen: A versatile and flexible binary Ti vector for Agrobacterium-mediated plant transformation. Plant Molecular Biology 42(6): 819-832
Oki, A.; Takamura, Y.; Ito, Y.; Horiike, Y. 2002: pH Change of buffer solution in a microcapillary chip and its suppression. Electrophoresis 23(17): 2860-2864
Harvitt, D.M.; Bonanno, J.A. 1998: pH dependence of corneal oxygen consumption. IOVS Investigative Ophthalmology and Visual Science 39(13): 2778-2781
Spiess, A.; Schlothauer, R.; Hinrichs, J.; Scheidat, B.; Kasche, V. 1999: PH gradients in immobilized amidases and their influence on rates and yields of beta-lactam hydrolysis. Biotechnology and Bioengineering 62(3): 267-277
Orta-Ramirez, A.M.rrill, J.; Smith, D. 2000: PH affects the thermal inactivation parameters of R-phycoerythrin from Porphyra yezoensis. Journal of food science 65(6): 1046-1050
Berdiev, B.K.; Mapstone, T.B.; Markert, J.M.; Gillespie, G.Y.; Lockhart, J.; Fuller, C.M.; Benos, D.J. 2001: pH alterations "reset" Ca2+ sensitivity of brain Na+ channel 2, a degenerin/epithelial Na+ ion channel, in planar lipid bilayers. Journal of Biological Chemistry 276(42): 38755-38761
Newcombe, N.; Clulow, J.; Man, S.Y.; Jones, R.C. 2000: PH and bicarbonate in the ductuli efferentes testis of the rat. International Journal of Andrology 23(1): 46-50
Duarte, M.Antonio.Hungaro.; Demarchi, A.Claudia.Cardoso.de.Oliveira.; Yamashita, Jé.Carlos.; Kuga, M.Carlos.; Fraga, S.de.Campos. 2003: pH and calcium ion release of 2 root-end filling materials. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics 95(3): 345-347
Németh-Cahalan, K.L.; Hall, J.E. 2000: PH and calcium regulate the water permeability of aquaporin 0. Journal of Biological Chemistry 275(10): 6777-6782
Gadda, G. 2003: PH and deuterium kinetic isotope effects studies on the oxidation of choline to betaine-aldehyde catalyzed by choline oxidase. Biochimica et Biophysica Acta 1650(1-2): 4-9
Legen, I.; Kristl, A. 2003: PH and energy dependent transport of ketoprofen across rat jejunum in vitro. European Journal of Pharmaceutics and Biopharmaceutics: Official Journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik E.V 56(1): 87-94
Sauvé, R.; Cai, S.; Garneau, L.; Klein, H.; Parent, L. 2000: PH and external Ca(2+) regulation of a small conductance Cl(-) channel in kidney distal tubule. Biochimica et Biophysica Acta 1509(1-2): 73-85